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Itch lies second only to disturbance of body image as a reported symptom in dermatology. 
This study started by concentrating on improving the measurement of itch. Itch has a paired 
physical response, scratch. The pairing can be exploited: preliminary work by this unit had 
validated the use of wrist-worn movement-measuring machines called ‘accelerometers’ to 
measure itch-related movement (scratch and rub). The first part of this research developed 
use of these machines. Simple accelerometers (‘Actiwatch Plus’) were used to observe the 
pattern of variation of itch over clusters of nights and in different conditions. The 
accelerometer scores were able to identify controls’ scores from those with itchy disease. 
Considerable variation (56%) was discovered in objective score between subject and 
considerable variation was noted (46%) even within subject. More complex accelerometers, 
(‘DigiTrac’) which could potentially specifically identify itch-related movement on the basis 
of frequency of action derived from Fast Fourier Transform (FFT), were validated against 
the ‘gold standard’ measurement of itch-related movement, directly observed movement (via 
infra red video recording). It was necessary to characterise the ‘frequency of action’ of itch 
on video and, as an aside, the characteristics of human itch-related movement were 
compared to other mammals’ itch-related movement ‘frequency of action’. The ‘frequency 
of action’ and video data was used to enrich the DigiTrac readouts to improve specificity of 
itch-related movement detection.  
During the accelerometer studies, an unexpected finding came to light: objective score of 
itch was not related to subjective score. To try to explain the lack of relationship, a 42 day 
longitudinal study of atopic dermatitis patients’ subjective and objective scores was 
undertaken. The results demonstrated autocorrelation for subjective scores, but not for the 
objective scores but still did not fully explain the lack of relationship.  
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In an effort to explain the disconnect between subjective and objective scores a second 
tranche of experiments and the second part of this research interrogated whether the methods 
with which we measure disease as a whole in dermatology are robust. One study 
investigated whether the way patients are asked about subjective symptoms in general was 
resistant to the effects of focusing and framing bias. The results were reassuring as they 
suggested that the commonly used and recommended symptom scoring systems were robust 
in the face of bias. In order to assess whether perspective or perception of disease explained 
the disconnect, a study was designed in collaboration with the Edinburgh College of Art.  A 
series of computer-generated images of different psoriasis severities were created and used 
to assess how doctors and patients assessed disease-extent. This study showed that, whilst 
each group had a naturally divergent opinion of extent of disease, by scoring disease using 
the models it was possible to unify the perspective and perception of extent. Finally, an 
exploratory study to reduce recall bias to a minimum, in case this had caused the disconnect 
between objective and subjective, was undertaken. This employed a novel questionnaire, the 





Itch lies second only to disturbance of body image as a reported symptom in dermatology. 
This study started by concentrating on improving the measurement of itch. Itch has a paired 
physical response, scratch, therefore, if you measure scratch-movements, you have a 
measure of itch. This unit had proved that wrist-worn movement-measuring machines called 
‘accelerometers’ could be used to measure itch. The first part of this research further 
developed use of these machines. Simple accelerometers (‘Actiwatch Plus’) were used to 
observe the pattern of variation of itch over clusters of nights and in different conditions. The 
accelerometer scores were able to identify non-itchy people (controls) from those with itchy 
disease (subjects). Considerable variation was discovered in the score between subject and 
nearly as much variation was noted even within subject. More complex accelerometers, 
(‘DigiTrac’) were acquired which could potentially specifically identify itch-related 
movement (as opposed to generally moving about) on the basis of the rhythm of the 
movements. These were validated against the ‘gold standard’ measurement of itch-related 
movement, directly observed movement (on video recording). It was necessary to find out 
the ‘frequency of action’ of itch from videos and, as an aside, frequency of human scratch 
was compared to other mammals’. The ‘frequency of action’ and video data was used to 
refine the DigiTrac readouts to specifically measure itch-related movement.  
An unexpected finding came to light: the accelerometer score (the objective measure), which 
we knew was accurate as it had been compared to video-studies and was not affected by 
conscious thought (as it was measured overnight) was not related to how itchy people felt 
and told us in questionnaires (subjective score). To try to explain the lack of relationship, a 
42 day-long study of itchy eczema patients’ subjective and objective scores was undertaken. 
The results further supported the lack of relationship and seemed to suggest that the 
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subjective scores rotated, day-by-day around a kind of personal thermostat of itch-sensation. 
The objective scores did not do this.  
In a further effort to explain the disconnect between subjective and objective scores, a 
second tranche of experiments and the second part of this research looked into the we 
measure disease as a whole in dermatology. One study investigated whether the way patients 
are asked about subjective symptoms affected the answers given. The results were reassuring 
as they suggested that the commonly used questionnaires were robust in the face of bias. To 
see whether having a disease or being a doctor affected how you assess disease extent, a 
study was designed in collaboration with the Edinburgh College of Art.  A series of 
computer-generated images of different psoriasis severities were created and used to assess 
how doctors and patients assessed disease-extent. This study showed that whilst each group 
had a naturally divergent opinion of extent of disease, by scoring disease using the models it 
was possible to unify the opinion. Finally, a questionnaire which improves the recall of 
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Itch is a common, distressing symptom. It is the second most common presenting complaint 
to the dermatologist (G. Krueger et al., 2001; Yosipovitch, Greaves, & Schmelz, 2003).  It, 
classically, represents a primarily cutaneous pathology but can, also, be a complication of 
systemic disease such as uraemia, haematoproliferative or cholestatic disorders. Itch can be 
distressing and disabling, not least because it also disturbs sleep, and anyone, even some one 
who has never experienced itch (however unlikely) can empathise with this. That the 
sufferers of oncocerciasis or ‘river blindness’ state that the itch is worse than the blindness 
probably paints a clear enough picture of what living with itch can be like (Kale, 1998). 
Unfortunately, the number of effective treatments available for itch does not match the 
number of afflicted patients and the main excuse given for this shortfall is that the 
pathophysiology of itch is not well understood. 
 
There have been a tremendous number of developments in the understanding of itch since I 
was first introduced to the subject in 2002 (Rees & Murray, 2005).  A renaissance in itch 
research was triggered by a paper, published in 1997, which excited new enthusiasm since it 
indicated that there were specific itch fibres to conduct the sensation (Schmelz, Schmidt, 
Bickel, Handwerker, & Torebjörk, 1997). Right now, although there is not complete 
understanding, there is a much more explicit understanding of how itch works. As with most 
topics, knowing more, does not necessarily simplify the situation and whilst the idea of a 
single pathway would be tidy, research now does not seem to indicate that a single pathway 
does exist. 
 
My interest in itch has always had a heavy clinical bias due to my background in clinical 
medicine and, specifically, as a dermatologist. I find myself fascinated by my patients when, 
in clinic, they report symptoms that ‘explain’ itch. For instance, patients with atopic 
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dermatitis complaining that they itch more after exercising and sweating (to do with 
acetylcholine and spinal disinhibition, most likely (Vogelsang, Heyer, & Hornstein, 1995). 
Patients with chronic itching tell me how the only relief they can get is by running their skin 
under cold water or by putting ice on their skin (spinal and central inhibition by cold 
(Atanassoff et al., 1999; Craig, Reiman, Evans, & Bushnell, 1996). Patients often seem quite 
relieved when I agree with them that their non-sedating antihistamines probably are not 
doing anything for the itch associated with their eczema – I am renowned for being the 
doctor that ‘crosses off’ antihistamines from the Drug Kardex, except, of course, if they are 
sedating ones for use overnight (Krause & Shuster, 1983; Rukwied, Lischetzki, Mcglone, 
Heyer, & Schmelz, 2000; Steinhoff et al., 2003). Sometimes, however, I am entirely 
flustered by my patients, even if they are the physical embodiment of the itch pathway: on 
my office shelf I have a series of stacking pots full of ‘bugs.’ There are, of course no bugs in 
the pots but fluff and dust. However, the patient who pressed these samples into my hand 
was quite convinced that they contained parasites and thus, was demonstrating the central 
processing of itch and psychogenic pruritus causing delusions of parasitosis. Trying to deal 
with this, as a dermatologist,  really does take me to the limit of my comfort-zone. 
 
My work in the field of itch has centred upon improving measurement of itch. The reason for 
this lies in the following thinking: “We do not really understand itch, therefore, we can not 
really treat it effectively, so we should do more research into itch. However, we can not 
accurately measure itch.  How are we going to be able to rely on our results, then? We 
should design a good way of measuring itch, preferably something objective.” This was my 
thought process. Unfortunately, as previously mentioned, whilst wishing to keep things 
simple, human biology and nature does not necessarily oblige and it became obvious that, 
whilst an objective measure of itch was logical, it was not capturing all the information and 
most specifically and importantly, the perception of itch. This led me to investigate the area 
of subjective disease measurement. If my world had been rocked by the discovery that 
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objective itch was not going to prove as useful as I had hoped, my universe was then, when I 
began to appreciate that some of the measurement tools, dogmatically upheld as ‘validated’ 
measures potentially provided inaccurate information. At this point I specifically have the 
Visual Analogue Scale in mind (Torrance, Feeny, & Furlong, 2001). To my mind the Visual 
Analogue Scale is a comfort-blanket: it is vehemently clutched and makes researchers feel 
better (they have some measurements to analyse) but it does not have much practical use. 
Trying to take that comfort-blanket away results in much wailing and gnashing of teeth.  
 
When considering how to introduce this work, I really wanted to avoid using the word 
‘journey’ as I find the term a little hackneyed (conjures up pictures as follow: my journey 
through weight loss, addiction etcetera). However, I do not know better how to describe this 
research other that the following journey: I started off trying to objectively measure itch. 
This was the holy grail for me. I developed the tools and capability to do this to the optimal 
extent and found that I was still missing a facet of quantifying itch. The objective measures 
did not marry up with subjective ones, so I began to review and develop measuring disease 






Since my research was an evolution, the layout of this thesis is slightly unconventional. 
Entire experiments including hypothesis, methodology, results and conclusions are confined 
to a particular chapter, as opposed to describing all the methods and results in separate 
chapters. I have tried to impart the flow of this research by using this layout. 
 
Chapter 1: Direct observation studies, meaning using the ‘gold standard’ of videoing to 
characterise itch. Describes in detail the action of scratching, first in humans and then in 
animals. 
 
Chapter 2: Introduction and further validation of accelerometers already used in the 
literature, the Actiwatch Plus accelerometers. Since night-to-night variation had been 
described in previous accelerometer research, this study sought to corroborate and explain 
this finding in larger night-to-night studies which were also validated against video 
recordings. Before the studies could take place, improvements in the handling of the 
accelerometer data had to be made and these are described too.  
 
Chapter 3: Introduction and validation of a newer accelerometer, the DigiTrac. This 
chapter talks about my developing the newer accelerometer which promised better specific 
discrimination of itch-related movement. In this chapter, basic inter-device validation is 
presented. Data behind decisions that were made about the sensing axis to use in further 
studies are demonstrated.  
 
Chapter 4: Clinical experiments using the newer accelerometer, DigiTrac. This chapter 
starts by integrating information about frequency of action of itch, gleaned in Chapter 1 with 
pilot-study data (acquired here) in order to optimise signal processing and specific itch-
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related movement detection. It then describes a larger study, using the DigiTrac in atopic 
dermatitis patients.  
 
Chapter 5: Measuring itch over time in chronic disease. This chapter contains published 
research. The thrust trying to disentangle the poor correlation between objective and 
subjective scores continually discovered. It does this is in a several week study comparing 
objective (accelerometer) scores to subjective ones. It also compares physician-assessed 
extent. A new questionnaire, not previously used in dermatology is introduced too, the Day 
Reconstruction Method.  
 
Chapter 6: The effect of bias on subjective disease scores. This chapter contains published 
research. Since I had developed concerns about the possibility of bias playing a role in 
subjective measurement of disease in dermatology, commonly used subjective disease 
measures were tested for this in three experiments. 
 
Chapter 7: Effect of computer generated 3D models and photographs on self and third 
person measurement of disease extent in psoriasis. This presents work from a very enjoyable 
collaboration with an artist who helped to develop models with a known body surface area 
coverage of psoriasis. It was hoped that these might unify the perspectives of disease extent 
between the specialist, non-specialist and patient. A short study investigates this and a longer 






Attributed to Hafenfaffer, 1660, ‘Unpleasant sensation which provokes the desire to scratch.’ 
Whilst some have quibbled with this definition over the years, I still think this statement 





Firstly, (Yosipovitch et al., 2003): 
•! Acute itch: itchy condition lasting a short period (a few seconds up to one week). 
Elicited by substantial inflammation or injury, for instance, following an insect bite.  
•! Chronic itch: itchy condition which responds to treatment transiently then relapses 
•! Intractable itch: itchy condition unresponsive to therapy 
•! Alloknesis: itch due to an innocuous stimulus which does not normally cause itch 
(such as touch). 
 
The merits of this classification lie in the fact that acute itch is more commonly histamine 
mediated and chronic not (thereby alluding to the fact that there may be two conduction 
mechanisms). It also raises the subject of alloknesis, the homologue of allodynia, but here 
representing spinal sensitization of itch. The downfall of this classification is that I can not 
really separate chronic from intractable itch unless the authors are aiming to allude to the 
fact that chronic itch is due to peripheral itch from inflammatory mediators and intractable 




Secondly, (Twycross et al., 2003): 
•! Pruritoceptive itch: due to peripheral inflammation, for example, from xerosis, 
urticarial, insect-bite. 
•! Neuropathic itch: due to pathology at any point of the afferent itch pathway, for 
example, post-herpetic, brachioradial pruritus. 
•! Neurogenic itch: originates centrally without evidence of pathology in the neural 
pathway, for example, cholestatic itch due to the effect of opioid neuropeptides on µ 
opioid receptors. 
•! Psychogenic itch: associated with psychological disease, for instance, delusions of 
parasitosis. 
 
Any of the above may co-exist. This, I feel is a more helpful classification as it helps, to 






This introduction’s literature review starts by describing how itch ‘works.’ I aim to impart 
current understanding as accurately and as clearly as I can despite on-going queries. Then, 
since this thesis focusses on the quantification of itch, I will describe the development of this 
field. This section will be divided into the psychophysical measurement of itch, and moves 
into true objective measurement. Finally, I will describe the commonly-used subjective and 







To this simple dermatologist’s mind, itch signalling is best understood as follows and the 
components highlighted in bold: 
 
1)! Entity to cause itch in the periphery: chemical, mechanical, electrical 
2)* Something in periphery to detect entity causing itch: receptors 
3)* Wiring to pass itch signal on from peripheral receptor: primary afferent nerves 
4)* Relay in wiring at spinal cord: dorsal root ganglion 
5)* Wiring to pass itch signal to brain: lateral spinothalamic tract 
6)! Parts of brain to make subject aware of itch sensation and other parts including 
motor cortex to provoke response with scratch. 
 
Now I will expand each section of the process 
 
1)* Entities to cause itch in the periphery: chemical, mechanical, electrical 
 
It is generally accepted that itch developed, evolutionarily, to deal with parasites: if a bug is 
walking about in your hair/fur, the itch and ensuing reflex to scratch removes the offending 
creature. The movement of the bug and your hairs causes mechanical stimulation. On a 
slightly more complex level, parasites and other toxic entities are dealt with by mast cell 
degranulation. The products of mast cell degranulation are chemicals. These chemicals 
include the archetypal inducer of itch, histamine, plus a myriad of others such as serotonin, 
serine proteases and lipid mediators. More recently, and more complexly, it has become 
apparent that other cells in the skin can produce itch-inducing chemicals including T cells 
and keratinocytes. Finally, it is worth considering old fashioned itching powder (not the poor 
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impersonator that they sell in joke shops these days). The itching powder was actually made 
up of spicules from the pods of the bean of Mucuna pruriens. The spicules enter the skin to 
cause mechanical stimulation of itch but also, thanks to a brilliant bit of inspired basic 
science (boiling the spicules to denature protein), we know they also cause chemical 
mediation of itch from proteases on the surface of the spicules (Shelley & Arthur, 1955a). 
 
Mechanical itch is elicited, obviously, by a mechanical force and detected by a pruritoceptor. 
This will be discussed in part 2 of the itch pathway. 
 
As far as chemicals that cause itch are concerned, histamine has long been regarded as the 
classic itch-mediator. Histamine manifests itself by Lewis’ triple response (T. Lewis, 1926), 
the hives or wheals that commonly afflict after type I hypersensitivity. Personally, however, 
a couple of clinical observations made me suspect, as others had, that it was not working or 
at least working alone in causing itch, in vivo. Firstly, if histamine caused itch in eczema, 
why were patients not covered in hives/wheals?  The only explanation could be 
tachyphylaxis. Secondly, if histamine was causing the itch in chronic diseases other than 
urticaria, why were antihistamines so ineffective? Part of the bias towards using histamine as 
an itch-mediator is probably because it is easy and readily available for use. Confusing 
results have been thought to be due to experimental methods involving the injection of 
histamine: this is obviously painful as well as itchy. However, histamine can successfully 
and painlessly be iontophoresed and this has been the application of choice more recently.  
Unfortunately, and perhaps tellingly, it is also known that high concentrations of histamine 
can cause pain and so it may not be as ‘clean’ a pruritogen as would be desirable, again 
accounting for some of the confusing experimental findings over the years most particularly 
in trying to determine a specific itch pathway: it was histamine that was used to identify the 
‘itch-fibres’ and these were not proven to be purely responsive to itch, they conducted pain 
too (Schmelz, 2001; 2003; Schmelz et al., 1997). 
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Other peripheral mediators which stimulate the ‘itch fibres’ include prostaglandin, 
particularly PGE2. This may work in a histamine independent way and certainly enhances 
histamine induced itch in the skin (Hägermark & Strandberg, 1977; Hägermark, Strandberg, 
& Hamberg, 1977). It has, more recently, been shown to be a histamine independent itch-
mediator in the eye (Woodward et al., 1995). Serotonin can cause pain and itch in humans 
(Hägermark, 1992) and is a particularly potent mediator of itch in mice (Inagaki et al., 2001). 
It is of note also that different strains of mice respond in different ways to pruritogens 
(Inagaki et al., 2001). This is only one of the many limitations of using mouse models for 
itch.  
 
As far back as 1955 and the Shelley and Arthur experiments, proteases (also called 
proteinases) were noted to be mediators of itch. They coined the term ‘mucainain’ for the 
protease which coats the spicules of cowhage, Mucuna pruriens (Arthur & Shelley, 1955; 
Shelley & Arthur, 1955b). Gradually, more endogenous proteases were reported as itch-
mediators, specifically mast cell products such as rat cell chymase (Hägermark, Rajka, & 
Bergvist, 1972) and tryptase, whose effect was found to be mediated by PAR-2 receptor (Ui, 
Andoh, Lee, Nojima, & Kuraishi, 2006). Importantly, the itch of cowhage is not 
accompanied by wheal and flare – the significance of this finding and its relevance to 
separate itch pathways will be discussed later (Namer et al., 2008). 
 
Acetylcholine has been reported to cause itch. It has been thought that it is this chemical 
which explains the fact that atopic dermatitis patients find sweat itchy rather than painful 
(Vogelsang et al., 1995). It is proposed that acetylcholine actually reduces the inhibition of 




More recently, cytokines have been suggested as itch-mediators. T cell derived Il-31 (Singer 
et al., 2013) which appears to cause itch in T cell lymphoma. Epithelial cell derived thymic 
stromal lymphopoietin (TSLP), otherwise known as epithelial stromal lipoprotein (S. R. 
Wilson et al., 2013) has been implicated in atopic dermatitis itch. 
 
 
2)! Something in periphery to detect entity causing itch: receptors. 
 
Pruritoceptors sense the peripheral itch stimuli. Multiple receptor molecules are expressed 
which have one thing in common: they are G protein-coupled receptors (GPCR). Examples 
of these receptors include histamine receptors, H1 and H4 (Bell, McQueen, & Rees, 2004) 
(Rossbach et al., 2011), serotonin receptors (Kim et al., 2008) and PAR-2 (Reddy, Shimada, 
Sikand, LaMotte, & Lerner, 2010).  
 
More recently, members of the Mas-related G protein-coupled receptor (Mrgpr) family were 
discovered which were activated by mast cell mediators and promoted histamine-
independent itch (Q. Liu et al., 2009; S. R. Wilson et al., 2011). These receptors are activated 
by exogenous chemicals which cause itch, such as chloroquine (MrpgpA3) and by 
endogenous itch mediator BAM 8-22 (MrpgC11 (S. R. Wilson et al., 2011)). 
 
Itch G protein-coupled receptors trigger G protein coupled signalling cascades via 
Phospholipase C and Gβσ (gamma) and ultimately mediate gating of TRP-ion channels 
(Imamachi et al., 2009; S. R. Wilson et al., 2011). TRP-ion channels include TRPV1 and 
TRPA1. TRPA1 is expressed in a subset of TRPV1 expressing neurons. These TRP channels 
are classically activated by pain producing compounds such as isothiocyanates which 
include mustard oil, brassicas, cinnamon and, of course, capsaicin (Costa et al., 2008). Cold 
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receptors are also TRP-ion channels (TRPM8) and whilst there is a reciprocal effect of cold, 
TRPM8 signalling on hot, TRPA1 (Takaishi et al., 2015) signalling, it’s not, therefore, a 
huge leap of faith to appreciate that a similar mechanism may explain the counterirritant 
effect of heat, pain and cold on itch. These receptors help in the ‘gating’ of itch as described 
in section 4. 
 
Apart from G-protein coupled receptors, there are non-G-protein coupled receptors involved 
in itch-mediation, and these are the receptors which appear to be activated by cytokines 
(Boulay, O'Shea, & Paul, 2003). The non-G-protein coupled receptors directly, or indirectly 
lead to signalling cascades which cause phosphorylation of multiple intracellular proteins. 
Examples of these receptors are the receptor for epithelial stromal lipoprotein or TSLP 
Thymic Stromal Lymphopoetin) receptor and Il-7Ra which is also activated by TSLP. These, 
as will be mentioned later have been found to be expressed in pruritoceptors in atopic 
dermatitis (S. R. Wilson et al., 2013). Also, IL-31Ra have been found to be expressed in a 
subset of sensory neurons which are activated by Il-31, the cytokine thought to be 
responsible for lymphoma-itch (Cevikbas et al., 2014).  
 
Finally, receptor-wise, Toll-like receptors are thought be be likely to contribute to itch-
mediation. Their expression in pruritoceptors has not been proven, however (Hoon, 2015). 
 
With regard to the specificity of pruritoceptors for itch, this field is developing and actually, 
moleculogenetic and pharmacological studies are providing of specificity in itch pathways in 
a way that electrophysiological studies are unable to. Moleculogenetic and pharmacological 
strategies suggest coding-specificity in pruritoceptors: MrgprA3 receptor coding neurons 
have been found to be required to detect most itch. Ablation of these receptors reduced, but 
did not abolish itch and activation of the receptors, even to high intensity, resulted in itch, 




3)* Wiring to pass itch signal on from peripheral receptor: primary afferent nerves 
 
Clearly, I have described the interface between mediators and the nerves for conduction in 
the previous section. The ‘wiring’ deserves a special mention as it was because of a paper 
published in 1997 which described specific itch receptors in the skin, that interest in itch-
research really resumed (Schmelz et al., 1997). 
 
Itch researchers have long asked, ‘Is there a specific itch pathway?’ It was originally thought 
that itch was just less severe pain conducted along the same pathways, ‘The Intensity 
Theory.’ This was not without reason: histamine at low concentration causes itch and at high 
concentration, pain. It was not until an abstract was published in 1981 that specificity of itch 
away from pain seemed a possibility. In the reported study, low concentration algogens were 
shown to cause less intense pain, not itch. Not only this, but intraneural microstimulation in 
afferent nerves in humans caused either pain or itch (admittedly, itch less frequently). 
Importantly, there was no switch from pain to itch, or vice versa with intensity of stimulation 
(Torebjörk & Ochoa, 1981). 
 
Due to the neurophysiological characteristics of the firing, it was evidenced that C-fibres had 
to be the wiring modality. These are unmyelinated, slow conducting fibres. These 
nociceptors, or C-fibres which conduct unpleasant sensations, were known to be 80% 
Chemo-Mechano-Heat (CMH) nociceptors, also called polymodal nociceptors, as they are 
stimulated by many modalities. 20% of nociceptors were considered ‘silent’ or sleeping 
nociceptors (Lynn, 1991). These ‘silent’ nerves are also called mechanoinsensitive (CMiHi). 
In 1974, it had been found that the majority of CMH neurons were insensitive or just weakly 
activated by histamine (Torebjörk, 1974).  
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Thanks to electrophysiological studies after iontophoresis of histamine, it was discovered 
that there were histamine-sensitive fibres amongst the CMiHi subset (Schmelz, 2001; 
Schmelz et al., 1997). The histamine sensitive fibres make up a fifth of the CMiHi or silent 
fibres, or 5% of C-fibres overall. 
 
The characteristics of itch-conducting fibres is that they are: low conduction velocity, high 
transcutaneous electrical threshold, large innervation territory nerves. The latter observation 
explains demonstrated poor two-point discrimination of itch (Wahlgren & Ekblom, 1996). 
 
When I came into the field of itch research, I was frustrated as it seemed that there was an 
obvious confounding factor in the research: all the neurophysiological studies, even ones 
which looked at how the fibres reacted to different itch mediators, initially identified the itch 
C-fibres by iontophoresing histamine. The C fibres were, therefore a self-selecting group. 
Thankfully, more recently, there has been a renaissance of the use of cowhage in studies and 
it is because of this that it is now appreciated that fibres which respond to proteases are a 
different type.  Histamine sensitive fibres are mechano-unresponsive whilst protease 
sensitive fibres and those using the PAR-2 pathway are mechano-responsive (Namer et al., 
2008). This finding does not concur with the concept of a single itch-pathway. 
 
4)! Relay in wiring at spinal cord: dorsal root ganglion 
 
In 2001, second order neurons were discovered in cats (Andrew & Craig, 2001). This 
followed evidence of similar neurons in rats but a criticism of this study had been that 
histamine had been injected which could have caused pain and which, of course could have 
confounded the readings (Jinks & Carstens, 1998; 2000). The cat study iontophoresed 
histamine and recordings were made from single spinothalamic neurons (Andrew & Craig, 
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2001). It was then discovered that cooling could reduce perceived itch intensity on a central 
level, presumably by reducing activity of primary afferents (Bromm, Scharein, Darsow, & 
Ring, 1995) although it is only thanks to more recent research that we appreciate that this is 
likely to be due to TRP-ion channels (Carstens & Akiyama, 2014). 
 
Much in the same way that identification of the primary afferent C fibres had been limited by 
using histamine to hunt for them, the same happened at the second order level initially. 
Primate experiments have, since, identified different populations of spinothalamic neurons: 
some relay histamine itch and another relay cowhage mediated itch (Davidson et al., 2007). 
 
As well as passing the itch message up centrally, it is at the cord level that other processing 
occurs. This would appear to be the pertinent moment to explain a feature of itch, alloknesis.  
Alloknesis is to itch what allodynia is to pain. Pain research had explained that the sensation 
has two facets: firstly there is acute pain sensation, the signal that leads to the central 
nervous system, helps us react (withdraw) and heads to the cortex to make us aware of the 
situation (perception). Secondly, there is sensitisation of secondary order neurons in the 
dorsal horn leading to ‘hyperalgesia.’ Hyperalgesia has two manifestations: allodynia and 
punctate hyperalgesia. Allodynia describes the phenomenon whereby normally painless 
touch is perceived as painful. Allodynia requires ongoing activity of the primary afferent 
nociceptor and is elicited by low threshold mechanorecptors, Aβ. Punctate hyperalgesia is 
that slightly painful pinprick like sensation. Punctate hyperalgesia does not require ongoing 
activity of primary afferent nociceptors and can persist for hours (LaMotte, Shain, Simone, 





The itch equivalent is as follows: 
a) Acute itch causes the reflex (scratch via spinal relay) and sensation of itch (perception at 
cortex). This is the message firing from the stimulus to the brain. 
b) Furthermore, activation of second order dorsal horn neurons produces alloknesis, whereby 
touch evokes pruritus (Simone, Alreja, & LaMotte, 1991a). Alloknesis requires ongoing 
activity in the primary afferent. The sensation is elicited by low threshold Aβ 
mechanoreceptors.  
c) Also, pricking ‘hyperknesis’ is produced. This was observed after histamine iontophoresis 
experiments, requires second order dorsal horn relay and is elicited by Aδ fibres (Atanassoff 
et al., 1999) This does not require ongoing primary afferent activity. 
 
The primary mediator of itch between primary afferent and second order neuron is 
glutamate. This is evidenced by the fact that post synaptic input from itch sensory afferents 
can be blocked by inotropic glutamate ion channel antagonists and also by the knowledge 
that all sensory neurons possess the equipment to generate glutamate (Koga et al., 2011; 
Lagerström et al., 2010; Y. Liu et al., 2010). Hinting, again, at a second pathway, is the fact 
that eliminating glutamate from pruritoceptors does not abolish itch (Lagerström et al., 2010; 
Y. Liu et al., 2010). There was considerable excitement when in 2007, data was published 
suggesting that Gastrin Releasing Protein (GRP) may be another candidate for 
transmitter(Sun & Chen, 2007). The group had found the GRP receptor (GRPR) co-localised 
with TRPV1 in appropriate situations in the dorsal horn and then showed that mutant GRPR 
mice had an attenuated response to pruritogens. The fact that RNA for GRP is sparse in 
pruritoceptors has raised a question mark over its relevance more recently, however 
(Goswami et al., 2014). 
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So what other candidate might there be for spinal itch mediator? Natriuretic peptide b  
(Nppb) is the latest proposal (Mishra & Hoon, 2013). This chemical has been found to be co-
expressed in with itch receptors and signalling components. Nppb is required to elicit an itch 
response in mice and if ablated in the spinal cord ablates itch behaviour. In fact, it may be 
that GRP and Nppb are both required, or work together: GRP deficiency (in mice), GRP 
antagonism and GRP ablation reduce the mouse response to histamine and to Nppb. 
However, blocking Nppb does not affect GRP induced itch behaviour. At this point I 
struggle for clarity but pharmacologists suggest that GRP is co-expressed with Nppb or that 
GRP is a secondary mediator (Hoon, 2015). 
 
A final feature of spinal itch is ‘gating.’ This is highly relevant to this thesis as it is the 
method whereby scratch is linked to itch. Itch causes scratching, scratching causes pain, the 
pain sensation counteracts itch. This takes the discussion back to glutamate. Groups have 
genetically eliminated a glutamate transporter, VGlut2, from a subset of sensory neurons 
(Lagerström et al., 2010; Y. Liu et al., 2010) and discovered that the mice were much itchier. 
The mice demonstrated spontaneous itch and hyperreactivity to pruritic compounds. At the 
same time they were less sensitive to pain (algogens). The explanation is that there is 
reduction in the tonic inhibition of pain sensing neurons which usually silence itch. 
 
Furthermore, mice lacking Bhlhb5 inhibitory neurons are also very itchy and exhibit the 
same behaviour as the Vglut2 deficient (Ross et al., 2010). Bhlhb5 is a neural-specific basic 
helix-loop-helix (bHLH) transcription factor. Bhlhb5 expressing neurons can be activated by 
capsaicin, mustard and menthol  all of which are itch counter-irritants. The neurons which 
express Bhlhb5 also contain the itch relieving neuropeptide, dynorphin and it is proposed 
that this is the mechanism for menthol counteractivity of itch (Kardon et al., 2014).  
Just a quick mention of opiates at this point: opiates were observed to cause analgesia after 
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epidural, but also sometimes intolerable segmental itch (Ballantyne, Loach, & Carr, 1988). 
Mast cell degranulation had been blamed for the problem but when this was negated, in 
microdialysis trials, and the itch prevailed, it was apparent that the opiates were having 
another effect (Blunk et al., 2004). Different types of opioids and their receptors have very 
different effects, but simply and for the benefit of this context, it is most salient to note that 
µ-opioids are good analgesics and so good that they reduce the tonal inhibition of itch at the 
spinal level (Andoh et al., 2008). Although known to be not directly mediated via opioid 
receptors, evidence for for tonal inhibition of pain by itch is derived from exacerbation of 
histamine induced itch by previous injection of local anaesthetic (Atanassoff et al., 1999). 
 
5)* Wiring to pass itch signal to brain: lateral spinothalamic tract 
 
I have alluded to the fact that the onward wiring pathway is via the lateral spinothalamic 
tract in section 4. It was Bickford who as long ago as 1938 identified this as the pathway by 
observing that disease and cordotomy involving this area abolished itch in humans 
(Bickford, 1938). Unlike other parts of the pathway this is not in question. 
 
6)* Parts of brain to make subject aware of itch sensation and other parts including 
motor cortex to provoke response with scratch. 
 
These areas have been elucidated by imaging of the brain. First, Hsieh (Hsieh et al., 1994) 
injected histamine and PET scanning highlighted the contralateral anterior cingulate cortex 
and limbic motor cortex, thought to confer the urge to scratch, and the supplemental motor 
centres bilaterally. Due to the injection of histamine, the results were open to confounding by 
pain. Further studies have ‘pricked’ histamine and imaging initially by PET and later by 
functional MRI has confirmed that the motor and supplemental motor areas are activated by 
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itch.  Involvement of ‘unpleasantness’ areas including the contralateral insula and primary 
somatosensory areas have been demonstrated  and most importantly, the areas activated by 
itch are separate from those activated by pain (Darsow et al., 2000; Drzezga et al., 2001; 
Walter et al., 2005). The particular cortical areas activated, the anterior cingulate cortex and 
insular cortex, marry up with the spinal wiring inasmuch as that is where the ascending 
lamina I axons connect (Craig et al., 1996) and so, at least for this part of itch signalling, a 





Why measure itch? 
Not having a good way of measuring an entity is a huge hurdle. Measuring something 
standardises it across the board. The problem of a lack of ways to measure disease in 
dermatology was considered significant enough for Professor Sam Shuster to comment in his 
Dowling Oration of 1966 (Shuster, 1966) that, “this metrophobia prevents us studying our 
problems in depth.” 
 
With a validated, objective measure for itch, within person measurements could monitor 
progress of treatment and thus effectiveness of treatment, or even forecast relapse. 
Measurement would be desirable in a clinical situation but could be argued to be vital in an 
experimental scenario. 
 
How to measure itch. 
Itch is a subjective symptom but it is, helpfully, coupled to a physical reaction, scratch-
movement. As such, the options available with regard to measuring itch are: 
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a)! to use the science and tools of psychophysics to convert the subjects’ observations 
into recordable values, or 
b)! to measure the movements that occur as a consequence of itch, viz definition, 
scratch. 
 
There are, of course, quantitative and qualitative features to itch, for instance, intensity 
would be the quantitative value and a description of the sensation, for instance, prickling, 
tickling, burning, would be qualitative. Of the two ways mentioned to measure itch, it would 
be hoped that subjective scores would provide measures of both intensity and quality, whilst 
objective measurement of scratch can only hope to provide a quantitative measure. Whilst an 
objective score is not as multi-faceted as a subjective one it is, at least, immune to the 
problems and bias of psychological overlay. 
 
a)* Using the science and tools of Psychophysics to convert the subjects’ observations 
into recordable values. 
 
Psychophysics is defined as ‘the science of relations between psychological dimensions 
(mind) and physical dimensions (body), i.e., between the perceived sensation and its 
stimulus, dealing with the measurement of sensory perception (Wahlgren, 1995).’ Itch is not 
the only sensory perception which has been required to be measured. Some of the simplest 
and earliest developed tools were scales, and their use is still prevalent today. 
 
The scales can be described as follows (Wahlgren, 1995): 
1)! Nominal scale – categorises only, for example: itch versus no itch 
2)! Ordinal scale – provides a rank order although the steps are not equidistant, for 
example: mild, moderately or severely itchy. 
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3)! Interval scale – categorises into a rank order, but with equidistant steps, for example 
the Celsius or Fahrenheit scale, zero is arbitrary, however. 
4)! Ratio scale – similar to the interval scale but with a true zero, for example Kelvin or 
even the Cardinal scale of numbers routinely used. 
 
Following on from this background of scaling, itch-rating scales used have included: 
1)! Ratio Estimation Scale – an intensity of sensation is compared to another, for 
instance electrically stimulated itch on one arm compared to the other. This scale is 
obviously most useful in measuring experimental itch but can apply in the pre/post 
therapeutic scenario (Tuckett, 1982). 
2)! Magnitude Estimation Scale – the subject merely chooses a number to assign 
intensity, there is no limit to the number they can choose. The numbers are 
standardised by a conversion equation afterwards (Wahlgren, 1995). 
3)! Graphic Rating Scale - developed in the 1920’s for ‘subjective feelings.’ A 
commonly known and used version is the visual analogue scale (VAS). This is a 
rating on a line of fixed length where only the extremes of the line are defined. The 
subject chooses a score which corresponds to their perceived itch intensity. The 
visual analogue (VAS) has been validated in the assessment of pain (Melzack, 
1975). It is simple, sensitive and easily reproducible. It has been proven to be 
sensitive enough to record a dose-response in experimental itch provoked by 
different concentrations of histamine (Wahlgren, 1995). 
4)! Numerical Rating Scales – a digital assessment scale with fixed steps, for instance, 
0-3, 0-10 with no descriptive terms except the end points. Again this scale has been 
validated in the evaluation of pain (Melzack, 1975; Wahlgren, 1995). 
 
One issue with the entire area of subjective reporting of disease is recall bias (Robinson & 
Clore, 2002a; D. L. Thomas & Diener, 1990). Basically, the further a report is from when it 
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happened, the more likely ‘semantic,’ stereotyped symptoms are reported over what was 
actually experienced, ‘episodic’ memory. For example, you ask someone if they had a nice 
summer holiday when you meet up several months later and they report that they did: in 
actual fact it was not very nice, their luggage was lost on the way out and the room was not 
great. However, looking back at this point it was good: it was a holiday after all, it is 
expected that it should have been enjoyable. It has been shown in medical situations that 
recorded subjective opinion is influenced by the peak and most recently experienced 
sensation and is not a true reflection of the entire experience (Fredrickson & Kahneman, 
1993; Kahneman, Fredrickson, Schreiber, & Redelmeier, 1993; Redelmeier & Kahneman, 
1996). Tellingly, one of two similarly painful experiences can be perceived as less painful by 
reducing the pain experienced at the end of the procedure (Kahneman et al., 1993; 
Redelmeier & Kahneman, 1996).  
 
As far back as 1989, a Swedish group (Wahlgren, Ekblom, & Hägermark, 1989) realised this 
potential for bias and attempted to tackle this by linking, first, a seven step graded fixed 
point non-verbal scale ('Paintrack') and second, a 100mm VAS, to a micro-computerised 
system ('Symtrack'). The system reminded the subject to carry out a score every hour by 
buzzing. The set-up encouraged good compliance and kept previous scores masked but even 
the most compliant subject found the system intrusive and they were less compliant after a 
few days. Nowadays, we are more used to personal portable devices and so I suspect 
acceptability would be improved. Whether compliance would be is questionable. Another 
interesting point is that ‘The 'Symtrack' was found to be limited by another of the down-
fallings of visual analogue scales: clustering of scores around the extremes and centre 
(Wahlgren, 1995; Wahlgren et al., 1989). This flaw in visual analogue scales is not well 
acknowledged but has been detected in all aspects of their use, not just in dermatology 
(Torrance et al., 2001).  
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Scales do not provide a qualitative assessment of itch, just a measure of intensity.  
Questionnaires add the dimension of quality. Based upon the McGill Pain Questionnaire 
(Melzack, 1975), the Eppendorf itch questionnaire (Darsow, Mautner, Bromm, Scharein, & 
Ring, 1997) was developed to incorporate the scales just mentioned and adds that other 
dimension, qualitative assessment. It was the first questionnaire created to capture itch and 
was designed for uraemic itch. The questionnaire integrates a score of intensity with three 
qualitative dimensions: the sensory, for example, temporal and spatial; the affective, viz fear, 
tension; and the evaluative which assesses the overall pain experience. The itch 
questionnaire is behavioural. A zero score represents, ‘I itch but never complain,’ whilst a 
score of five is, ‘I itch and itch interferes with rest plus/minus activity.’ It provides an ordinal 
scale - rank orders without equidistance (Darsow et al., 1997). Yosipovitch created another 
questionnaire designed to assess uraemic itch in 2001(Yosipovitch et al., 2001). Whilst both 
of these enquired in the present tense about symptoms (did not require participants to report 
back over a time period) they were of limited value as they did not yield a summative score. 
An Itch Severity Scale was published in 2007. It added a score to Yosipovitch’s 
questionnaire of 2001 (Majeski, Johnson, Davison, & Lauzon, 2007). Interestingly, it 
includes a diagram for the respondent to indicate where they experience the itch. A 
limitation to the usefulness of all these questionnaire is, however, that they are very detailed 
and take a long time to complete. 
 
More recently developed questionnaires have been described specifically as ‘Quality of Life’ 
(QoL) questionnaires. The idea of QoL was derived from the perspective that, if you are 
operating in a medical system where resources are scarce, you should distribute the wealth 
fairly. Health Economists developed the concept of Quality Adjusted Life Years (QALY’s) 
and these are presently used to justify health spending (Torrance, 1986; Tsuchiya & Dolan, 
2005). QoL questionnaires and scores can be generic, for all diseases, and specific for 
system, for instance, dermatology QoL questionnaires and even specific to a condition.  
! 45!
 
Since this section is about quantifying itch, specifically, I will mention the first specific QoL 
questionnaire to measure the impact of itch, the ItchyQoL (Desai et al., 2008). This was 
based on the dermatology QoL questionnaires, Skindex-12 and Skindex-29. It enquires about 
the present state and requires answers to impact overall (not for a specific time). A further 
itch-specific QoL questionnaire is the 5-D itch scale (Elman, Hynan, Gabriel, & Mayo, 
2010) measures five dimensions of living with itch: duration, degree, direction, disability 
and distribution. It yields a score and is quick to complete (5-10 minutes) It enquires about 
symptoms over the last two-weeks. Both of these questionnaires are quick to complete and 
yield a score. 
 
b)! Measuring the movements that occur as a consequence of itch: scratch 
 
The method of attempting to measure itch by using scratch as a proxy, is an obvious 
proposition based on its definition: scratch is ‘coupled’ to itch. Methodologically, it makes 
much more sense to quantify itch-related movement at night. Firstly, there is no issue 
regarding psychological overlay (consider how many people start to scratch at the mere 
mention of scabies) and secondly, organic conditions usually result in more itch at night 
(possibly a consequence of the warmth in bed). Thirdly, if motion monitors are to be used, a 
more specific result should be gained by a nocturnal study - other (rhythmical) motions, such 
as walking, should not complicate the picture. In this section I will report the chronological 
development of the field. 
 
The 1970’s 
Dr. Savin, a dermatologist based here in Edinburgh, was the first to publish his observations 
of nocturnal scratch in itchy patients (Savin, Paterson, & Oswald, 1973). His group used 
facilities available in Edinburgh’s Sleep Laboratory and in initial studies, four patients with 
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atopic dermatitis were directly observed overnight whilst recordings of EEG 
(electroencephalogram), EOG (electro-oculogram) and EMG’s (electromyograms) of the 
forearm and sub mental area were made. It was noted in this study (and again demonstrated 
in further similar studies of more patients with atopic dermatitis as well as other pruritic 
conditions (Savin, Paterson, Oswald, & Adam, 1975)) that there was a higher frequency and 
duration of scratching bouts in stages I and II of Orthodox sleep whilst fewer occurred in 
stage III and even fewer in stage IV of Orthodox sleep. REM (unorthodox sleep) resulted in 
an intermediate, stage II level of scratching. The pattern of scratching, it was felt, was 
associated with the physiology of the sleep stage rather than condition. The studies, the 
group proposed, offered frequency and length of scratching bouts as quantifying features of 
itch-related movements.  
 
Savin’s desire to study scratch at the various stages of sleep had been stimulated by his 
observation that, as far as antipruritics were concerned - and especially antihistamines - it 
had not been demonstrated whether they worked by hypnotic effects or by acting as ‘true’ 
antipruritics. By this time - the early Seventies - suspicion was starting to arise that, although 
histamine was the classical experimental inducer of itch, it was unlikely to play a large role 
in chronic clinical itch where no wheal and flare was apparent. Therefore, having 
characterised the pattern of scratching in relation to stage of sleep, Savin’s group went a step 
further and, in a trial whereby a sedating antihistamine and a non-sedating antihistamine 
were used in atopics, monitored in the sleep lab as before (Savin, Paterson, Adam, & 
Oswald, 1979), he showed that although the sedating antihistamine resulted in less 
scratching than the non-sedating drug, it’s hypnotic actions placed the patient in stages III 
and IV of sleep for longer. This meant that less time was spent in stages I and II of sleep 
where more scratching occurs. When stages I and II were analysed with respect to the 
number of bouts of scratching, no fewer occurred than in a usual night. Savin, therefore, 
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surmised that the antihistamine reduced the amount of scratching because of its hypnotic 
effects, not because it was a true antipruritic. 
 
One of the main limitations of Savin’s studies are that the equipment required and all the 
wiring meant that similar studies were impractical for the Outpatient situation. This also 
meant that the observed characteristics may not have been ‘natural’ due to the lack of 
familiar surroundings and because of the awareness of electrical pads and wires. The 
specialised situation also meant that a long-term study of chronic disease patterns would be 
difficult - a subject is unlikely to consent to reside in a sleep lab for weeks on end. I also feel 
that a knowledge of the stage of sleep is only necessary if a therapeutic's action is being 
evaluated, i.e., whether it is sedative or not, and is not required outside this scenario.  
 
One advantage to the EEG monitoring is that there can be no question about whether the 
patient is asleep or not. Scratch bouts were found to last longer if the subject was awake in 
this study. Due to the level of detail of observations made, useful information regarding the 
pathophysiology of itch, especially regarding the level of consciousness required to scratch 
was gained. Interestingly, the relationship between other repetitive movements, such as tooth 
grinding and scratch was made: both occur more often in stages I and II of sleep and, less 
often, in stages III and IV. Finally, and of great relevance to my studies into the frequency of 
action of human scratch, an EMG of the forearm is printed (Savin et al., 1973). Although the 
frequency of action is not stated in the paper I have calculated the EMG of the forearm as 
having a frequency of roughly 2Hz from the published ‘read-out.’ This frequency of action, 
2Hz, is consistent with my own observations of disease/itch-related movement which will be 
reported in this thesis. 
 
Another dermatologist, Professor Sam Shuster’s interest in quantifying itch, it seems to me, 
came from a different aspiration. His determination was to be able to measure a subjective 
! 48!
experience in order to aid the understanding of itch’s pathophysiology and also to allow the 
monitoring of chronic, itchy disease. In a paper published in 1975 (Felix & Shuster, 1975), 
two approaches made in order to quantify itch were described. In the first method, itchy 
patients were required to sleep overnight on the ward, in a hospital bed mounted on a metal 
frame with a proximity vibration transducer attached to one of the legs. Any body movement 
which moved the bed leg was detected by the transducer. The signal was amplified and 
continuously recorded on paper. The patients were directly observed (although not camera 
recorded) in order for the scratch movement read-out to be characterised/defined. The bed-
leg recordings detailed the frequency of action of individual movements as well as the 
frequency and length of bouts of movement. The read-outs allowed the discrimination of 
scratch (rhythmical around a straight baseline) from restlessness (less rhythmical with a 
wandering baseline) and other (non-rhythmical) movements. Scratch movements were 
calculated, purely from the bed-leg read-outs (not from observation of limb movement) as 
having frequencies of 2Hz. Again, this is within the range of frequency of itch-related 
movements that I have observed. The bed-leg monitor also showed that less itchy people 
scratched in less frequent bouts but that the length of bouts and frequency of action of 
scratch was similar. 
 
This group, having carried this study out and having noted limitations - especially regarding 
numbers of patients that could be studied in the one adapted bed on the ward - adapted a self-
winding watch which logged a cumulative overnight score of itch and assessed this as an 
‘itch-monitor.’ The main advantage, it was felt, was that if the watch's use proved successful, 
it could be used in the Outpatient scenario and the equipment would be unobtrusive. Using 
the bed-leg machine as the ‘gold standard,’ the self-winding watch scores were compared to 
this and to subjective itch scores. The overnight-movement score correlated well with the 
bed-leg measured scratch-movement time. The watch scores also correlated well with the 
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patients’ subjective score of itch: mild, moderate or severe. Overall, itchy patients were 
shown to have higher watch scores than controls (Felix & Shuster, 1975). 
 
Unfortunately, the self-winding watches were subject to criticism: they were inadequately 
sensitive to respond to all scratch movement; the mass of the pendulum meant the devices 
had positional sensitivity; the response was related to the velocity of the movement so that 
vigorous scratch registered a higher score than gentle scratch. Due to all of these facts, it was 
argued that the calibration technique employed (on a turntable revolving at a constant 
velocity) was invalid (Summerfield & Welch, 1980) The fact that the watch presented a 
cumulative score was another drawback as a pattern of movement could not be defined and 
scratch could not be separated from other movements.  
 
The 1980’s 
Dermatologists are not the only specialists whose patients present with itch. Some devices 
designed to measure scratch have arisen from a desire to quantify cholestatic itch. In 1980, 
Summerfield described an electromagnetic movement detector which provided a cumulative 
duration of nocturnal limb movements (Summerfield & Welch, 1980). The detector was a 
little larger than a wristwatch and was tested when worn on the wrist/ankle. The group had 
studied Shuster’s self-winding watches closely and attempted to improve on the design. 
Their sensor, which they claimed measured in all directions, registered a score when a 
movement exceeded a certain amplitude threshold (set after observing simulated scratch). 
The registered movement caused an increment in a mechanical or quartz watch. The devices 
were tested on Liver Ward in-patients - some with cholestasis and itch, some controls and 
some restless patients (they had non-itchy liver disease but due to encephalopathy did not 
sleep well). The device was sensitive enough to separate all three groups and there was good 
correlation with subjective scores. The group argued that, as the itchy patients moved their 
arms relatively more, then their movements represented scratch - the restless moved their 
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legs relatively more. Interestingly, a few patients with cholestasis were examined before and 
after biliary drainage interventions and the subjective score of itch improved before the 
objective score of movement, they expected to feel better, we assume. Unfortunately, the 
lack of longitudinal discrimination throughout the night (resulting from the cumulative 
score) and the motion sensor's not being specific for itch presumably accounts for these 
devices limited clinical use. 
 
These early motion sensors, mounted on one limb, were too insensitive to register 
movements of other parts of the body and thus missed many of the non-stereotypical itch-
related movements such as rubbing the face into the pillow or even legs rubbing together. 
Newer digital accelerometers (such as I have used) are so sensitive that even when the 
accelerometer is worn on the right wrist, scratching with the left hand is registered, as is 
truncal or leg movement (Benjamin et al., 2004; Bringhurst, Waterston, Schofield, 
Benjamin, & Rees, 2004).  
 
Also in 1980, Aoki described the use of another new device (Aoki et al., 1980). It involved a 
paper strain gauge being attached to the back of the hand and relayed to an amplifier. In 
conceiving the design, it had been hoped that the finger movement associated with 
scratching could be measured and filtered according to the frequency of movement. The 
group described how they developed a computer analysis system for the strain-gauge read-
out and decided to exclude movement outside 1-3Hz and only registered movement lasting 
more than 2 seconds – the basis of this was simulated scratch in controls. The group chose to 
study atopics, generalised eczema patients and controls who were studied overnight, on the 
ward and scratch was expressed as ‘total scratching time.’ Analysis of the read-outs showed 
that the device could separate those with itchy skin from controls and did not separate the 
atopics from those with generalised eczema. In a separate study (Aoki, Kushimoto, 
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Hishikawa, & Savin, 1991), the system was used alongside EEG monitoring and reflected 
Savin’s previously discovered pattern of scratching activity in itchy conditions.  
 
One problem with this study’s design would appear to be that the filter frequency was 
decided after analysing a paper read-out of simulated scratch in a normal volunteer who was 
awake – could this be equivalent to an atopic's scratch overnight? It is known that 
decerebrate cats scratch at a lower frequency than cerebrate (Kuhta & Smith, 1990; Nojima 
& Carstens, 2003), and human studies have demonstrated that scratching whilst asleep is 
different from that when awake (Savin et al., 1975). It may have been more reliable to 
observe elicited experimental itch. However, the range of frequency for scratch-action which 
the group adopted is consistent with my detailed observations of subjects genuinely suffering 
from itch which I will present later. Despite the success of the studies using this system, 
Aoki’s design has proved not to be robust enough for long-term use; mainly because the way 
the device had to be fitted made it impractical for home-use and resulted in the usual 
problems related to obtrusiveness of equipment on human behaviour.  
 
The 1990’s 
An unusual method to measure scratch movement appears in the literature in 1991 
(Mustakallio, 1991). Mustakallio describes his SCRADAR (Scratch Radar). The only 
information available on this device - which appears never to have been used in a clinical 
study - is an abstract. The device was described in more detail and demonstrated at a 
meeting. The SCRADAR required the subject to be covered in a fluorescent ointment whilst 
a radar was trained on the subject. The radar noted a disturbance in the fluorescence that 
occurred after scratch movements. No description on the frequency of radar sweeps or on 
how the data would be logged/analysed is given. It is difficult to ascertain how problems 
such as the cream rubbing off overnight with the usual nocturnal restlessness would have 
been avoided. The device appears not to have been used clinically at all. 
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There is a six-year gap in the literature before another device is described. In 1997 a 
‘Scratch-Monitor’ was tested in atopics versus controls (Endo, Sumitsuji, Fukuzumi, Adachi, 
& Aoki, 1997). This device was a 25g box with a pressure sensor in the base which was 
taped to the back of the hand.  After three or more pressure changes had occurred the number 
of scratch movements to occur was counted and the sensor was designed to filter out 
movements outside 1-2 Hz (again, this range was chosen after examining readouts from a 
sensor attached to a volunteer simulating scratch, the frequency stated results from a 
machine read-out, not direct observation). In practice, however, the design meant that there 
was considerable potential for variability in score: depending on how tightly the device was 
taped down (as it was a pressure sensor) also clenching the fist, for example, gave 
anomalous results. The authors talk about the 'frequency of scratch' being measured, this is 
not the case, however. The sensor, it seems was not sensitive enough to detect all movement 
and so a reliable frequency of cycles per second could not be made. They therefore rated the 
outputs by giving them an arbitrary number but then referred to the scores as 'frequency.' 
Use of the device was not extensive most probably due to its inconsistent sensitivity. 
 
Two very similar systems involving piezoelectric sensors were inspired by the desire to 
quantify cholestatic itch (Molenaar, Oosting, & Jones, 1998; Talbot, Schmitt, Bergasa, 
Jones, & Walker, 1991). A piezo-electric pressure-sensor (acting as a contact-microphone) 
was glued to the nail of the middle finger then attached by a wire to a data processor and 
logger. The original design by Talbot's group was not portable and necessitated a hospital-
based study whilst Molenaar’s design utilised a chip, stored in a device worn on the waist to 
store data for later downloading. The pressure sensor was set to filter out movement outside 
30 -100 Hz which was calculated, by Fourier transformation, as the frequency of nail 
vibration when scratching occurred. This appears to be a very high frequency until the 
length/flexibility of the nail as well as the ridging of skin is considered. The original and 
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improved piezo-electric devices have been used in clinical trial settings with some success 
(Bergasa et al., 1995; 1998; 1992). The device is, even so, rather impractical for day-to-day 
use and does not lend itself for chronic use - the subject cannot carry out their normal 
routines (including showering or bathing) with the device glued to the nail and probably do 
not behave naturally as they are aware of the system. Fitting the sensor requires trained 
hands. Apart from these standard criticisms, the sensors themselves are delicately hand-made 
items open to variation resulting in worries about score variability between devices.  
 
In being very specific about the motion to be measured it is possible that some itch-related 
movements are excluded. The paper-strain gauge device, the ‘Scratch-Monitor’ and the nail-
mounted monitor all aim to quantify finger movement and specifically scratch. It is evident, 
on watching itchy patients, that apart from the expected stereotypical scratch movements 
made with the hands, other movements also occur including rubbing with the hands, wrists 
and feet and rubbing the face into the pillow. A significant amount of time is spent rubbing 
the eyes with a balled fist. The paper-strain gauge, the 'Scratch Monitor' or the nail-mounted 
monitor would not detect these types of movement; therefore, a considerable amount of itch-
related movement would go unnoticed.  
 
Although time-intensive with regard to data processing, the present gold standard of scratch 
quantification is infrared video recording of itch-related movement. This was described in 
1996 by Ebata's group (Ebata, Aizawa, & Kamide, 1996). Adult subjects (atopics and 
controls) were invited to the ward, videoed overnight and then the amount of time spent 
scratching compared between the two groups. The atopics were found to spend hundreds to 
tens of thousands of seconds scratching compared to the zero to one hundred seconds of 
controls.  The same system was used, in hospital, to further characterise nocturnal scratch in 
atopics (Ebata, Aizawa, Kamide, & Niimura, 1999)  and also to evaluate the effect of 
hypnotics on scratch (Ebata, Izumi, Aizawa, Kamide, & Niimura, 1998). Ebata’s group 
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aimed to quantify the frequency of bouts only, not the frequency of action of scratch 
movements. Due to the fact that all itch-related movement can be logged and separated from 
restlessness, the system would appear to be sensitive and specific. Some difficulties occur 
when movement occurs under the cover, but since all the vast majority of itch-related 
movement is rhythmical, most of the movement under the covers can be classified and 
recorded (although rub versus scratch cannot be separated. A drawback to the system is that 
for some subjects it proves difficult to ignore a camera, video recorder and infrared light in 
the bedroom – even if it is their own. 
 
The 2000’s 
Most recently, digital accelerometers have become the movement monitors of choice when 
assessing itch. Two groups have validated these machines against infrared video recordings 
although only Rees’ group has observed subjects in the familiar surroundings of their homes 
(Bender, Leung, & Leung, 2003; Benjamin et al., 2004; Bringhurst et al., 2004).  
Digital accelerometers were developed for the field of sleep research, for assessing tremors 
and to detect seizures. Available from two companies, commercially, they are similar in size, 
shape and weight to a wristwatch and, as such, are relatively unobtrusive. Their technology 
is described in detail in Chapter 2. 
In validation studies the accelerometers scores showed a high correlation with the video 
observations and proved able to separate those with itch (atopics and others) from controls 
(Benjamin et al., 2004; Bringhurst et al., 2004; Ebata, Iwasaki, Kamide, & Niimura, 2001). It 
was observed in these studies, too, that the itch-related movements were not purely of the 
scratch-type, rubbing and writhing also occurred (Benjamin et al., 2004). Atopics were found 
to be asleep or motionless, on average, 46 minutes less than non-itchy controls - it must be 
assumed that atopics, therefore, expend much more energy overnight. The group showed that 
subjective scores (VAS of itch and sleeplessness) did not correlate well with the objective 
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accelerometer scores (Benjamin et al. 2004; Bringhurst et al. 2004). This result had been for 
the child subjects - where the parent is required to fill out the VAS score - but in fact, there 
was a (slightly) better correlation for children's scores than for the adults who had scored 
themselves. 
The accelerometers are not, however, able to discriminate between itch-related movements 
and generalised movement. Even after one group set a 'threshold value', accelerometer scores 
were found not to be discriminatory (particularly against subjects getting up in the night, for 
example (Ebata et al., 2001)). The fact that the devices cannot discriminate between 
movements may not be considered a great downfall if it is accepted that, due to discomfort, 
itchy people do just move more that controls (and that therefore a cumulative score of 
movement is satisfactory). The lack of specificity may explain why the expected pattern of 
intensity of itch and related scratch according to stage of sleep throughout the night (as 
observed in Savin’s studies) has not been demonstrated yet. 
The present 
When I first entered this field of research, the accelerometers were ‘cutting edge 
technology.’ At this point, I suspected that the (distant) future of the monitoring of itch-
related movement was most likely to be a spin-off of CGI (Computer Generated Image) 
technology such as that used in the 'movie industry.' Sensors, which resemble ECG pads, are 
placed on specific sites of the body, limbs, even parts of the face and these provide reference 
points so that a computer, wirelessly tuned into these reference points, can generate an image 
which moves realistically. One example of the development of this technology used in 
medicine, is a vest which can monitor respiratory rate and ECG by using sensors woven into 
the cloth ('Smart shirt,' SensaTex, New York). This has been used to monitor firemen as they 
carry out their work. Another example is of sleeves with monitors woven inside, which have 
been developed to help assess the extent of flexion/extension after joint replacement.  More 
ambitious designs include a wireless body area network of intelligent motion sensors which, 
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it is hoped, will assist rehabilitation (Jovanov, Milenkovic, Otto, & de Groen, 2005). The 
wearable networks can be integrated into clothing and use wireless technology - for ease of 
wearing and for transmission of data. The sensors transmit to a 'personal server,' for 
example, an enabled PDA, mobile phone or home computer carried on/nearby the subject 
and the 'personal server' downloads, remotely, to the health provider's computer. The health 
provider uses the information to direct/develop the rehabilitation exercise programme.  
 
I did not predict the rapidity of development of technology for the fitness/personal training 
industry. Vast amounts of information can be gathered from technology which is not just 
portable but wearable (Jawbone, Applewatch, etcetera). As it stands, these devices have 
become ubiquitous and possess accelerometers, gyroscopes and are GPS enabled and so 
detailed movement data could be mined.  What is disconcerting, is the report of variable 
sensitivity depending on the device and processing software. Indeed, worryingly, I detected 
processing errors in the software supplied with both of the accelerometers I used for my 
studies. Therefore, whilst the idea of an app to install on a patients’ mobile device is 
attractive, there would be issues with interdevice variation which would make stansardised 
treatment protocols difficult to impose. Information from these modern, commonplace 
devices have a feature which would help solve a problem I found in my research: how to 
discern generalised locomotive movement from itch-related. GPS movement information 
would be able to discern this. No itch-app is available yet, but it not a huge leap to imagine 
that one could be designed. Not only could this capture objective movement data but offer 
the availability of daily, or more frequent diarising of subjective itch – one of the least biased 







A number of tools have been developed with the goal of measuring the functional burden of 
disease as experienced by the patient. I introduced the idea in the ‘Quantification of itch.’ In 
a medical and economic climate where resource is scarce, the assessment of impact of 
disease and how it may be influenced by medical intervention, has become a major research 
programme. In England, the British Association of Dermatologists and the National Institute 
of Health and Clinical Excellence (NICE) has advocated the use of the Dermatology Life 
Quality Index (DLQI) and Psoriasis Area and Severity Index (PASI) as disease assessment 
tools for doctors to use on patients with psoriasis to determine whether they should receive 
certain expensive biological therapies (C. H. Smith et al., 2005) 
(http://www.nice.org.uk/Guidance/TA134).  
 
The measures employed in this study have been chosen because they are used ubiquitously 
or are recommended in guidelines from bodies such as NICE (National Institute for Clinical 
Excellence). Descriptions have been limited to those directly pertinent or used in this thesis. 
 
Disease-measurement tools, are divided into those assessing the impact of disease and those 
assessing disease-extent. As previously mentioned, the aim of developing these tools was to 
have a standardised measure, across the board. The problem with the disease-extent tools 
which require an estimation of skin involvement, is that intra and inter-observer variability 
occurs (Charman, Venn, & Williams, 1999; 2002), even with the aide of the ‘rule of 9’s’ 
(Berth-Jones et al., 2006). 
 
Disease impact measures used in this thesis 
Disease-impact measures can be divided into generic, system specific and disease specific. 
The ones used in my studies follow. 
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1.! Generic: Global health question (GHQ).  
‘In general, would you say that your health is excellent, very good, good, fair or poor?’ 
(Ware, 1976). Poor scores ‘0’ and Excellent scores ‘4.’ The question takes seconds to 
complete. It is able to provide an overall assessment of patient-perceived health. Although 
deceptively simple, the question is powerful: decay of results has been demonstrated towards 
‘end of life. (Bjorner, 2005)’ It is thought that it is as a function of its simplicity that 
respondents are able to combine information from all psychological and physical domains to 
give an unbiased, complete response. 
 
2.! Generic: SF-36 or RAND-36 
This is the most extensively used health related quality of life questionnaire. It consists of 96 
items and takes 5-10 minutes to complete (Stewart, Hays, & Ware, 1988; Ware & 
Sherbourne, 1992). The system was developed from the Rand Corporation's Health 
Insurance Experiment in the U.S.A. (Ware & Sherbourne, 1992). Questions pertain to the 
individual's typical day, the past 4 weeks, and experiences in general. The SF-36 measures 
health-related quality of life with 36 items along eight dimensions yielding one physical and 
one mental component summary score. The eight different dimensions are: (i) physical 
function: limitations in physical activities because of health problems; (ii) role plus or minus 
physical function: limitations in usual role activities because of physical health problems; 
(iii) bodily pain; (iv) general health perceptions; (v) vitality: energy and fatigue; (vi) social 
function: limitations in social activities because of physical or emotional problems; (vii) role 
plus or minus emotional function: limitations in usual role activities because of emotional 
health problems; and (viii) mental health. The eight dimensions range in score from 0 to 100, 
with higher scores indicating higher levels of function and/or better health. 
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3.! System specific: Dermatology Life Quality Index (DLQI). 
The DLQI was developed by Finlay and Khan in 1994 (Finlay & Khan, 1994) as a disease- 
specific measure intended to be simple, compact and applicable to patients with any skin 
disease. The DLQI is a questionnaire that measures how much a skin problem has affected 
the life of the patient over the previous seven days. It consists of ten items, six dimensions 
and one overall summary score. Each question has four answering alternatives: ‘not at all’, ‘a 
little’, ‘a lot’ and ‘very much’, with corresponding scores of 0, 1, 2 and 3, respectively. The 
overall summary score aggregates the score of each item and ranges between 0 (the best 
score) and 30 (the worst score). The six dimensions are: (i) symptoms and feelings; (ii) daily 
activities; (iii) leisure; (iv) work and school; (v) personal relationships; and (vi) treatment. 
This tool was developed after studying 120 consecutive dermatology patients and evaluating 
the areas of life most affected. The designers of the tool had practicality in mind - it was 
considered a priority that the tool should be short and quick to answer, in order to aide 
assessment during clinic visits –and they achieved this. In a ten year review of the DLQI’s 
use, it was noted to have been used in 36 different skin diseases and to have been translated 
into 21 different languages (V. Lewis & Finlay, 2004). 
 
4.! Disease-specific: Visual Analogue Scale (VAS),  
These can be used as a measure of a range of specific symptoms such as itch or pain 
(Hägermark & Wahlgren, 1992; Wahlgren, 1995). They have been described in an earlier 
section (IV, Psychophysics). In my studies and in other validated scores (Atherton et al., 
1993) the visual analogue scales are standard 0-100mm scales or lines where 0 represents the 
most negative experience and 100 the most positive. The participant is required to make a 
mark on the line corresponding to the extent relevant to them at that time.  Three horizontal 
visual analogue scales were used to assess the respondent's subjective measure of disease 
activity. The first question assessed the respondent's amount of itch on that day, with anchors 
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of ‘No itch’ (at 0) and Most terrible itch’  (at 100). The second VAS assessed sleep 
disturbance, with anchors of ‘No sleep’ (at 0) and ‘Best possible sleep’ (at 100). The third 
assessed disease extent, with anchors of ‘No disease’ (at ) and ‘Worst possible disease’ (at 
100). 
 
5.! Generic: The Day Reconstruction Method 
This is a questionnaire which employs experience sampling methods to gain a report of 
emotions experienced whilst avoiding some the recall biases frequently encountered in 
questionnaires (Kahneman, 2004). Experiential Momentary Assessment (EMA) is a way  to 
access experiential rather than stereotyped semantic memories (Robinson & Clore, 2002b; 
2002a). The gold standard for accessing this memory is on-line reporting but the Day 
Reconstruction Method was developed as a more ’practical’ solution: it helps the respondent 
access the experiential memories by making them write a detailed diary of the previous day 
and then answer questions about each episode of the diary. The questionnaire consists of 
four packets: 
 
Packet 1:  Global satisfaction scores and demographics 
Packet 2:  Diary of previous day, required to break the day down into episodes 
Packet 3:  Questions about each of yesterday’s episodes 
Packet 4:  Questions about yesterday in general. 
The questionnaire, according to the literature, takes 30-45 minutes to complete. This 
questionnaire has never been used in medical or dermatological research previously. 
 
Disease-extent tools used in this thesis 
There are a myriad of disease-extent tools available to dermatologists. An especially large 
range are available for scoring atopic dermatitis: EASI (Eczema Area Severity Index) (Tofte, 
1998), SASSAD (Six area, Six sign, Atopic Dermatitis Score) (Charman et al., 2002), NESS 
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(Nottingham Eczema Severity Score) (Emerson, Charman, & Williams, 2000), to name a 
few but SCORe for Atopic Dermatitis extent (SCORAD) was most suitable for my studies 
as it integrated physician-assessed disease extent with subjective scores of itch and insomnia. 
I used the subjective itch score to compare with my objective accelerometer score.  
SCORAD is the recognised extent tool  for the European Working party for atopic dermatitis 
(Atherton et al., 1993; Kunz et al., 1997). SCORAD takes roughly five minutes to complete:- 
 
First, SCORAD involves an estimation of area affected (A): a diagram using the ‘rule of 
nines’ is shaded to provide an interpretation of percentage of area affected. Second, severity 
of clinical signs is scored (B): a score of ‘0’ for absence, through mild, moderate and severe, 
which scores ‘3’, is applied for each of a) erythema, b) oedema/papulation, c) oozing/crust, 
d) excoriation, e) lichenification and f) dryness. Finally, VAS scores of itch and insomnia are 
completed (C): ‘0’ indicates no itch or no sleeplessness and ‘100’ indicates worse possible 
for itch or sleeplessness. These details are processed to give a score through the equation, 
A/5 + 7B/2 + C. !
 
Psoriasis Area and Severity Index (PASI) (Fredriksson & Pettersson, 1978; Marks, 1989)was 
my obvious choice when the psoriasis extent studies were proposed. This is the disease 
extent tool advocated for psoriasis by NICE (National Institute of Clinical Excellence) (C. H. 
Smith et al., 2005).  This tool requires no subjective input from patients and so it is a pure 
extent tool. PASI is assessed as follows:- 
 
First, a representative area of psoriasis is selected for each body region: head and neck, arms, 
trunk and legs. The intensity of redness, thickness and scaling of the psoriasis is assessed as 
none (0), mild (1), moderate (2), severe (3) or very severe (4).  
Second, the three intensity scores are added up for each of the four body regions to give 
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subtotals A1, A2, A3, A4. Each subtotal is multiplied by the body surface area represented 
by that region: A1 x 0.1 gives B1, A2 x 0.2 gives B2, A3 x 0.3 gives B3, A4 x 0.4 gives B4. 
Third, the percentage area affected by psoriasis is evaluated in the four regions of the body. 
In each region, the area is expressed as nil (0), 1-9% (1), 13-29% (2), 30-49% (3), 50-69% 
(4), 70-89% (5) or 90-100% (6). 
Fourthly, each of the body area scores is multiplied by the area affected: B1 x (0 to 6) = C1, 
B2 x (0 to 6) = C2, B3 x (0 to 6) = C3, B4 x (0 to 6) = C4. 






Over the past twenty-five years, the field of cognitive behavioural psychology has 
developed. It has become important to measure well-being or happiness. This importance is 
borne out of continuing allegiance to Jeremy Bentham’s ideas: maximising goodness for all, 
to clumsily paraphrase. If it has proven hard to capture itch, I am only relieved that I have 
not had to capture happiness: there is no reflex motor reaction for this. In any event, in trying 
to measure happiness, a number of problems surrounding the measurement of subjective 
states, quality of life and utility have been revealed (for reviews see ‘Well-being: the 
Foundations of Hedonic Psychology’ by Daniel Kahneman (Kahneman & Diener, n.d.)) 
 
Individuals appear to have trouble accessing their own feelings (Robinson & Clore, 2002a; 
2002b; D. L. Thomas & Diener, 1990). The way information is gathered may alter, or 
influence, the patients own perception of their own feelings (McColl, 2005; Robinson & 
Clore, 2002a). Cognitive limitations may limit the value of subjective knowledge. This 
means that patients, due to adaptation or the hedonic treadmill, may not be able to remember 
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changes in their functional status, nor predict the effects of particular interventions or change 
in state (Kahneman, Krueger, Schkade, Schwarz, & Stone, 2006; Redelmeier, Rozin, & 
Kahneman, 1993).  
 
In an effort to translate these findings to my research, I concentrated on the effect of two 
biases: framing and focusing on commonly used subjective disease tools. 
 
‘Framing bias’ is the term widely used to explain the bias that stems from how the feeling, 
emotion or symptom is enquired about. Questions can be ‘framed’ in language or presented 
in a context that may elicit a stereotyped answer, for instance, by implying than an aspect of 
disease should be considered as a negative phenomenon, leading a respondent who may not 
have considered this aspect as negative before could, in this situation, consider it as such 
(McColl, 2005; Wright & Goodwin, 2002). As will be seen later, the enquiries in the DLQI 
questionnaire were rewritten in seemingly more neutral frames to assess whether it was 
vulnerable to this type of bias. 
 
‘Focusing’ (bias) describes the way that the immediate context may alter how individuals 
perceive their own symptoms. For example, patients frequently anchor or skew their own 
assessment of disease by reference to others who they think are less or more fortunate (Del 
Missier, Ferrante, & Costantini, 2007; Kahneman et al., 2006; McColl, 2005; T. D. Wilson, 
Wheatley, Meyers, Gilbert, & Axsom, 2000). In order to test this I utilised sets of words 
used in psychology research which are proven to elicit emotions: negative, positive and 
neutral to see if response patterns changed in the face of this focalising. I also used a film 
about a person living with a distressing skin disorder in another study to see if the focus 







Ethics committee approval for these studies was granted from Lothian Ethics 
Committee. The study reference numbers issued were: 
1)! LREC/2005/JLR/2/CM) 05/S1104/25*
2)! Derm/06/JLR/1/CM (6/S1104/56) 
 
So far as they can apply, I believe the protocols used in this work are in line with the 
Declaration of Helsinki (URL: http://www.wma.net/e/policy/b3.htm) and subsequent 










•! The level of significance was set to 0.05, throughout the studies.  
 
Comparison of two groups:  
•! If data was parametrically distributed, Student’s t test was undertaken.  
•! If the groups were within person, paired t tests were applied and if not 
unpaired t tests were applied.  
•! In some studies, the variance was difference between groups, specifally in 
accelerometer studies where subjects were compared to controls 
(heteroscedasticity), and so a t test to compare means of groups with 
different variance were used.  
•! If data was non-parametrically distributed, the Kruskal-Wallis test was 
applied. 
 
Comparison of several groups: 
•! In this thesis, when comparison of variance across several groups was 
required, the data was found to be normally distributed and so one-way 
ANOVA was applied. 
 
Correlation and correlation coefficients: 
•! Perfect correlation is represented by an ‘r’ level of 1.  
•! As a general ‘rule of thumb’ in this thesis, where mechanical components 
were being tested (for example, the accelerometers against each other), the 
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relationship was required to be as near to 1 as possible and preferably, over 
0.95, as this is the accepted standard in engineering/mechanics.  
•! When biological systems were being compared (to each other or to 
mechanical components) an r level of over 0.5 was considered to represent 
a strong relationship.  
•! Pearson r was used to describe normally distributed, linear data.  
•! Spearman rank correlation was used for non-normally distributed data.  
 
Regression analysis: 
•! Regression is used in Chapter 5. Following inspection using univariate analyses, 
non significant terms were removed from the regressions, and examination of 
factors were performed using Holm’ s correction for pairwise t-tests 
•! Linear analysis was employed in Chapter 7. R and R square have been presented 
along with standard error and ANOVA’s. The intercept, slope and standard error of 
the slope are presented too. 
 
Autocorrelation: 
•! Longitudinal scoring patterns of objective accelerometer measured itch and 
subjective VAS score in Chapter 5 were analysed for autocorrelation.  




•! Most of the experiments in Chapter 5 ‘nested’ previous conclusions in each 





•! Formal power calculations were not performed as the experiments and studies 
described in this these were exploratory. There were no previous studies upon which 
to base power calculations. 
 
Software: 
•! All software was run on Mac OS X (Apple, California, USA). 
•! For general data management, Excel (Microsoft Ltd,, Seattle, USA). was used. 
•! Basic statistical analysis was carried out in Excel, using its Data Analysis plug-in. 
•! IBM SPSS, version 21, (IBM Corporation, New York, USA) was used for my 
analysis 
•! R, version 2.9 (R: The R Project for Statistical Computing, https://www.r-
project.org) was used for analysis by Professor Rees. 
 
The majority of statistical analysis was carried out by me. Professor Rees undertook the 
autocorrelation and regression analysis presented in Chapter 5 and published in the paper 












People have often asked me what my field of research is. I have explained that I am 
attempting to measure itch. The usual response is polite interest and then a change in 
conversation subject. A couple of people have asked me what ‘I.T.C.H.’ stands for. A few 
have asked to hear some more detail. If I have been invited to expand, I have explained that 
itch is coupled to scratch and that this is very fortunate as, unlike other sensations, there is a 
coupled physical response. I have explained that this scratch movement can be observed to 
give an ‘itch-score.’ I explain that direct-observation (and preferably a recording of this) is 
the most accurate way to measure the scratch movement that ensues from the itch sensation.  
 
Direct observation of itch-related scratch movement is not a new phenomenon. The first 
studies started off in ‘Sleep laboratories’ (Felix & Shuster, 1975; Savin et al., 1973; 1975) 
and, as technology improved and became more portable, it was possible to actually 
undertake the study in the subject’s own home (Benjamin et al., 2004; Bringhurst et al., 
2004). Studying participants in their own homes is obviously preferable on many levels, but 
most particularly because the subject’s behaviour does not have the potential for being 
altered by being in an ‘unnatural’ situation. 
 
Direct observation of itch related scratch movement remains the ‘gold-standard’ to which all 
other methods of itch-related scratch movement quantification need to be measured against. 
It therefore made sense, since my purpose was to quantify itch, to start my research using 
this technology. In this chapter, I present details on the system I developed for my particular 






The system comprised: 
1) an infrared light source  
2) an infrared camera on tripod 
3) a time generator 
4) a particular video cassette recorder (VCR): Panasonic NV-HS880 fitted with ‘Extra long 
play.’ 
 
Figure 1.1 is a photograph detailing the equipment. 
 
The infrared source was positioned to shed light across the subject’s room. The infrared 
camera was positioned on a tripod to allow an unimpeded view across the subject’s sleeping 
form. The camera was then connected to the video cassette recorder (VCR) and the recorder 
switched on. A specific type of VCR was required as this allowed ‘Extra long play’ which 
meant that a standard 4-hour VCR tape could record over 12 hours.  
 
The mini-television was connected to the video recorder and the ‘Time generator.’ The 
‘Time generator’ was set to accurate time. The mini-television allowed a way of ensuring 
that the ‘Time generator’ output was detected in the recording and that the positioning of the 
camera was seen to be satisfactory for capturing an unimpeded view of the subjects’ sleeping 
form.  
 
A 4-hour tape was inserted into the VCR. The VCR was set to record in ‘Extra long play’ 
mode and a test recording made for a few seconds and functionality checked. The recording 
was then stopped and the VCR left, turned on. When bedtime came, the parent was requested 
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to press the red, labelled, ‘Record’ button. At waking time, the parent was requested to turn 
the VCR off. Parents received full instructions in written, verbal and demonstrated forms. 
 
This system improved upon previous systems which only allowed eight hours continuous 
recording: a child may have been sent to bed at 18:00hr and, if the recording was started 
immediately, recording would then cease at 02:00hrs, before the child awoke and out-with 
the Actiwatch’s original Macro’s output times, 22:00hr until 06:00hr. As I will explain, I 
created a new Macro which extended the available Actiwatch Plus-monitored time (see 
Chapter 2). 
 
It should be noted that the system was placed as unobtrusively as possible within the room and 
merely effected an insignificant red-glow along with the quiet purr of the VCR and so it was 





































The objective of this study was to characterise the frequency, in Hertz (Hz), of human, 
nocturnal itch-related movement. 
 
Background 
When considering the design of a specific itch-monitor, there are two features of disease-
related movement which can be exploited: the frequency of action of the movement and the 
length of bout of movement. Definitive data on the frequency of action of human itch-related 
movement was not available in the literature (whilst length of bout was (Savin et al., 1973; 
1975)). Data on the frequency of action of other animal scratch are available: murine scratch, 
10-30Hz (Brash et al., 2005); rat scratching, average frequency 8Hz (De Castro-Costa, 
Gybels, Kupers, & Van Hees, 1987) and cat scratch, average frequency 6.5Hz (Kuhta & 
Smith, 1990). Observations of primates in the literature state the frequency of the bouts of 
scratching, not the frequency of action of scratch. Without knowing the frequency of action 
of human scratch it was not possible to know what kind of range of frequencies as measured 




Eight children, all of whom had a diagnosis of atopic dermatitis, were studied. The children 
were recruited from a secondary care Paediatric Dermatology clinic and had been were 
diagnosed as having atopic dermatitis by a Consultant in the clinic (as described by Hanifin 
and Rajka (Hanifin et al., 2001)). Children with atopic dermatitis were chosen because their 
having itchy skin is a requirement for their diagnosis - so they would be expected to reliably 
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demonstrate itch/disease-related movement. The severity of disease was, as would be 
expected by the subject’s being recruited from secondary care, moderate: SCORAD range 
13.7 to 90.5, mean 33.3, median 32.2. The group's median age was 6 years (age range 2-




Each study subject's nocturnal movements were observed using infrared video recordings. 
This involved my visiting the subject's house and setting up the infrared videoing system 
(see Section I.II). 
The subject's parent was issued with verbal and written information including being asked to 
press the 'Record' button on the VCR when the child went to bed. The equipment and tape 
was recovered from the subject's house the next day. The infrared video recordings were 
played back in 'real-time' and the following observations were made: 
 
1)! For each hour of sleep the next 
a.! generalised movement, 
b.! scratch, 
c.! rub, 
to occur after a specified, randomised time-point was observed and characterised. 
 
2)! For each of the episodes of movement,  
a.! the length of the bout, measured in seconds with a stopwatch and 
b.! the number of complete cycles of movement to occur within the episode 
were recorded. A ‘bout,’ or cycle of movement was counted when the part of the 
body being observed reached its starting point again. 
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A firm definition of each category of movement was made. 
a)! Definition of scratch: a rhythmical movement during which the fingernails make 
contact with the skin. 
b)! Definition of rub: a rhythmical movement where fingernails are not the point of 
contact with the skin, for example, rubbing the wrists together, rubbing eyes with a 
balled fist. 
c)! Definition of generalised movement: a non-rhythmical, adjusting movement. 
 
When the frequency of an action is described, in the unit Hertz (Hz) it is considered to 
represent the number of complete cycles of movement completed in a second. Therefore, the 
observations were converted into frequencies by dividing the number of completed cycles to 
occur in the observed episode by the number of seconds the episode lasted for. 
 
The range of overnight recording was from eight to twelve hours, depending on how long the 
child slept for. Potentially, there should have been eight to twelve observed episodes for each 
category of movement, however, sometimes a subject did not scratch or rub in a one-hour 
period in which case no observation could be made.  The definition about whether an 
observed action was scratch or rub (viz. contact with fingernails) was strictly adhered to and 
if there was any uncertainty then consecutive episode was studied. 
 
Results 
All of the subjects exhibited itch/disease-related actions. All demonstrated stereotypical 
scratch and rub movements. As noted in previous observatory studies, the children also 
demonstrated what may be considered non-stereotypical movements such as: rubbing the 
wrists together, rubbing the feet together, generalised body writhing-rubbing, eye-rubbing 
and kneeling up to rub the face into the pillow. Although non-stereotypical, these 
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movements were all rhythmical. All of the subjects also 'turned over,' adjusted the 
bedclothes and made other generalised, non-rhythmical movements. 
 
The mean ‘frequencies of action’ for each movement were: 
•! Generalised movement, 0.48Hz (standard deviation, ± 0.25). 
•! Rub, 0.98Hz (standard deviation, ± 0.36). 
•! Scratch, 1.85Hz (standard deviation, ± 0.55). 
 
Individual’s mean ‘frequency of action’ for each observed category of movement and the 
standard deviation is listed in Table 1.1. When analysed by one way ANOVA, the categories 
of movement are significantly different: F2:21=56, p<0.001. There was some overlap of 
frequencies between the categories of movement, as illustrated in Figure 1.2 (red X = mean, 
red _ =median). 
 
Individuals’ ‘frequency of action’ rose consistently within person through ‘Generalised 












Mean Standard)deviation Mean Standard)deviation Mean Standard)deviation
Subject)1 0.488 0.265 0.734 0.128 1.639 0.300
Subject)2 0.443 0.239 1.280 0.412 1.957 0.264
Subject)3 0.391 0.201 0.995 0.438 1.933 0.062
Subject)4 0.485 0.224 1.044 0.250 1.774 0.309
Subject)5 0.264 0.153 0.797 0.214 1.444 0.514
Subject)6 0.768 0.000 1.072 0.225 2.421 0.961
Subject)7 0.316 0.168 0.725 0.393 1.381 0.236




































































The mean values for ‘frequency of action’ for each category of movement were significantly 
different. This means that it should be possible to distinguish scratch, rub or adjusting 
position based on the video-observed frequency of the action. There is, however, a lot of 
overlap in range of frequencies that each category of movement includes. There is less 
overlap if all itch-related movement, i.e. scratch and rub are considered as one group. 
Sometimes it is difficult to differentiate between scratch and rub so it could, therefore, be 
argued that it is valid to include these two categories of rhythmical movement together in 
opposition to the non-rhythmical 'generalised movement.' Grouping rub and scratch is also 
valid as both of these actions inflict damage upon the skin and, it is presumed, result in the 
clinical appearance of the rash of atopic dermatitis 
 
The frequency of human scratch proved much lower than murine scratch: 10-25Hz. The 
observed range of frequency of action of itch-related movement is, however, consistent with 
Shuster's stated frequency of scratch, as measured by the bed-leg monitor, 2Hz (Felix & 
Shuster, 1975). It is interesting to note how the frequency of action of scratch would appear 
to be inversely proportional to the size of animal.  
 
Overall, this study achieved its aim, namely, to characterise the frequency of human 
itch/disease-related movement. It has been shown that, by direct observation of subjects, it is 







To characterize itch-related movement for a range of mammals and compare their 
characteristics to human itch-related movement. 
 
Background 
A literature search for information on the frequency of action of scratch movement in 
humans and other animals revealed a dearth of information. There was clear literature to 
demonstrate that the frequency of action for murine scratch was 10-30Hz and 12.5Hz on 
average (Brash et al., 2005). This information was available from an objective measure of 
scratch. There was also published data on rat (8Hz) (De Castro-Costa et al., 1987) 
 and cat (6.5Hz) (Kuhta & Smith, 1990) scratch-frequency of action. With respect to 
primates, however, there was no information on the ‘frequency of action.’ The focus of 
objectively measuring scratch in primates shifts away from the actual ‘frequency of action’ 
to how long ‘bouts of scratch’ are. Some human studies had mentioned putative ‘frequency 
of action’ of itch from analysis of electronic recordings (Aoki et al., 1980; Felix & Shuster, 
1975; Savin et al., 1973; 1975) but none had measured the action through gold-standard 
direct observation. 
 
From the published findings, it was hypothesised was that ‘frequency of action’ of scratch 
movement was inversely related to the size of the animal. The theory was that the speed of 
the movement (frequency of action: number of limb-cycles per second) should more 
precisely be related to limb length. In the absence of information exactly pertaining to limb 





A literature search was undertaken to glean any information on frequency of action of 
scratch in animals (Felis catus (cat), Rattus norvegicus (rat) and Mus musculus (mouse). In 
order to glean more information than that available in the published literature, animals were 
directly observed: one day was spent at Edinburgh Zoo, if animals were spotted scratching, 
they were videoed opportunistically. YouTube was searched for video recordings of animals 
scratching. To qualify for the study, the scratch movement had to be undertaken by any limb, 
in clear view of the camera in such a way that digits could be seen making contact with 
another part of the body. 
 
For each of the episodes of movement,  
1)! the length of the bout was measured in seconds with a stopwatch and 
2)! the number of complete cycles of movement to occur within the episode 
were recorded, 
3)! a ‘bout,’ or cycle of movement was counted when the part of the body being 
observed reached its starting point again. 
4)! the episode was then re-watched two more times and mean values taken. 
 
The frequency of an action is described in the unit Hertz (Hz). It is considered to represent 
the number of complete cycles of movement completed in a second. Therefore, the 
observations were converted into frequencies by dividing the number of completed cycles to 
occur in the observed episode by the number of seconds the episode lasted for. 
 
Results 
During the visit to Edinburgh Zoo, mammals Saimiri boliviensis (squirrel monkey) and 
Nomascus leucogenys (white cheeked gibbon) were successfully video-recorded whilst 
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scratching. Due to the unpredictable nature of scratch bouts, further recordings were 
unsuccessful (due to difficulties capturing the event in time) despite other animals also being 
seen scratching on the day of the visit. The YouTube search yielded qualifying recordings of 
Pan troglodytes (chimpanzee) and Gorilla graueri (gorilla) scratching.  
 
The ‘frequency of action’ observed from the video-recordings are summarized in Table 1.2 
alongside standard lengths and masses of the animals (mean for male/female) sourced from 
the National Primate Research Center, University of Wisconsin – Madisons’s website, 
‘Primate Info Net’ and from University of Michigan Museum of Zoology ‘Animal Diversity 
Web’ website. Mean and standard deviation (for the animals I observed) are stated. It can be 
seen that ‘frequency of action’ does correlate with mass and length of the animal. The 
smallest animal, the mouse, exhibits highest frequency (or fastest) scratch with a mean 
frequency of 12Hz, and the largest animal, the gorilla, scratches with a frequency of 1.3Hz. 
Humans, which are the second biggest mammals observed, scratch at 1.8Hz on average. 
 
Figure 1.4 includes graphs of log. mean ‘frequency of action’ for each animal versus log. 
mass and log. length. There is a linear relationship indicating a strong relationship between 
both average log. mass and average log. length versus frequency of action. The relationship 













Gorilla'graueri 1.248%±%0.186 1.750 157.500
Homo'sapiens 1.850%±%0.361 1.730 70.000
Pan'troglodytes 1.807%±%0.145 0.816 50.000
Felis'catus 6.500 0.460 2.500
Nomascus'leucogenys 2.599%±%0.033 0.546 5.700
Saimiri'boliviensis 4.447%±%0.186 0.294 0.950
Rattus'norvegicus 8.000 0.250 0.200












































































This small experiment was an exploratory gesture to see how well the observed ‘frequency 
of action’ of human itch fitted with that of other species of mammal. The lack of published 
information required the video-observations to be undertaken. 
 
It can be seen that there is a powerful relationship between mass and ‘frequency of action’ of 
scratch. There is a less powerful relationship between ‘frequency of action’ of scratch and 
length. It had been hypothesized that the greatest relationship would be between limb length 
and ‘frequency of action’ but the information on species standards for this data was not 
readily available. It had been hypothesized that length or height would correlate most closely 
with ‘frequency of action’ but the results do not concur with this. This could be explained by 
the fact that length is quoted as head to tail, a length of head to base of the spine would 
possibly be more relevant especially since humans do not have tails. 
 
It is intriguing to see the demonstrated allometric relationship between the ‘frequency of 
action’ and mass or length. Allometric relationships are a feature of biological systems and 
well known examples include the relationship between Basal Metabolic Rate (BMR) and 
body mass and perhaps more significantly, for legged motion – indeed length of limb has 
been used to predict mode of action of locomotion for extinct creatures. 
 
Overall, the study confirms that size is related to ‘frequency of action’ of scratch and that 
based on humans’ standard sizes, the ‘frequency of action’ ascertained from our direct-













Actiwatches are wrist worn accelerometers. The ‘Actiwatch Plus’ were bought from 
Cambridge Neurotechnology, now known as CamNtech Ltd (Cambridge, U.K).   
 
Accelerometers measure ‘proper acceleration.’ This means they measure acceleration relative 
to free fall. If an accelerometer is lying at rest on the floor, it measures gravity, 1G upwards, 
whereas if it were in freefall it would measure 0G.  
 
The accelerometer works by containing a mass on a spring. When there is acceleration, the 
mass is displaced and the spring is able to accelerate the mass at the same rate as the casing. 
Measurement of the displacement gives the acceleration. In the Actiwatch accelerometer, a 
piezoelectric crystal is used to convert the mechanical movement into an electrical signal, see 
Figure 2.1. 
 
The accelerometer integrates intensity, amount and duration of movement. The actiwatch 
senses movement 32 times per second and logs the highest counts every second. The epoch 
score is the sum of those highest scores per second. The Actiwatch is an analogue analyser, 
this means it uses a variable bandpass filter whose mid frequency is tuned to the range of 
frequencies to be measured. The unit Actiwatch has a bandpass filter of three to 11 Hz.  
 
The Figure 2.2 demonstrates that the Actiwatch is the size and shape of a standard 
wristwatch. These accelerometers weigh approximately 20g. The measuring unit has slots at 
either end through which nylon (hypoallergenic) straps can be attached. Different straps were 


























Epoch length Recording time 
2 seconds 36h, 12 mins 
5 seconds 3 days, 18h, 30mins 
10 seconds 7 days, 18h, 24mins 
15 seconds 11 days, 8h, 20mins 
30 seconds 22 days, 16h, 40mins 
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The Actiwatch Plus yields data in ‘epochs.’ A summary value for each epoch is recorded. 
The length of epoch can be set before a recording period. The shorter the epoch the shorter 
the recording time (as the memory is filled sooner). An epoch time of two seconds will allow 
recording for 36 hours, 12 minutes. No data is ‘lost’ with longer recording epochs as the 
output is a summary value, all that is lost is second-by-second discrimination of action. Table 
2.1 illustrates the relationship of recording epoch to recording length. 
 
Data is downloaded from the units by placing the measuring unit on a proprietary reader, also 
bought from Cambridge Neurotechnology. The reader can be connected to a PC. Cambridge 
Neurotechnology provided software for the analysis of movement and sleep. There are two 
problems with this software. The first problem is one specific to this study: the Cambridge 
Neurotechnology software yields summarized data, it sums the acceleration per epoch for 
chunks of time (for example, 30 minutes or one hour) and does not allow minute by minute 
scrutiny of acceleration. We really did need access to real time, second by second data in 
order to compare the accelerometer to video-recordings for validation purposes. The second 
problem has huge implications for all users of the Actiwatch Plus: when the raw data output 
acceleration is compared to the software output acceleration there is a difference. When I 
examined where the difference occurred and why, I found it to be to due to an error in the 
Cambridge Neurotechnology software coding: epochs were skipped by the software. The 
fault acts like a frame-shift mutation (to use DNA transcription as an analogy) so that 
summarized data yielded by the Cambridge Neurotechnology software after this point is out 
of synch with similarly analysed data passed through my own Macro. Due to these issues, 
raw data was extracted from .AWF and .AWD files and exported into Excel for the purpose 
of this study’s analyses. The files of raw data are large: 20,000 Excel cells for a two second 
epoch ten-hour recording.  
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In order to prove that no data was lost by extending the epoch lengths, I carried out 
experiments where two watches were worn on the same wrist overnight. This experiment 
may sound superfluous based on my explanation of the physics of these devices, but the 
research team which had carried out pilot studies (Benjamin et al., 2004; Bringhurst et al., 
2004) had been advised by a technical expert that this would be the case. Once I understood 
how the accelerometers worked I suspected that this was not the case and that data would not 
be ‘lost’ if longer recording epochs were used (the data would be summed, no acceleration 
data skipped or lost). The technical expert had also written a ‘macro’ which summarized the 
two second data into hourly chunks for the recording times of 10pm to 8am on the first night 
of recording only. This meant that even if the accelerometer had been worn and recorded for 
three nights, only one night’s data was available. 
 
To prove that no data was lost by increasing the recording epochs, a control subject wore two 
accelerometers on one wrist. One accelerometer was set to record two second epochs and the 
other 15 second epochs. I wrote my own macro which extracted hourly scores for two, 10, 15 
and 30 second epochs. In my macro I summarized every recording hour from when the 
accelerometer was set to start at 18:00hr. The Actiwatch Plus which was set to capture 2 
second epochs yielded 1800 Excel cells per hour and the Actiwatch Plus set to capture 15 
second epochs which yielded 240 Excel cells per hour, the percentage difference is 13.3% 
and so you might expect this level of difference is data was being ‘lost’ in the capture 
process. The result is demonstrated in Figure 2.3. It can be seen that there is minimal 
difference in recording output when the 2 second epoch-recording Actiwatch Plus data is 
compared to the 15 second epoch-recording. The percentage difference between the devices 
is 4.1% which is most likely accounted for by variance between the devices and not by data 
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The pilot study (Bringhurst et al., 2004) had also involved a few consecutive-night studies 
and these had demonstrated huge night-to-night variation in scores. One of my study aims 
was to increase the number of consecutive night studies to see if these variations were real 
and if there were any pattern or way of predicting the size of scores. I felt that compliance 
and participation would be increased and be more appealing if I could give the participants 
their accelerometers at the beginning of the study period (initially three nights but eventually 
six weeks) and not have to try to meet them each day to download data and reset the 
accelerometer. Therefore, as well as writing macros to compress various epoch lengths, I also 







The Actiwatch Plus had previously been validated against the gold-standard of infra-red 
video recording(Benjamin et al., 2004). Significant night-to-night variation in score was 
detected in preliminary consecutive night studies (Bringhurst et al., 2004). This study sought 
to validate the Actiwatch Plus against infrared video recording in night-to-night recordings 
to see if the variation was a genuine phenomenon.  
 
Background 
The download from an accelerometer, or ‘score,’ can represent genuine scratch activity but 
is non-specific: it can equally represent other movements such as walking, playing etcetera. 
To try to skirt this problem, my group had always sought to quantify 'nocturnal activity.' 
Previously, these 'nocturnal hours' were determined by the limitations of a macro which only 
allowed data from 22:00h to 08:00h to be extracted and also by parent-recorded bed/sleep 
time of the child. Unfortunately, software errors were detected in the company supplied 
software and so it was necessary to deal with the raw data-downloads, see Chapter 2.I. My 
involvement in this research started by my writing a new macro which was not confined to 
22:00-08:00hrs.  
 
Previous subjects’ consecutive night data was reanalysed primarily to address the question as 
to why there was such marked night-to-night variation in accelerometer score. It was 
observed that the hourly scores at the beginning of the recording night were markedly higher 
than those later in the recording. It was suspected that the early evening peak in score was 
most likely related to the subject not actually being asleep and therefore parent-recorded 
sleep-times not marrying with reality and not to be relied upon. In order to ascertain whether 
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the early evening surge in score was an itch-related activity, however, and thus an 
observation which could be exploited in capturing itch, further video studies were 
undertaken and are described here.  
 
The study also afforded directly observed overnight activity to compare to Actiwatch Plus 
and further validate them in night-to-night studies (checking that the data was not corrupted 





Six children, all of whom had a diagnosis of atopic dermatitis, were studied. The children 
were recruited from a secondary care Paediatric Dermatology clinic and had been were 
diagnosed as having atopic dermatitis by a Consultant in the clinic (as described by Hanifin 
and Rajka (Hanifin & Rajka, 1980)). The subjects had moderate to severe atopic dermatitis 
(assessed by SCORAD) as would be expected from their being recruited from a secondary 
care Dermatology clinic. The range of SCORAD was 16.2 to 33.6 and the median 25. The 
group's median age was 7 years (age range 3-10yrs, four male and two female).  
 
Study method 
Each study subject's nocturnal movements were observed using infrared video recordings. 
This involved my visiting the subject's house and setting up the infrared videoing system 
(see Chapter 1.II). 
 
The subject's parent was issued with written and verbal instructions. They were asked to 
press the 'Record' button on the VCR when the child went to bed. The accelerometer was 
attached to the dominant hand’s wrist two hours before retiring. The videotape was 
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recovered from the subject's house the next day. The Actiwatch Plus data was downloaded 
and the infrared equipment set up to record the next night. The aim was to record data for 
three consecutive nights. The subjects were issued a questionnaire which asked for 
information such as the time of retiring to bed and VAS for symptoms. 
 
Early evening analysis 
The full video observations and parental noted bed-times were used to characterize 
movements throughout the recording period: specifically, early evening activities were 
scrutinized in order to explain the early evening peak in Actiwatch Plus recordings. The 
hourly total acceleration was extracted from the Actiwatch Plus data. The hours of analysis 
were dictated by the parent's recorded 'bedtime.' To illustrate, if a parent recorded bedtime as 
20:00h, then the score from 20:00h to 21:00h was considered that for 'Hour 1' of sleep, and 
21:00h to 22:00h 'Hour 2' etc. The videos were watched and the time of getting into bed was 
recorded, as was the time of 'presumed sleep' (defined as when the child was consistently 
lying still). The parent-recorded bedtime was compared to the actual sleep-time as reflected 
by the video recording. The waking times were noted and compared too, but this period of 
time was not scrutinized as no peak in score had been noted in this period. 
 
Comparison of directly-observed movement 
The infrared video recordings were played back in 'real-time' and every movement noted 
down. This viewing process took over one month to complete. For the purposes of analysis, 
although rhythmical and non-rhythmical movement was denoted, since the Actiwatch Plus is 
purely a movement monitor without any suggested or implicit sensitivity for a specific 
frequency of action, total movement recorded or timed per hour was compared to hourly 
Actiwatch Plus score. In order to investigate the night-to-night variation in Actiwatch Plus 




One subject (subject 3) only managed to complete video-recording for one night and so this 
subject was not able to be included in the night-to-night analysis although the one night’s 
video-recording was useful for the characterizing activity part of the experiment. The same 
subject’s Actiwatch Plus was only worn on one night and not the same night as the video-
recording.  There were 14 night’s recordings to examine overall. Not all hours of Actiwatch 
Plus recording yielded a similar video-tape hour’s recording if the child were mobile during 
the night (and not on camera). 
 
Early evening analysis and hour-by-hour consecutive night Actiwatch Plus scores 
All of the following subjects’ individual night-to-night hourly activity is summarized in 
Figure 2.4 and the sleep/waking times as recorded by the parent and observed on video 
displayed in Table 2. 
 
Subject 1 
This subject competed the three-night study. The early recording activity on Actiwatch Plus 
was shown to be due to the subject being awake. There was a mismatch in parent reported 
sleep time and the video-observed reality. There seems to be a similar scoring pattern each 
night longitudinally (note peaks at Hour 5 and Hour 8, see Figure 2.4). 
 
The early peak in Actiwatch Plus score (hours one to three) is characterized on video as 
follows:- 
 
Night 1: being in bed at 22:00h, watching TV, generally restless and scratching often. 
Night 2: in bed at 19:38h, watching T.V. and frantically scratching until 19:50h when plays 
with dolls house. When playing, no scratching. At 21:15h puts dolls house away, watches 
TV and absent-mindedly scratches. 21:30h settles to sleep. 
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Night 3: in bed at 21:07h playing with dolls house, watching TV, no scratching. Puts dolls 
house away at 22:20h, watches TV and occasionally scratches. At 23:00h turns off TV and 
settle to sleep. 
 
Subject 2 
This subject also competed the three-night study. The early recording activity on Actiwatch 
Plus was shown to be due to the subject being awake. Although he was not asleep when the 
parent thought or recorded he was, he was in bed. This subject is very restless in bed and 
takes a long time to settle down to sleep. He scratches a lot but also generally moves a lot. 
There is hour-by-hour pattern for Actiwatch Plus score when nights are compared.  
 
Subject 3 
This subject only undertook the study for one night (as previously mentioned). The parent-
noted sleep and wake times are only ten minutes apart. In the extra time before actually goes 
to sleep, the subject is in bed but is generally restless and scratches a lot. 
 
Subject 4 
This subject wore the Actiwatch Plus on each night, but due to some kind of malfunction, no 
movement was detected by the accelerometer until after the eighth hour of recording. The 
successfully completed two nights again illustrate the early peak in score but otherwise no 
pattern on hour-by-hour recording. This subject is in bed pretty much as the parent records 
and settles quickly without too much restlessness. 
 
Subject 5 
This subject successfully competed the three nights of the study. The early peak in score is 
noted again, but no hour-by-hour pattern when nights are compared. During the delay 
between recorded and presumed sleep-time, the subject is in bed and generally restless but 
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also scratches a lot. When the recorded time of getting up differs on night 3, the subject gets 
out of own bed at 00:05h and goes to her mother's bed. The parent recorded awake time is 
actually when the subject pulled the accelerometer off. 
 
Subject 6 
This subject completed two study nights. A small early recording hour peak is noted on night 
two. It is noted that the broad pattern of hour-to hour recording is similar one night to the 
next: peaks at Hour 4 and Hour 7. For both recording nights, during the mismatched time, 
the subject is in bed fidgeting. It is notable that there is a bigger mismatch in timings on 








































































































































































Subject Study night Parent says asleep Observed sleep Difference Parent says awake Observed awake Difference
1 21:00h 22:30h +90 mins 08:00h 07:30h -30 mins
2 21:00h 21:30h +30 mins 08:00h 08:55h +55 mins
3 21:00h 23:00h +120 mins 08:00h 08:55h +55 mins
1 22:00h 22:05h +5 mins 08:00h 06:50h -70 mins
2 21:00h 21:30h +30 mins 08:00h 07:20h -40 mins
3 21:00h 21:30h +30 mins 08:00h 05:00h -180 mins
3 1 19:30h 19:40h +10 mins 07:30h 08:00h+ +10 mins
1 22:00h 22:05h +5 mins 08:00h 06:20h -100 mins
2 21:00h 21:20h +20 mins 08:00h 07:20h -40 mins
3 21:00h 21:15h +15 mins 08:00h 06:10h -110 mins
1 20:10h 20:50h +40 ins 07:05h 07:00h -5 mins
2 21:35h 21:40h +5 mins 06:05h 06:05h 0 mins
3 21:00h 22:20h +80 mins 02:10h 00:05h -115 mins
1 00:00h 00:20h +20 mins 08:30h 09:50h +80 mins







Subjects’ combined data 
The mean difference in observed versus recorded sleep times is +39.7minutes (range +5 to 
+120 mins). This means that, on average, the parent recorded the child's sleep time 
approximately 40 minutes earlier than the actual time. When the difference between 
recorded sleep times and observed sleep times is analysed by paired t test, the difference is 
significant, p=0.005.  
 
The mean difference in observed versus recorded wakening times was -30minutes (range -
180 to +80 mins). This means that, on average the parent recorded the child's waking up time 
30 minutes later than actually occurred. The paired t test analysis of the difference between 
recorded and observed waking times gives a p value of 0.047.   
 
Validation of consecutive-night Actiwatch Plus scores against direct-observation of 
movement on video. 
Each subject, except subject 3 (who had worn the accelerometer one night and completed the 
infrared videoing another night), had data available for analysis. The mean hourly Actiwatch 
Plus score per individual across nights was compared to the mean amount of time spent 
moving during the same hour, as observed from the video recording. The mean hourly data 
was analysed to allow for nesting of data: one subject having the same measurements each 
night, if all nights were correlated together would give a ‘dishonest’ picture.  As expected, a 
close relationship is demonstrated between the gold-standard video recording and the 
Actiwatch Plus scores per hour.  Each individual’s Spearman rho demonstrates significance: 
Subject 1 ρ=0.618 p=0.043, Subject 2 ρ=0.829 p=0.042, Subject 4 ρ=0.889 p=0.019, Subject 































































































































































This study sought to check that the night-to-night variation in Actiwatch Plus score was a 
‘real’ phenomenon. It answered this question by affording the means of physically observing 
the subjects on consecutive nights on infrared video whilst the subject also wore the 
accelerometer. The study allowed any patterning of scoring to be observed too. The study 
allowed for further validation of the use of accelerometers to quantify nocturnal movement 
and confirms that there is no corruption in data, for instance or any other accelerometer 
recording error to account for the variation. The night-to-night variation in Actiwatch Plus 
score is reflected in directly-observed video movements and no generalized scoring patterns 
are reliably demonstrated (possibly minor peaks in score at about Hour 5 and Hour 8 for 
some individuals). 
 
The early recording period Actiwatch Plus score was proven, in this experiment, to be due to 
two phenomena: inaccuracy in parent-recording sleep times and wakeful activity occurring 
in this period. Inaccuracy between actigraphic sleep-time and diarised wake/sleep times has 
been reported (Baker, Maloney, & Driver, 1999) (van den Berg et al., 2008) but in the 
published report by this group, the possibility of inaccuracy was raised as the actigraphy 
software was relied upon for sleep/wake times. At least in this study there can be no question 
of reliability: the times are available for direct observation on video. 
 
The results demonstrate an expected close relationship between the amount of movement 
observed on camera and the Actiwatch Plus score. This is further validation for the use of the 
devices. It should be noted that time spent in any movement was compared to the 
accelerometer score. This was a deliberate choice as the accelerometer used in this 
experiment is a simple device which does not offer or attempt to specifically sense itch-
related movement (as opposed to the DigiTrac).  
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Overall, therefore, it would appear that the night-to night variation in score is a real 
phenomenon. A larger multiple night, within subject Actiwatch Plus study was proposed on 
the basis of these results in order to characterize the night-to-night variation in score and 










During the course of the study, new accelerometers became available. The newer digital 
accelerometer sensed much more detailed information (detected three axes of movement) 
and furthermore which could transform data to detect acceleration at particular frequencies 
of action. It was hypothesized that, if we could determine the frequency of action of itch-
related movement (scratch and rub), then these instruments should be able to specifically 
determine and measure this rhythmical movement. The recordings would, we felt be more 
accurate or discriminating than the Actiwatch Plus accelerometer.  These newer instruments 
are known as DigiTrac accelerometers “DigiTrac - movement recorder,” 2007 
http://www.imsystems.net/DigiTrac/DigiTrac.htm IM Systems, Baltimore)  
 
DigiTrac are wrist or leg-worn instruments that are capable of measuring acceleration 
movement in three axes (as opposed to the Actiwatch which measures in one axis, two 
planes). They contain three piezoceramic accelerometers (one for each measurement axis) 
and a gyroscope (to indicate the device’s position). 
The DigiTrac is larger than the Actiwatch and measures five centimeters in the long axis. 
When sensing in three axes, its recording time is ten hours. If it is sensing in just one axis the 
recording time is 30 hours. Figure 3.1 contains a photograph of the device on a woman’s 
wrist (to allow size comparison). 
The DigiTrac samples and records more frequently than the Actiwatch (the sampling rate is 
between ten and 40Hz). DigiTrac are sensitive to a range of frequencies from 0.8-14Hz by 
use of a band pass filter (as opposed to three to 11Hz in the Actiwatch).  
The high frequency of sampling means that ‘frequency of action’ can be calculated.  This 
means that the device is a ‘spectrum analyzer.’ A spectrum analyzer is a device used to 
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examine the spectral composite of electrical, acoustic or optical waveforms. A signal (here a 
movement) has a waveform that can be broken down into individual sine waves, and these 
are known as the ‘spectral composite.’  
Spectrum analysers can be: 
a)! Analogue analysers: use a variable bandpass filter whose mid frequency is tuned to 
the range of frequencies to be measured. 
b)! Digitral spectrum analysers: uses Fast Fourier Transform (FFT) to transform a 
waveform into the components of a frequency spectrum. 
The DigiTrac is both an analogue and a digital spectrum analyzer. The output yields a 
detailed account of the acceleration at a range of frequencies of action.  
The Fourier Transform decomposes a function of time or signal (here movement) into its 
component frequencies: any signal or waveform can be constructed by adding together a 
series of pure tones (sine waves) with appropriate amplitude and phase. The Fourier 
Transform is an equation to calculate the frequency, amplitude and phase of each sine wave 
within a signal. 
The Discrete Fourier Transform (DFT) is a numerical equivalent of the Fourier Transform. 
The Fast Fourier Transform is just a computationally fast way to calculate DFT. A Fast 
Fourier Transform (FFT) is an algorithm to compute the discrete Fourier transform (DFT) 
and its inverse. FFT rapidly computes transformations by factorizing the DFT matrix into a 
product of sparse (mostly zero) factors. As a result, fast Fourier transforms are widely used 
for many applications in engineering, science, and mathematics. 
The output from the digital accelerometer takes the form of ‘bits’ or ‘points.’ These are 
multiples as follows: 2, 4, 8, 16 etc.  For fast Fourier Transform to be most accurate, the 
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epoch length should be as long as possible. An output of 256Pts equates to an epoch length 
of 6.4 seconds (it is possible to export 128Pts but this equates as a less preferable and shorter 
epoch length of 3.2 seconds). The accelerometer samples 40 times per second or once every 
0.025seconds, an output of 256 (0.025x256) yields a 6.4 second epoch. The output also 
determines the discrimination wavelength or Hertz-wise: 256Pts equates to increments of 
0.16 alternating with 0.15Hz (128Pts would equate to 0.32Hz increments). 
 
The FFT read-out from the DigiTrac is a table. A sample is provided in Figure 3.2.  The 
columns, running horizontally represent different frequencies, from 0.16-10Hz and the rows, 
running vertically represent consecutive epochs of the recording period. The FFT produces 
the frequency and amplitude composition of the DigiTrac signal, therefore, within the table 
is a value, in G-seconds (G-s), of the amplitude or acceleration, happening that specific 
category of frequency within a specific epoch of time. As can be seen in Figure 3.2, a 
frequency ‘pure-tone’ labels each column and then, vertically, epochs are labelled. Inside 
each box of the table is the acceleration for that frequency in that epoch of time. 
 
A separate file is available and downloadable for each recording for each of the axes (x, y 
and z) as long as the device is set to record all three axes (as opposed to one).  
 
I.M.Systems technical staff advise that a high pass filter in the unit removes the gravitational 
component so the orientation of the unit is irrelevant. This would negate the problem of the 
sensing axis for a particular movement being different with the subject being in a different 



















Frequency 0.16 0.31 0.47 0.63 0.78 0.94 1.09 1.25 1.41 1.56 1.72 1.88 2.03 2.19 2.34 2.5 2.66 2.81 2.97
22:00:00.PM 116 110 104 96 88 78 74 68 62 56 52 50 46 44 42 38 38 36 34
22:00:06.PM 0 0 2 0 0 0 0 2 2 0 0 0 0 0 2 0 0 0 0
22:00:13.PM 0 0 2 0 0 2 0 0 0 0 0 0 0 0 2 0 0 0 0
22:00:19.PM 0 0 0 0 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0
22:00:26.PM 0 0 2 0 2 2 0 2 2 0 0 0 0 0 0 2 0 0 0
22:00:32.PM 0 0 0 0 0 2 0 0 0 2 0 0 0 0 0 0 0 0 0
22:00:38.PM 0 0 2 0 2 2 0 2 0 2 0 2 0 0 0 0 0 2 0
22:00:45.PM 0 2 0 2 2 0 0 0 0 0 2 0 0 0 0 2 0 0 0
22:00:51.PM 0 0 0 0 2 0 2 2 0 2 0 0 2 0 0 0 2 2 0
22:00:58.PM 0 2 2 2 0 2 2 0 0 2 0 2 0 0 0 0 0 0 2
22:01:04.PM 0 0 0 0 2 0 0 0 0 0 2 2 0 0 0 0 0 0 0
22:01:10.PM 0 2 0 0 0 0 0 2 0 0 0 2 0 0 0 0 0 0 0
22:01:17.PM 0 0 0 0 2 0 2 0 0 2 0 0 0 0 0 0 0 0 0
22:01:23.PM 0 0 0 0 0 0 2 2 0 0 0 2 0 2 0 0 0 0 0
22:01:30.PM 0 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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II:*Experiment*to*validate*interSmachine*DigiTrac*accuracy!
It was necessary to assess the precision of the DigiTrac in the first instance. These 
experiments were not necessary for me to undertake on the Actiwatch, as they had been 
previously validated (Benjamin et al., 2004; Bringhurst et al., 2004). 
Aim 
To test how similar the DigiTrac read-outs are when moving at exactly the same speed, in 
the same direction: to test the 'precision' of DigiTrac. 
Background 
•! Accuracy is the degree of conformity of a measured/calculated to quantity to its 
actual (true) value: how far the measured value is from the known reference level. 
Accuracy is a measure of veracity. 
•! Precision (also called reproducibility or repeatability) is the degree to which several 
measurements will show the same results. 
•! The relationship between accuracy and precision is illustrated in Figure 3.3 (over). 
•! Precision is characterised in terms of the standard deviation of the measurements. 
The coefficient of variation (CV) is a measure of dispersion of a probability 
distribution and is commonly applied in reliability theory.  
•! The coefficient of variation (CV) is defined as the ‘ratio of the standard deviation to 
the mean’ and is reported as a percentage. A CV of 20% or less is generally 





























All the DigiTrac (n=7) were placed face-down on a platform-style laboratory shaker (see 
Figure 3.4: the numbers indicate the serial number of the DigiTrac). 
The DigiTrac were set to record three minutes of activity at each of eight increasing arbitrary 
shaker speed settings. This was repeated three times at each speed setting. 




Table 3.1, lists the recorded mean acceleration, standard deviation and coefficient of 
variation for the seven devices (combined) at each shaker speed, from 1 to 8. It can be seen 
that the CV ranged from 4.9% for shaker speed setting number seven rising steadily to 
14.3% for the lowest shaker speed setting, number one. This suggests better inter-device 
accuracy at higher frequency movement than at lower frequency movement. As previously 
mentioned, reassuringly, in the fields of electrical component testing, a CV of less than 20% 
is considered acceptable and so the devices detect acceptably at all frequencies of action. 















1 67.2 9.6 14.3
2 64.5 7.2 11.2
3 61.2 5.5 9.0
4 99.0 8.8 8.9
5 105.6 7.6 7.2
6 186.2 9.6 5.2
7 243.9 12.1 4.9



























The DigiTrac are acceptably precise (CV less than 20%). There is less inter-device accuracy 
at a lower frequency of action compared to a higher one but the experiment reassured us that 






To test the sensitivity of the DigiTrac to itch-related movement in vivo.  
Method  
One subject was studied. The subject wore the DigiTrac on her right wrist. The subject had a 
good understanding and ability to simulate stereotypical movement as she has previously 
been involved in scratch-measuring videotape experiments. The subject was simultaneously 
time-index videotaped. The experiment was in two parts: 
1)! First, the subject was required to simulate scratch by scratching her left forearm with 
her right hand for one minute. This experiment was designed to characterise the FFT 
of scratch movement and to see where the maximal activity was frequency-wise: 
was there favourable comparison with the video-observed mean frequency of scratch 
(1.85Hz). 
 
2)! Second, the subject was required to undertake a series of prescribed, stereotypical 
itch-related movements, scratch and rub only (and no non-rhythmical movements 
such as adjusting position) with both her right hand and her left hand. It was known 
that the Actiwatch Plus were sensitive enough to detect itch-related movement 
carried out on the non-Actiwatch PLus bearing arm (Benjamin et al., 2004; 
Bringhurst et al., 2004), but it was not known if the DigiTrac were similarly 
sensitive. The actions were carried out for ten second episodes starting at the 
beginning of the minute.  
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The prescribed movements were scripted as follows: 
1)! Scratching head with fingers left hand 
2)! Scratching head with fingers right hand 
3)! Scratching head with left arm 
4)! Scratching head with right arm 
5)! Scratching left elbow with right hand fingers  
6)! Scratching right elbow with left hand fingers 
7)! Scratching left elbow with right arm  
8)! Scratching right elbow with left arm 
9)! Scratching right loin with right fingers 
10)!Scratching left loin with left fingers 
11)!Scratching right loin with right arm 
12)!Scratching left loin with left arm 
13)!Rubbing left foot on right foot 
14)!Rubbing right foot on left foot 
15)!Rubbing eyes with left hand 
16)!Rubbing eyes with right hand 
17)!Rubbing face into pillow 
! 117!
The DigiTrac-derived FFT scores for all axes were extracted and uploaded to a PC. The sum 
of the FFT for each episode of movement was examined and compared to the time-index 
videoing of each movement. Since our video-study (Chapter1.III) had suggested that 0.5-
2.5Hz should be the most discriminating output to detect itch-related movement, this range 
of outputs was also more closely examined.  
 
Results 
1)! The FFT output was examined with a sum of activity at the pure tone frequencies 
and also with the mean at each frequency. As can be seen from the two graphs in 
Figure 3.6, the peaks and troughs at the frequency pure-tones is reflected similarly 
whether sum (Figure 3.6a) or mean (Figure 3.6b) of FFT is analysed. It can also be 
seen that the maximal activity is at 1.72Hz and at 1.88Hz and thus closely reflects 
the video-observed mean frequency of scratch. 
 
2)! The graph in Figure 3.7 shows the acceleration output of the DigiTrac for the sum of 
FFT (total score) and for the limited spectrum of 0.5-2.5Hz (all in G-s). Spikes in 
activity can be seen for all movement, most markedly if the movement was carried 
out by the arm bearing the DigiTrac. It can also be observed that movement carried 
out by the non-DigiTrac-bearing arm causes a rise above baseline and a small spike 
in activity. The limited spectrum of 0.5-2.5Hz also reflected the Total FFT pattern 
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The DigiTrac accelerometer has been demonstrated as capable of capturing itch-related 
movement in this experiment.  
The fact that the maximal pure-tone frequency score was at exactly the mean video-observed 
score is encouraging for use of the DigiTrac as a movement-monitor able to discriminate and 
identify itch-related movement. 
The sensitivity of the DigiTrac appeared to be at least as favourable as for the Actiwatch: it 
can detect scratch movement carried out by the non-accelerometer bearing arm. 







Decide which accelerometer axis output to use when measuring scratch movement. It was 
hypothesised, from observation of videos of scratch that the greatest sensitivity for scratch 
would be in the X axis as this would represent best detection of rhythmical movement at the 
wrist of the forearm through the elbow joint (see diagram of axes in Figure 3.8). 
Method  
One subject was studied. The subject wore the DigiTrac on her right wrist. She was required 
to undertake a series of prescribed, stereotypical itch-related movements (scratch and rub) 
and non-itch related movements (adjusting position) carried out for ten second episodes 
(starting at the beginning of the minute). The subject had a good understanding and ability to 
simulate stereotypical movement, as she has previously been involved in scratch-measuring 
videotape experiments. The subject was simultaneously time-index videotaped. The axes of 
movement in relation to the DigiTrac are illustrated in Figure 3.8. 
 
The prescribed movements were scripted as previously but stereotyped ‘generalised 
movements’ were added in between the itch-related movements as follows: 
1.! Stretching  
2.! Twitch 
3.! Lying on back, turn onto left side 
4.! Lying on back turn onto right side 
5.! Lying on left side turn onto right side 
6.! Lying on right side turn onto left side 
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7.! Lying on front turn onto back 
8.! Lying on front turn to right  
9.! Lying on front turn to left 
10.!Bring covers up.  
 
The DigiTrac-derived FFT scores for each of the axes was extracted and uploaded to a PC. 
The sum of the FFT for each episode of movement in each axis was compared. The type of 
movement was identified and confirmed with the recorded timing of events and by 
observation of the time-indexed video. 
For the purpose of analysis, anything itch-related (i.e. scratch and rub) was labelled ‘scratch’ 























The different types of stereotyped movement as measured by each axis and the DigiTrac 
output is illustrated in Figure 3.9’s graph. It demonstrates a consensus between the 
measuring axis. The graph also demonstrates that the maximal acceleration most often 
occurs during itch-related movement (S). 
Table 3.2 demonstrates the comparison between X, Y and Z axes for the stereotyped 
movement. The overall mean sum of FFT for X axis was 261 G-s (SD 272.7), for Y was 
396.5 G-s (SD 478.3) and for Z axis was 257.7 G-s (SD 258.6). Figure 3.10 summarised the 
data graphically. The amount of data overlap suggests no more sensitivity in any particular 
































Type of stereotyped action
X sum of FFT Y sum of FFT Z sum of FFT
X"sum"of"FFT Y"sum"of"FFT Z"sum"of"FFT X"0.5/2.5Hz Y"0.5/2.5Hz Z"0.5/2.5Hz
Scratch:"sum 12266.0 18634.0 12110.0 5088.0 6920.0 4214.0
Scratch:"mean 261.0 396.5 257.7 108.3 147.2 89.7
Scratch:"median 130.0 184.0 164.0 36.0 40.0 38.0
Scratch:"mode 88.0 106.0 38.0 30.0 12.0 6.0
Scratch:"st"dev 272.7 478.3 258.6 126.9 197.5 105.5
Adj"posiition:"sum 4008.0 5142.0 4868.0 1664.0 1884.0 1792.0
Adj"position:"mean 66.8 85.7 81.1 27.7 31.4 29.9
Adj"position:"median 15.0 23.0 12.0 10.0 14.0 8.0
Adj"position:"mode 10.0 24.0 6.0 8.0 10.0 4.0
Adj"position:"st"dev 167.5 215.3 232.4 58.1 64.2 82.0
Nil:"sum 426.0 532.0 284.0 310.0 360.0 212.0
Nil:"mean 11.2 14.0 7.5 8.2 9.5 5.6
Nil:"median 12.0 13.0 8.0 8.0 10.0 6.0
Nil:"mode 12.0 12.0 8.0 10.0 10.0 6.0
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The results suggest that any axis should be just as discriminating in order to pick up itch-
related movement. For consistency’s sake, the X axis was used in further experiments. 
NB: Observed video studies demonstrated that frequencies of action for itch related 
movements were: scratch, 1.85Hz (SD±0.55) and rub, 0.98Hz (SD±0.36) and for non-itch 








To see if the DigiTrac read-out can distinguish between different movement: itch-related and 
other rhythmical non-itch related. If it were able to do so, it would be possible to study 
outside the usual night time restriction and also possible to recognise where there may be 
confounding: when a subject got up in the night to visit the toilet, for example. 
Method 
During a Paediatric clinic afternoon, ten subjects (patients and accompanying non-patients) 
were asked to wear a DigiTrac on each limb and walk around the Out-patient department for 
one minute. 
DigiTrac outputs for the X axis were downloaded and compared. 
Results 
One subject’s DigiTrac fell off the right arm. This readout was therefore removed for the 
purposes of analysis. 
The graph in Figure 3.11a demonstrates the pattern of acceleration across the FFT in each 
pure tone. It can be seen that acceleration is higher in the legs than in the arms and that there 
is most acceleration at 2.03Hz for all four limbs and that there is a minor peak at 3Hz for leg 
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The graph in Figure 3.11b superimposes stereotyped movement data onto the walking 
movement graph. This demonstrates that there is a slightly different pattern to the maximal 
accelerations on the pure tones for itch-related movement (black line) compared to walking: 
there is a peak at a lower frequency of action, 1.72 and 1.88 Hz with a minor peak at 3.59Hz 
for stereotyped scratch movement. It can be seen that generalized adjusting position 
movement (grey line) has minimal acceleration and no true peak. 
 
Conclusion 
It would appear from this data that walking has a different characteristic DigiTrac readout 
from itch-related movement. There are a couple of qualifications to note, however: firstly, 
walking is quite a natural movement and this has been compared to entirely manufactured 
scratch. Secondly, n=10 for the walking observation and the superimposed scratch data is 
from just one subject. When adjusting position is superimposed on the walking data, it can 
be seen that this is a low acceleration movement with no peak activity at any of the pure 
tones. This would fit with the observation that this movement is not rhythmical and not fast. 
 
It should be noted that, unfortunately, the range of pure-tones for analysis which should 
discriminate itch-related movement (suggested from the video-observation study), 0.5-
2.5Hz, does overlap with walking movement’s (2-3Hz). However, the experiment’s results 
do suggest that discrimination may be improved by taking magnitude of movement or 
acceleration into account as well as frequency of action, something which had not previously 
been considered. 
 














To use directly observed videos of subjects with itch in order to characterise the DigiTrac 
signal readout.  
 
The study was also used, opportunistically, to validate the DigiTrac recording against 




The DigiTrac output yields data on acceleration in specific frequencies of action. In theory, 
therefore, since it is known that the spectrum of frequency of action of itch-related 
movement is 0.5-2.5Hz, it should be possible to gain specific itch-related movement 
measurement in this frequency range. In this experiment, DigiTrac output was compared to 
simultaneous overnight infra-red video recordings and the type of movement recorded at the 




Six child-subjects were recruited. All had atopic dermatitis (as defined by Hanifin and Rajka 
criteria (Hanifin & Rajka, 1980). The subjects were recruited from the Paediatric 
Dermatology clinic, had been diagnosed by a Paediatric Dermatology Consultant and had, as 
would be expected from patients in a secondary care clinic, moderate eczema: SCORAD 
range was 18.8 to 37.0 and the median 27.7. The age range of the subjects was 3-15 years 




All subjects wore a DigiTrac accelerometer overnight on the dominant wrist, an Actiwatch 
Plus on the non-dominant wrist and were simultaneously infra-red videoed at home in their 
own beds (as described in Chapter 1.II). Only one night was studied. Although, normally, 
accelerometers would be worn on the dominant wrist, the children were essentially too small 
to fit both devices on one forearm. Previous research had shown that there was a negligible 
difference in Actiwatch Plus score on dominant versus non-dominant wrist (Benjamin et al., 
2004; Bringhurst et al., 2004) and so this device was placed on the non-dominant wrist.  
 
Instructions were given verbally and in written format including when and how to start the 
video recording. Parents were also issued with a short questionnaire to complete which 
included general information such as when the child went to bed and got up and if they had 
taken medications. 
 
The overnight DigiTrac recording started at 21:00hrs but, because of previous data 
suggesting a discrepancy between parent-recorded sleep-time and actuality, only the activity 
between 02:00hrs and 04:00hrs was analysed. 
 
The DigiTrac and Actiwatch Plus outputs were uploaded into an Excel file.  
a)* Extracting a specific itch spectrum from DigiTrac output.  
The DigiTrac analysis required the sum of acceleration, 0.5-2.5Hz to be extracted 
for each epoch. The sum and epoch was then ranked so that there was a table of Sum 
of FFT (G-s) starting with the largest magnitude in the first column, and the 
corresponding epoch was in the second column. In total there were 1125 epochs for 
the recording period. The video-recording was then examined and the action at the 
corresponding epoch was noted (in the third column). The movement was recorded 
as four categories: scratch, S, (itch-related rhythmical movement including scratch 
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and rub), adjusting position, A, nil, N, and off-camera, O. The process was repeated 
for each subject. The examination of the recordings in this intricate way took over 
one month to complete. 
The data was organised into chunks of acceleration of 10G-s. The highest sum of 
FFT 0.5-2.5Hz was 680G-s and a large proportion were 0G-s. The proportion of 
each type of action for each these groups of 10G-s was plotted. 
b)! Validating DigiTrac against Actiwatch Plus 
Total hourly scores for the DigiTrac entire sum of FFT and for 0.5-2.5Hz was 
compared to the hourly Actiwatch Plus score. 
 
Results 
a)! Extracting a specific itch spectrum from DigiTrac output.  
The individual’s results are plotted in separate graphs in Figure 4.1. The graphs 
show the amplitude or size of acceleration on the x axis and the type of movement 
for that amplitude of movement on the y axis. Imagine a horizontal cut off at 50% (y 
axis-wise), the simplest way to appreciate the data is to consider that whatever 
colour line and whatever movement this represents, is the predominant movement at 
this point (running left to right across the x axis). It can be seen that at a low 
amplitude, most frequently, there is no movement and that above 400G-s the 
majority of movement is generalised or scratch.  
 
Figure 4.2 combines the data for all the subjects. The graph shows that the majority 
of the movement in the amplitude 50-550G-s is scratch, but not exclusively scratch. 
Generalised movement happens at a similar amplitude but happens less often than 
scratch movement. If the amplitude is less than 50G-s the likelihood is that no 
movement at all is detected on the video. Over 550G-s, movement is just as likely to 
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b)! Validating DigiTrac against Actiwatch Plus 
The total nightly DigiTrac score was compared to the same night’s total nightly 
Actiwatch Plus score. It was apparent from the data download that Subject 1 forgot 
to put the Actiwatch Plus on. 
 
The total 2-4am Actiwatch Plus score was compared to the full spectrum 2-4am 
DigiTrac score. It was decided to compare the full spectrum FFT on the basis that 
the Actiwatch Plus was a general movement monitor. Correlation was noted for total 
Actiwatch Plus score versus total DigiTrac FFT score (Pearson ρ=0.753). The 2-4am 
Digitrac data for the restricted spectrum of 0.5-2.5Hz was also available and this was 
also compared to the Actiwatch Plus 2-4am score. The correlation between the 
limited DigiTrac spectrum and the Actiwatch Plus was higher (Pearson’s ρ=0.937). 
The limits of the spectrum were determined by the directly observed frequency of 
action of itch-related movement, scratch and rub (see Chapter 1.III) Graphs to 





































































This experiment demonstrates that the majority of movement in the frequency range 0.5-
2.5Hz and between the amplitudes 50-550G-s, is itch-related ‘scratch’ movement. An 
amplitude of 0-100G-s suggests stillness. An amplitude of 400-500G-s upwards is a larger 
movement than scratch and suggests generalised or ambulatory movement. Unfortunately, 
not all movement of medium amplitude is itch-related, some can be low velocity, low 
amplitude movement related to changing position in bed. 
 
A complicating factor is that it would appear that the majority of human movement occurs in 
the frequency range 0.5-2.5Hz too (as evidenced by my DigiTrac walking experiment, 
Chapter 3.V). This finding could be related to overall size and limb length of Homo sapiens 
as a species (a longer limb will take longer to complete a cycle of movement than a short 
one). One problem is that although psychological overlay and generalised movement is 
assumed to be kept to a minimum by undertaking studies overnight, it can not be assumed 
that a subject, especially a child will stay in bed. Children can quite often be on the move if 
they are not ‘good sleepers.’ It has been observed by personal anecdote and from discussion 
with contemporaries that children will get up out of their beds and bedrooms in the search 
for comfort, milk, etcetera. This could account for the ‘Not on camera’ movement. A bleary-
eyed parent may not record such events: I have often woken up to find my little boy in bed 
with me in the morning never having been aware of his arrival in the night. Therefore, 
although parents were issued with questionnaires enquiring about the child’s night’s sleep 
which included asking what time they went to bed and if they had arisen overnight, it is 
entirely possible and likely that nocturnal excursions were not recorded as the parent may 
not have even consciously registered them.  
 
The study offered the opportunity to validate the DigiTrac against the Actiwatch Plus. As 
expected, a relationship between the outputs of both types of device has been demonstrated 
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in this experiment. The relationship between the scores becomes stronger when the DigiTrac 
score is limited to the sum of 0.5-2.5Hz FFT. One explanation that can be offered to explain 
this would be differences in the band-pass filters for the devices and that introducing a 
further band-pass filter in the form of a restricted range of frequency from the FFT brings the 
results into closer alignment. A further explanation could be related to the fact that the 
devices were not worn on the same arms and so the filtering of DigiTrac score somehow 
again provided alignment for this. 
 
On the basis of the observations and data from this experiment, it was hypothesised that the 
data should first be ‘enriched’ for the frequency range 0.5-2.5Hz. Since little or no 
movement was detected below 50-100G-s and larger amplitude, non-itch-related movement 
occurred at greater than 400-500G-s, a second ‘enrichment’ was proposed for an amplitude 
range: either 100-400G-s or 50-550G-s. Therefore, it was assumed that enriching for this 
frequency of action and amplitude of movement of DigiTrac should provide the most 







“Data enrichment is a general term that refers to processes used to enhance, refine or 




To ascertain whether discrimination of itchy subjects from controls can be improved by 
enriching for a specific range of ‘frequency of action’ and furthermore by a range of 
‘amplitude of movement.’  
 
Background 
The DigiTrac had been specifically sought out as, a specific itch-measuring device. Through 
its ability to report data based on ‘frequency of action,’ and since itch-related movement, 
scratch and rub is rhythmical, it was postulated that its output should allow a more 
discriminating account of itch-related movement in nocturnal recordings. This study was an 
exploratory study to ascertain whether the enrichments of data (selecting or narrowing) 
suggested by previous studies would improve discrimination of itchy subjects from non-
itchy controls.  
 
The FFT of DigiTrac data allows break down of the signal for each epoch into a series of 
pure-tones 0-10Hz (see DigiTrac technical description, Chapter 3.I). If you add the 
acceleration across the pure tones you get the total acceleration per epoch (comparable to the 
Actiwatch Plus reading per epoch). Direct observation of subjects’ itch demonstrated that 
itch-related movement occurs most often in a range of 0.5-2.5Hz. The absolute minimum 
‘frequency of action’ of itch-related movement was 0.5Hz and the maximum 5Hz. The first 
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part of this experiment sought to decide if discrimination of itchy subjects from non-itchy 
controls would be improved by narrowing the DigiTrac output to a specific frequency range. 
 
The study which compared DigiTrac output 0.5-2.5Hz to direct video recording (Chapter 4.I) 
suggested that a second enrichment of the DigiTrac readout should be applied for a specific a 
range of amplitude of movement or acceleration. For instance, it would appear, from video 
and accelerometer studies that most human movement occurs under 5Hz. Some of these 
movements will not be rhythmical, and so detecting a certain, specific ‘frequency of action’ 
may prove helpful. However, rhythmical movement is not exclusively itch-related scratch or 
rub: for example, walking is a rhythmical action, but a large amplitude (entire limbs swing 
around the pendulums of shoulder and hip joints). It was hypothesised therefore, that 
excluding large amplitude rhythmical movements should improve the specificity of itch-
related movement. A ceiling was therefore placed on amplitude of movement. Since no itch-
related movement occurred below 50-100G-s a lower cut-off was proposed to improve 




This was an exploratory study. Subjects who complained of itch associated with their 
conditions were compared to non-itchy controls.  
 
Study subjects 
Subjects were adults and children recruited from General and Paediatric clinics at the 
Department of Dermatology, Edinburgh. Controls were people who had no skin condition or 
itch who attended the department with patients. Nine subjects, four males and five females, 
age range 3-61 years and median, 12 years were recruited. Twelve controls, three males and 




All participants were asked to wear a DigiTrac on the dominant wrist for one night. The 
DigiTrac were set to record movement from 18:00hrs. Participants were issued with a 
questionnaire to note the time of retiring to bed and if they had got up in the night.  The 
recordings of between 02:00hrs to 04:00hrs were chosen for analysis as these were the hours 
which would mostly account for those spent in bed: adults presumed to have gone to bed, 
children not likely to have arisen yet. 
 
a)!Enriching for ‘frequency of action.’ 
The DigiTrac data was uploaded to a P.C. To extract the data: 
1)! The entire FFT of the x axis acceleration data for 02:00hrs to 04:00hrs was exported 
into Excel. 
2)! Three different spectra were examined and where necessary, extracted from the 
entire FFT (0-10Hz) in order to enrich for ‘frequency of action.’ 
a.! Total sum of FFT (0-10Hz) 
b.! 0.5-2.5Hz: as suggested by mean direct video-observed frequency of itch-
related movement. 
c.! 0.5-5Hz: chosen as 5Hz was highest possible observed scratch frequency 
and 0.5Hz the slowest. 
Subjects’ outputs were compared to controls’. 
 
b)!Enriching for ‘amplitude of movement.’ 
The full DigiTrac spectrum was uploaded to a P.C. 
1)! The entire FFT of the x axis acceleration data for 02:00hrs to 04:00hrs was exported 
into Excel. 
2)! The 0.5-2.5Hz spectrum was extracted. 
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3)! Each epoch for each participant was then ranked for amplitude of movement (1125 
for the 02:00hr to 04:00hr period).  
4)! The sum of acceleration for: 
a.! all amplitudes 
b.! 50-550G-s as broadest range dictated from previous study 
c.! 100-400G-s as narrowest range dictated from previous study 
Subjects’ outputs were compared to controls’. 
 
Since the data was normally distributed, parametric testing was applied (unpaired t test). 
 
Results 
Due to a software handling error, data was irretrievably lost on three control subjects such 
that only the data for FFT 0.5-2.5Hz was accessible.  Data was only available on nine control 
subjects for all other analyses. 
 
The itchy subjects’ scores were generally higher than controls’ even without enrichment of 
the DigiTrac output. The separation increases and the overlap decreases stepwise with 
enrichment for spectrum, or ‘frequency of action’ see Table 4.1a and Figure 4.4a. The 
maximal separation (marginally) is seen with enrichment for 0.5-5.0Hz. There is a lot of 
overlap between groups. 
 
The results of the second enrichment for ‘range of amplitude’ on top of that for ‘frequency of 
action’ are summarised in Tables 4.1b and 4.1c and Figures 4.4b and 4.4c. The range 
becomes narrower and scatter is seen to be reduced by the enrichment. The effect is similar 

























Mean Median Standard*deviation Mean Median Standard*deviation Unpaired!T!test
Total*FFT,*all*amplitudes 34320 35216 10801 23463 21868 7548 0.020
*0.5?2.5Hz,*all*amplitudes 16749 16894 3955 12825 12910 3836 0.034
0.5?5Hz,*all*amplitudes 24131 24694 6538 17206 17220 6047 0.033
Subject!(n=9) Control!(n=9!except*0.5?2.5Hz*n=12)
Subject(vs(Control
Mean Median Standard*deviation Mean Median Standard*deviation Unpaired(T(test
*0.502.5Hz,*all*amplitudes 16749 16894 3955 12825 12910 3836 0.034
0.502.5Hz,*500550G0s 4086 3728 2784 898 721 596 <0.001
0.502.5Hz,*1000400G0s 5128 4386 2902 1395 1264 739 <0.001
Subject((n=9) Control((n=12)
Subject(vs(Control
Mean Median Standard*deviation Mean Median Standard*deviation Unpaired(T(test
*0.505.0Hz,*all*amplitudes 24131 24694 6538 17206 17220 6047 0.033
0.505.0Hz,*500550G0s 10469 11228 4208 3558 4110 1582 <0.001













































































































































































































This was a small exploratory experiment to see whether specificity of itch-related movement 
detection could be improved by using a more complex accelerometer, the DigiTrac, which 
was capable of providing information on frequency of action. There are some imperfections 
in the study but as a proof of concept study it fulfils its remit.  
 
The imperfections implied above include that the study subjects are a mix of children and 
adults with different itchy conditions and that the controls are not matched in any way, a 
different range of ages and different distribution of sexes. The experiment offered a learning 
curve in handling the data: through the unfortunate incident of loss of data on three control 
subjects, safety-guards were put in place to prevent this occurrence in future studies. 
 
There is evidently an advantage in enriching for ‘frequency of action.’ There is not much 
difference between the two proposed ranges. It would appear that, similarly, the further 
enrichment for amplitude improves specificity but that there is little difference between the 
two proposed ranges of 50-550G-s or 100-400G-s. The enrichment seems to work by 
improving closer clustering of the data (for controls). The experiment implies that the 
marginally superior separation is achieved by enriching first for a frequency range of 0.5-
2.5Hz as both further enrichments for amplitude of 50-550G-s and 100-400G-s prove highly 
significant on unpaired t test. 
 








1)! To use the DigiTrac accelerometer as an objective and specific measure of itch in 
children with atopic dermatitis for consecutive nights and compare these scores to 
controls subjects’.  
2)! To evaluate objective DigiTrac scores to subjective measure of itch (VAS) and 
disease-extent as measured by SCORAD. 
 
Background 
Use of a digital accelerometer had been validated to measure itch in children (Benjamin et 
al., 2004; Bringhurst et al., 2004).The study had raised interesting observations, firstly that 
there was considerable variation in night-to-night score and secondly that there was a 
disconnect between subjective and objective score. This study sought to discover whether 
the night-to-night variation and disconnect between subjective and objective score was 
because the Actiwatch Plus accelerometer was a non-specific movement monitor as opposed 





Subjects were consecutive children with atopic dermatitis (as defined by Hanifin and Rajka 
criteria (Hanifin & Rajka, 1980)) approached at the Paediatric clinic at the Royal Infirmary 
of Edinburgh and whose parents then agreed for them to participate. Controls were siblings 




•! Patients with atopic dermatitis defined by the Hanifin and Rajka criteria or patients with 
itchy skin due to other causes (skin or systemic either due to primary skin disease or 
systemic disease). 
•! Age >3 months 
•! Able to give meaningful consent or have a parent/guardian to give their consent if <16 
years. 
Controls 
•! Age >3 months 





•! Children under 3 months of age 
•! People not able to understand what is involved or, if ages <16 years do not have a 
parent or guardian who can understand and allow what is involved. 
•! People allergic to rubber. 
Controls 
•! Children under 3 months of age 
•! People not able to understand what is involved or, if ages <16 years do not have a 
parent or guardian who can understand and allow what is involved. 
•! People allergic to rubber. 
•! People with itchy skin. 
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26 subjects and 26 controls were recruited. The subjects comprised 15 males, 11 females. 
The age range for subjects was 3 years to 15 years and the median was 6 years. The controls 
comprised 12 males and 14 females. The age range for controls was 2 years to 15 years and 
the median age was 11 years. As would be expected by the fact that subjects were recruited 
from a secondary care clinic, the range of SCORAD was 19.2 to 63.4 and the median 36.9. 
 
Study Method 
All participants were asked to wear a DigiTrac on the dominant wrist for three consecutive 
nights. The DigiTrac were set to record movement from 18:00hrs. The investigator met with 
the participant after each recording night in order to download the data and reset the 
DigiTrac for the next night. The opportunity was also taken to complete a disease extent 
score, SCORAD in subjects each time. Participants were issued with a questionnaire on 
which to note the time of retiring to bed and if they had got up in the night. Wherever 
possible, the questionnaire was completed by the actual participant but some of the children 
were too young to do this and so the forms were completed by proxy by the parent(s). The 
questionnaire also included a visual analogue scale (VAS) to be completed for itch and 
insomnia for the children with atopic dermatitis. Since there was only one investigator, no 
allowances needed to be made for inter-observer variability 
 
The DigiTrac downloads for 02:00hrs to 04:00hrs were analysed for reasons previously 
described. Since best discrimination had been found in the previous study by combining the 
0.5-2.5Hz spectrum with 100-400G-S and 50-550G-s amplitude range, these were the main 
enrichments applied. For comparison, full FFT spectra (or full DigiTrac readout) per epoch 
was also used for analysis. 
 
Each individual’s nightly DigiTrac data was uploaded to a P.C. Data was extracted as 
previously described: 
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1)! The entire FFT of the x axis acceleration data for 02:00hrs to 04:00hrs was exported 
into Excel. 
2)! The limited spectra of 0.5-2.5Hz were extracted and each epoch output summed.  
3)! Each epoch sum for each participant was then ranked for amplitude of movement 
(1125 for the 02:00hr to 04:00hr period).  
5)! The sum of acceleration for: 
a.! 50-550G-s as broadest range dictated from previous study 
b.! 100-400G-s as narrowest range dictated from previous study. 
 
Subjects’ outputs were compared to controls’. Since mean and median were closely related, 
a parametric test was applied, an unpaired t test. The subject and control groups had different 
variance and thus two sample t tests for heteroscedastic (or samples of unequal variance) 
were run. When data was combined for all nights, mean data for all three nights was 
compared to allow for nesting of experimental results.  
 
Subjects’ subjective data (VAS) and SCORAD were compared to DigiTrac 0.5-2.5Hz 100-
400G-s data. Unpaired t tests for heteroscedastic data were run. 
 
Results 
One subject’s entire data had to be excluded as it became evident from the download of the 
DigiTrac that it had either malfunctioned or she had forgotten to put the DigiTrac on. 
Therefore, analyses were for 25 subjects (15 males, 10 females, the age range and median 
unchanged from previously stated). Regarding completeness of data otherwise: out of 75 
nights’ recordings for subjects, 11 (15%) were missed (no data on DigiTrac) For the 
controls, 4 nights were missed out of 78 (5%). There were more missing nights’ data as the 
nights progressed for subjects due to their being less compliant as the nights went on. 
 
! 153!
The Table 4.2 summarises the subject characteristics, subjective score and disease extent 
score, SCORAD.  Table 4.3 summarises the controls’ characteristics.  
 
Comparison of subjects’ to controls’ scores at varying levels of data enrichment 
The DigiTrac downloads for each night were extracted and enriched as detailed in the 
Methods section, see Table 4.4 (subjects) and Table 4.5 (controls). The subject data was 
compared to controls’ by unpaired t test. Firstly, it was analysed night-by-night (so that the 




















































































































































































































































































































































































































































































































Gender Age Previous.eczema Atopy Food.allergy
Control'1 Male 12 Yes Hayfever No
Control'2 Male 9 No No No
Control'3 Female 15 No No No
Control'4 Female 6 No No No
Control'5 Female 11 No No No
Control'6 Female 13 Yes No No
Control'7 Male 15 No No No
Control'8 Male 15 Yes Asthma No
Control'9 Female 11 No No No
Control'10 Female 11 No No No
Control'11 Male 12 Yes No No
Control'12 Female 9 No Asthma No
Control'13 Female 4 No No No
Control'14 Male 15 No Hayfever No
Control'15 Male 2 No No No
Control'16 Female 7 No No No
Control'17 Female 4 No No No
Control'18 Male 15 Yes Asthma Dairy'and'fish
Control'19 Female 4 No Asthma No
Control'20 Female 8 No No No
Control'21 Female 12 No No No
Control'22 Male 15 No No No
Control'23 Male 7 No No No
Control'24 Male 12 No No No
Control'25 Female 4 No No No











Total 100.400G.s Total 50.550G.s 100.400G.s Total 100.400G.s Total 50.550G.s 100.400G.s Total 100.400 Total 50.550 100.400
Subject*1 25018 2256 15872 1336 980 61426 6560 27300 9686 6820 38204 4524 18750 5332 4244
Subject*2 21860 2582 12222 2344 2200 20008 3340 11416 5844 2206 25884 4126 12834 3812 3060
Subject*3 12928 1758 7082 2378 1886 26752 5088 14614 4926 3638 80100 15442 28578 20576 17870
Subject*4 51572 12018 22180 11044 8900 20592 5154 11058 3340 2594 36250 10466 15948 7512 4046
Subject*5 22100 3054 13510 1766 1324
Subject*6 47962 7838 19596 8240 6612 55180 6546 22076 10016 7552 120014 27378 36720 23878 17422
Subject*7 28832 3774 12416 4696 3286 40736 6386 15346 7482 4898 17476 4104 9570 1680 1170
Subject*8 39210 6606 17980 8140 7304 30474 5332 15622 6028 3802
Subject*9 20612 3720 10228 2230 1554 20480 2548 10954 2958 2578
Subject*10 81654 11190 30036 15604 11922 59046 16270 24758 16256 13620 28810 4868 15210 3014 2352
Subject*11 26778 7498 12252 5276 3920
Subject*12 30302 2446 17248 1608 1186 37522 7546 19702 3700 2162 35742 4656 19790 2890 2260
Subject*13 60448 6962 18130 9004 7170 56444 6810 19160 11966 8656 75298 8604 23414 15664 9734
Subject*14 25762 6282 13524 3970 2746 100748 46290 30718 18346 10042
Subject*15 37806 10980 18338 8634 6154 62470 13962 24584 15238 11514
Subject*16 68506 1798 24120 15268 8964 35482 2938 15582 7346 4100 35332 4228 15448 7204 5794
Subject*17 7058 2490 4082 1480 720 16348 9150 6322 2848 1570 30110 8774 15712 6558 3808
Subject*18 35238 5684 16786 7028 5450 22332 2644 12362 3946 3488
Subject*19 75378 24972 26002 14228 9486 33480 6928 14376 5270 3710 22582 6732 13114 3218 1972
Subject*20 21766 3214 12416 4666 2904 26800 2560 14124 4520 3708 21328 2998 11248 5368 3758
Subject*21 65302 14284 20960 14420 10226 33584 4616 12788 7812 4808 25672 4346 10708 4498 2664
Subject*22 24842 4804 11824 4310 3690 137264 15556 39144 28458 17002 99636 13810 28322 19640 14910
Subject*23 25304 6610 12158 2670 1250 91490 9322 32364 22554 17030 27998 5776 13402 5016 3842
Subject*24 56394 12688 23140 13470 10124 70766 18568 26978 17436 13294





Total 100-400G-s Total 50-550G-s 100-400G-s Total 100-400 Total 50-550 100-400 Total 100-400 Total 50-550 100-400
Control)1 25196 4790 12450 4134 2952 35726 7894 17298 8214 5444 14330 3130 7774 2228 1786
Control)2 23692 4272 14390 2746 1886 33570 4946 16818 5382 4180 31846 3020 16588 4440 2288
Control)3 30922 3422 18604 4946 2466 24620 4330 14758 2822 2396
Control)4 20360 5462 10130 4946 2096 16056 3306 8568 2822 1272 10074 2458 6486 17444 414
Control)5 31068 4070 17064 3828 2472 42420 8570 20318 1992 4828 47226 9166 22100 908 5464
Control)6 21026 3230 10244 3238 3340 22988 3774 11448 6468 2700 37746 7512 15898 7446 7228
Control)7 22420 3154 13720 4600 1862 20340 1384 12642 4208 628 20082 1976 12590 10618 648
Control)8 27224 3300 12302 2160 2630 15718 2726 7658 946 1270 24658 5290 11142 974 3080
Control)9 34910 5954 17670 4012 5954 46756 8144 19932 1868 5392 48312 10760 20934 4270 6998
Control)10 42042 6254 21602 4192 5168 21608 2702 13500 7508 1228 31624 2798 18016 9310 3600
Control)11 30260 9680 14832 8370 3938 20550 5722 11322 1978 2200 24326 5006 12996 4488 3320
Control)12 45618 4326 24534 6414 3536 37426 1764 20696 3032 3040 32116 2178 18358 4128 1266
Control)13 22240 2986 14306 5714 378 30258 6510 16682 2572 1286 28430 5110 16322 1656 1176
Control)14 34642 5348 18756 784 2030 40446 7786 21268 2458 4280 4874 1242 2766 2294 252
Control)15 23522 3808 11820 2706 2676 17922 2376 10550 5590 1090
Control)16 18850 8408 9142 546 2038 34192 15564 13836 3280 5402 14566 6800 7704 1828 1392
Control)17 43352 4234 21790 3428 4732 41938 2018 22746 8152 2898 41040 4170 22994 2268 4322
Control)18 16086 3026 9572 5604 1034 17378 4602 9730 4370 664 16690 3778 9556 5604 1246
Control)19 22616 5366 9180 1526 2378
Control)20 18008 4348 8578 1500 1422 20624 3508 9518 1750 3174 15982 1468 8306 3242 2230
Control)21 27146 5728 14628 2284 1518 32190 5714 15506 3904 2788 30998 3828 15584 2560 2784
Control)22 28022 6562 14320 2388 1914 20506 2696 12184 3828 238 20604 1466 12666 3626 860
Control)23 30422 3634 15136 2650 2796 25820 4432 14362 812 2056 26054 3538 13824 1176 1266
Control)24 31620 6482 12906 3594 4484 30428 11008 12394 2978 2722 22842 4302 10748 2078 2486
Control)25 16146 3338 9070 5750 1414 39686 5714 15786 264 20148 3120 10340 5384 2070
Control)26 23360 8996 11698 3418 1836 17748 4608 9604 2378 390 49784 15966 18498 2516 6246
Night)1 Night)2 Night)3









Mean Median St)deviation !T!test Mean Median St)deviation !T!test Mean Median St)deviation !T!test
Subjects:)total)FFT,)total)acceleration 37965 29567 20574 47226 35482 30249 45027 32721 30980
Controls:)total)FFT,)total)acceleration 27337 26171 8003 28708 28039 9551 26345 24492 12053
Subjects:)total)FFT)100B400GBs 6790 5318 5385 9201 6560 9266 8177 5322 6291
Controls:)total)FFT)100B400GBs 5007 4337 1859 5393 4605 3247 4602 3658 3415
Subjects:)0.5B2.5Hz,)total)acceleration 16334 16329 6105 18852 15582 8266 18048 15580 7603
Controls:)0.5B2.5Hz,)total)acceleration 14171 14013 4308 14524 14099 4293 13448 12831 5204
Subjects:)0.5B2.5Hz)50B550GBs 6724 4681 4950 9620 7346 6953 8491 5350 7165
Controls:)0.5B2.5Hz)50B550GBs 3672 3511 1822 3640 2978 2154 4420 3434 3745
Subjects:)0.5B2.5Hz)100B400GBs 4920 3488 3584 6640 4100 4821 6182 3825 5611









It can be seen that, if the nights are examined individually (Table 4.6), the separation 
between subjects and controls does not consistently reach significance. Using the entire FFT, 
for nights 1, 2 and 3, subject versus controls’ means are 37965G-s and 27337G-s (p=0.025), 
47226G-s and 28708G-s (p=0.009) and 45027G-s and 26345G-s (p=0.033) respectively.  
With enrichment for amplitude (100-400G-s) the means for subjects versus controls for 
nights 1, 2 and 3 are 6790G-s and 5007G-s (p=0.135), 9201G-s and 5393G-s (p=0.064) and 
8177G-s and 4602G-s (p=0.050) respectively. It can be seen that the variance is large in 
Figure 4.5 impairing the ability to separate subjects from controls. 
 
However, in the night-to-night analysis, enrichment for ‘frequency of action’ (whether 0.5-
2.5Hz or 0.5-5Hz), with or without further enrichment for amplitude reliably separates the 
groups to the point of significance. Enrichment purely for ‘frequency of action’ 0.5-2.5Hz 
yields means for subjects versus controls for night 1, 2 and 3 of 16334G-s and 14171G-s 
(p=0.158), 18852G-s and 14524G-s (p=0.032) and 18048G-s and 13448G-s (p=0.045) 
respectively. Enrichment for ‘frequency of action’ 0.5-2.5Hz and amplitude 50-550G-s 
yields means for subject versus controls for night 1, 2 and 3 of 6724G-s and 3672G-s 
(p=0.008), 9620G-s and 3540G-s (p<0.001) and 8491G-s and 4420G-s (p=0.049) 
respectively. There is little difference in the improvement of separation by applying the filter 
of amplitude by 50-550G-s or 100-400G-s, but the later is slightly more effective: means for 
subject versus controls for nights 1, 2 and 3 are 4920G-s and 2652G-s (p=0.007), 6640G-s 
and 2531G-s (p<0.001) and 6182G-s and 2646G-s (p=0.027) respectively. The enrichment 
appears to reduce spread of the controls’ scores whilst the subjects’ remain very variable. 
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Secondly, all three nights’ data was amalgamated to compare subjects’ scores to controls.’ 
Each night’s data for each subject was meaned to allow for nesting in the study. The results 
are summarised in Table 4.7. It can be seen that whether the DigiTrac data is enriched or not, 
the groups are separated to the point of significance (Table 4.7).  The means for subjects 
versus controls of the DigiTrac total FFT, unenriched are 41697G-s and 27253G-s 
respectively (p<0.001). The means for subjects versus controls of the DigiTrac total FFT 
enriched for amplitude 100-400G-s are 8054G-s and 4971G-s respectively (p=0.010). The 
means for subjects versus controls of the DigiTrac output enriched only by frequency 0.5-
2.5Hz are 17345G-s and 13923G-s respectively (p=0.009). When the DigiTrac output is 
enriched for both frequency 0.5-2.5Hz and amplitude, the means of subjects versus controls 
are 8526G-s and 3855G-s (p<0.001) for 50-550G-s and 5644G-s and 2593G-s (p<0.001) 
respectively. 
 
The overlap is reduced by clustering the data, or reducing variance, most especially of the 
control subjects through the enrichment. The combined data echoes the night by night 
analysis inasmuch as most separation is achieved by applying the enrichments of 0.5-2.5Hz 
and 100-400G-s: mean for subjects 8230G-s and mean for controls 3855G-s (t test p<0.001). 












All#three#nights#combined Mean Median St#deviation #T#test
!!Subjects:!total!FFT,!total!acceleration 41697 39927 18262
!!Controls:!total!FFT,!total!acceleration 27253 26815 7288
Subjects:!total!FFT!100?400G?s 8054 7236 5310
Controls:!total!FFT!100?400G?s 4971 4068 2102
!!Subjects:!0.5?2.5Hz,!total!acceleration 17345 16801 4994
!!Controls:!0.5?2.5Hz,!total!acceleration 13923 13053 3852
Subjects:!0.5?2.5Hz!50?550G?s 8526 7813 4282
Controls:!0.5?2.5Hz!50?550G?s 3855 3244 1806
Subjects:!0.5?2.5Hz!100?400G?s 5644 5180 3164


























































































































Night-to-night variation in score. 
Night-to-night scores for each individual (and the mean, red X) are plotted to examine the 
amount of variation within individual and between individual, night by night. The data is 
summarised in Figure 4.7’s graphs. The graphs demonstrate the large variance within and 
between person. The variance is greater for subjects rather than controls. The data also shows 
that there are not inherently ‘high-scorers’ or inherently ‘low-scorers’, by this, I mean there 
are not individuals who consistently give a high score night by night nor those who always 
yield low scores night-by-night. The graphs further illustrate how the enrichment steps, 
especially 0.5-2.5Hz and 100-400G-s improves the clustering, or reduces the variance, of 
controls’ scores. 
 
Subjective VAS score and SCORAD compared with objective (subjects only). 
For the purposes of this part of the study, the DigiTrac data enriched by 0.5-2.5Hz and 100-
400G-s was used as this seemed to provide the best separation of itchy subjects from 
controls, and therefore – it was assumed - was most likely to represent the objective 
measurement of itch. Tables 4.6 and 4.7 summarises the data. Figure 4.8 demonstrates the 
relationship between DigiTrac score (on x axis as deemed most likely to be a true, objective 
score) and subjective VAS score of itch. A poor relationship was noted between DigiTrac 
score and VAS: correlation coefficient, rho= 0.289. To answer whether a lack of relationship 
was related to whether the subject (rho=0.253) or a proxy (rho= 0.616) had completed the 
subjective data, these subjects were separated. Again, no significant relationship is 





































































































































































































































































































































































































































































































































































































Figure 4.9 demonstrates the comparison of objective DigiTrac score and disease extent as 
measured by SCORAD: correlation coefficient, rho= 0.269. It can be seen that there is a poor 
relationship between the two. Since SCORAD involved combining VAS scores of itch and 
insomnia, and since it was thought that this may be a source of error (the majority of scores 
were made by proxy), the SCORAD without subjective data was also plotted and compared: 
correlation coefficient, rho=0.196. It can be seen that there is a lack of relationship between 































































This experiment had two objectives, firstly to extend the use of the DigiTrac, as a specific 
objective itch monitor into a larger study in order to answer some queries previously raised 
about variation in accelerometer score. The opportunity was also taken to see if the specific 
objective itch monitor scores correlated better than the non-specific movement monitors 
(Actiwatch Plus).  
 
The results confirm postulations made on the basis of the previous, smaller study (Chapter 
4.III), that DigiTrac could reliably separate itchy subjects from controls on the basis of the 
enriched data. Enrichment could be seen to improve separation stepwise through enrichment 
for ‘frequency of action’ and then for amplitude. The fact that the three nights’ combined 
analysis demonstrates separation to the point of significance without so many levels of 
enrichment may allude to the fact that the separate night analysis is under-powered. The 
numbers of subjects and controls were made with the purpose of estimation of effect size 
rather than formal power calculations as this was an exploratory study. 
 
There was large variation, within person, night-by-night in DigiTrac score whether the 
participant was an itchy subject or a control. It was suspected that some subjects may just 
score higher or lower than others, but the data does not suggest this: there was night to night 
variation in any direction. The range of scores reached much higher in the itchy subjects. 
The enrichment improves separation of itchy subjects from controls, and it would appear, as 
previously suggested in the pilot study, that this is in some ways because the enrichment 
allows better clustering of the controls whilst the massive range of itchy subjects’ score 
remains untouched.  
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It is suspected that the age of subject may have implications on the accelerometer scores. As 
witnessed in infrared video studies and noticed by anecdote at home, small children 
generally move about more that teenagers and adults at night. Some condition could be 
added to the DigiTrac enrichment data to allow for this by a suitably qualified signal analyst. 
Unfortunately, this study did not afford the opportunity for this, but a later study described in 
Chapter 5.I did. 
 
Overall, on the basis of this study, video-observation and previously published work by this 
unit, night-to-night variation in score would appear to be a true phenomenon. 
 
Comparing objective to subjective measures was undertaken in order to see if the previously 
noted lack of correlation (Bringhurst et al., 2004) was to do with the fact that Actiwatch Plus 
accelerometers are non-specific movement monitors. DigiTrac-enriched data should provide 
a specific objective measure of itch to allow comparison with subjective and extent of 
disease data (SCORAD). However, no relationship was detected between objective DigiTrac 
score and VAS of itch. There was no correlation even when scores made by proxy were 
removed. This concurred with the Actiwatch Plus experiment findings. It would therefore 
appear that there is a true disconnect with subjective and objective itch scores.  
 
No relationship was discovered, either, between the enriched DigiTrac score and SCORAD. 
SCORAD does involve and incorporate VAS scores of itch and insomnia and so, in an effort 
to correct for any bias afforded by this, the subjective scores were removed but correlation 
was still very poor. It is difficult to offer an explanation for why two seemingly objective 
scores should be divergent. It may be related to the previously mentioned variation in score: 
fleeting changes related to hotness, urticarial, for instance, may result in a very transient and 
abrupt itch response. This may account for the labile objective night-to-night DigiTrac score. 
DigiTrac responds to quick changes in condition. SCORAD is designed to assess the chronic 
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changes that skin makes in response to eczema such as lichenification. It may be because of 
this that the scores diverge. 
 
It was at this point, that, having extended the use of accelerometers to my maximal ability 
(as a clinician and not a signal analyst) and frustrated by there seemingly being unanswered 
questions regarding subjective and objective disease measure divergence that the second part 





















To use the Actiwatch Plus to characterise the features of night-to-night variation in objective 
itch score and to compare this to subjective measures of itch and disease extent. 
 
Background 
The experiments that led to this point had demonstrated: 
a)! Large night-to-night variation in objective accelerometer scores in small cluster 
studies. 
b)! That variation in objective score was a ‘true’ phenomenon, as verified by 
comparison to gold standard direct observation on infra-red video in consecutive 
night studies. 
c)! That accelerometers which had the potential to measure specific itch-related 
movement, (DigiTrac), as opposed to generalised movement (Actiwatch Plus) also 
demonstrated night-to-night variation. 
d)! A disconnect or lack of relationship between the verified objective accelerometer 
scores and subjective scores. 
 
An objective score provides a logically attractive measure of disease: a ‘true’ measure which 
can be used to monitor disease or treatment, however, it misses a truly important dimension 
of disease, namely, how that individual actually experiences or perceives it. To provide an 
illustration, two individuals may have exactly the same disease extent as measured by PASI 
(Psoriasis Area Severity Index) but one, who enjoys swimming for instance, may regularly 
be placed in a situation where he/she is embarrassed by that disease and therefore notices 
more impact of the disease on their daily life than another individual who does not swim. 
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The experiments up to this point provided a source of confusion and concern: why were the 
objective and subjective not at all related? This experiment sought to further characterise the 
objective score night-to-night variation looking for patterns of scoring and, at the same time, 
to characterise night-to-night variation in subjective scores in the same way. 
 
Methods 
Participants were patients attending the Department of Dermatology in Edinburgh for 
treatment of itchy skin conditions. As such, as in previous experiments, these subjects 
represented a cohort with a more moderate to severe disease severity as they were attending 
secondary care clinics. After patients were approached and requested to consider taking part 
in the study, they were given written and oral information to consider. The patients were 
given time (at least 24 hours) to consider the invitation to participate in the study, and then 
contacted again by telephone. Those who agreed to participate then met the researcher at a 
mutually agreed appointment time and if they consented themselves or were consented by 
proxy the study went ahead 
 
The studies have the use of Actiwatch Plus in common. Subjects were required to wear this 
for the prescribed number of nights of the study on the dominant wrist, or right wrist in a 
child who had not declared dominance, two hours before retiring to bed (reasons previously 
declared (Benjamin et al., 2004; Bringhurst et al., 2004)). The Actiwatch Plus has the facility 
of being able to alter recording epoch length. In order to be able to issue the accelerometer 
and for it to be set up to detect for the entirety of even the longest stint of the study (21 
days), the epoch length was set to one minute. As explained in Chapter 2.I, lengthening the 
recording epoch does not reduce the sensitivity of the monitor as data is still sensed 32 times 
per second and the digital signal summed for whatever epoch is selected. For consistency’s 
sake, the same epoch setting was used for all these studies. 
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Study 1: short cluster night-to-night study (up to 7 days). 
Inclusion criteria 
Subjects comprised 68 itchy adults and 50 itchy children. The control participants were 12 
adults and 12 children. The subjects’ diagnoses and characteristics are specified in Table 5.1. 
All the child-subjects had atopic eczema (as defined by Rajka and Hanifin criteria (Hanifin 
& Rajka, 1980)). The broad groups of diagnoses for adult-subjects were: eczema, psoriasis, 
cholestatic liver disease and pruritus of unknown cause (PUC). A total of 1654 nights were 
studied: 1573 subject-nights and 81 control-nights. 
Subjects:  
•! Patients, children or adults, attending the department for treatment of itchy 
skin conditions. 
•! Age >3 months 
•! able to provide consent for self or parents able/willing to do so by proxy 
Exclusion criteria 
Subjects: 
•! Subjects under 3 months of age 
•! People not able to understand what is involved.  
•! People allergic to rubber (due to possible allergy to actiwatch). 
 
Study method 
Subjects were requested to wear the Actiwatch Plus (digital accelerometer) for three to seven 
nights. Participants were issued with written and oral instructions plus a questionnaire on 
which to note information such as any medications used, if they had got up overnight and 
subjective scores. Every day of the study, the participants were asked to complete a 10cm 
VAS of extent, itch and insomnia. In the case of children, adults (parent/guardian) completed 
the scores for the participants.  
! 177!
Study 2: longitudinal study for 42 nights 
20 patients were recruited. Eleven females and nine men agreed to participate. The subjects’ 
characteristics are listed in Table 5.1.  
Inclusion criteria 
Subjects:  
•! Adults, attending the department for treatment of atopic dermatitis (as 
defined by Hanifin and Rajka criteria (Hanifin & Rajka, 1980) 
•! Age 16 years 




•! Subjects under 16 years of age 
•! People not able to understand what is involved.  
•! People allergic to rubber (due to possible allergy to Actiwatch Plus). 
 
Study method 
The subjects were issued with a digital accelerometer and instructed to wear it every night 
for the next 42 nights. A total of 761 nights were studied (some participants forgot to apply 
the accelerometer every night). All subjects were issued with written and oral instructions 
plus a questionnaire to list information pertinent to the study (medications used, nocturnal 
ambulatory movement). 
 
The participants were issued with dated sheets so that every day they should complete VAS 
scores of itch, disease extent and insomnia plus a ‘ballot box’ to post each day’s scoring 
sheet into immediately after completing it. This was to enable, as far as possible, ‘blinding’ 
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to the previous day’s VAS score and to reduce anchoring bias as much as possible. The sheet 
for Day 0 was completed and deposition demonstrated to the researcher by the participant.  
 
On (or as near to) Day 21 of the study, the participant and researcher met so that the 
accelerometer could be downloaded and checked for full functionality.  On (or as near to) 
Day 42 of the study the researcher met with the participant to collect and download the 
digital accelerometer and to collect the completed forms – all, it was expected, to be 
contained in the ballot box.  
 
As well as the daily VAS, a measure of disease extent, SCORAD (Severity Scoring of 
Atopic Dermatitis) was completed by the researcher at the beginning, at the mid-point and at 
the end of the study. Subjective scores SF-36 (Ware & Sherbourne, 1992) and an adapted 
Day Reconstruction Method (DRM) (Kahneman, 2004), in which GHQ (Global Health 
Question) (Bjorner, 2005) was embedded and into which questions directly relating to skin 
disease and itch were added, were completed at the beginning, mid-point and the end of the 
study. See Figure 5.1 for a flowchart of the study. For descriptions of and the rationale 
behind choosing these subjective measures, please see Introduction, section VII. 
 
Use of the DRM questionnaire was exploratory. The adapted DRM includes a 7-point Likert 
scale of itch and allows analysis of amount of time (in minutes) experiencing itch and other 
symptoms and emotions. A vast array of data was gleaned: information about every hour of 
the previous day on three occasions. Some of the data simply not relevant in this context, for 
instance, happiness whilst child-caring, cleaning, etcetera was not analysed. The adapted 
DRM is attached in Appendix III. 
 



























Number M:F*ratio Mean*age*(yrs) Age*range*(yrs) Nights*studied Eczema Psoriasis PUC Liver
Child*subjects 50 26:24 6.92 2)15 229 50 0 0 0
Child*controls 12 2:10 10.33 6)14 42 n/a n/a n/a n/a
Hepatic5itch Adult*subjects 6 27:40 43.5 16)78 1344 30 25 4 8
Adult*controls 13 5:8 38.23 24)71 39 n/a n/a n/a n/a
Adult*subjects 20 11:9 40.55 16)67 761 20 0 0 0
Subject code Completed VAS (days) Total study days Completion % VAS Completed Actiwatch (nights) Completion % Actiwatch
1 37 44 84.1 36 83.7
2 44 46 95.7 38 84.4
3 43 43 100 37 88.1
4 42 43 97.7 33 78.6
5 42 43 97.7 16 38.1
6 42 43 97.7 38 90.5
7 40 42 95.2 35 85.4
8 43 43 100 22 52.4
9 43 43 100 19 90.5
10 43 43 100 38 90.5
11 43 43 100 17 40.5
12 43 43 100 32 76.2
13 42 43 97.7 33 78.6
14 40 44 90.9 19 44.2
15 43 43 100 40 95.2
16 43 43 100 25 59.5
17 39 43 90.7 21 50
18 43 43 100 29 69
19 39 43 90.7 22 52.4
20 39 43 90.7 39 92.9
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Analysis 
This was an exploratory study and so formal power calculations were not made. The 
numbers of subjects recruited were decided with the purpose of estimation of effect size in 
mind and were opportunistic. The approach was to report p values or confidence limits on a 
pragmatic sample group based on previous experiments, availability and costs.  Most of the 
experiments ‘nested’ previous conclusions in each successive experiment, implicitly testing 
the conclusions of previous analyses. 
 
Actiwatch Plus data was downloaded via the proprietary reader into Excel (Microsoft Ltd, 
Seattle, USA) and managed in this software. The subjective and disease extent was also 
entered into and managed using Excel. Statistics were analysed in ‘R’ v2.9 or SPSS v21 
(IBM) running on a Mac (OS 10). 
 
In order to differentiate (in Study 1) between adults completing their own subjective 
symptom-scores and child-subjects, who had required an adult to complete them for them, 
analyses which involved examination of VAS itch scores were conducted separately for 
those under and over 16 years of age. Actiwatch Plus scores are non-normally distributed 
and were usefully log transformed. Following inspection using univariate analyses, non-
significant terms were removed from the regressions, and examination of factors were 
performed using Holm’s correction for pairwise t-tests. Holm’s correction is required when 
it is necessary to counteract problems associated with multiple comparisons and issue also 
known as the  Family-wise error rate (FWER). FWER is defined as, “the probability of 
making one or more false discoveries, or type I errors, among all the hypotheses when 
performing multiple hypotheses tests.” It is similar to the Bonferroni method but more 
powerful and most appropriate in this particular circumstance. Within and between person 
variance was examined using analysis of variance. 
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Longitudinal scoring patterns of objective accelerometer measured itch and subjective VAS 
score in Study 2 were analysed for autocorrelation. This type of analysis is one more 
commonly used to predict weather or financial fluctuations (Kravchenko, Grechany, & 
Gadjiev, 2006; Lewellen, 2002). The subjective data was normally distributed and so 
parametric analyses were employed for comparisons within this type including Student t test 
and Pearson correlation coefficients. 
 
Results 
Study 1: Characterising determinants of actigraphy scores using short cluster night-to-
night study (up to 7 days). 
 
The majority of subjects completed three or more nights of the study. Just as in previous 
experiments, a large variation in Actiwatch Plus score was discovered. Slightly more 
variation in objective score, 56%, was found between person, and slightly less, 44%, existed 
within person: an individual’s scores, overall varied by 44% night-to-night.  
 
Subsequent analyses used mean Actiwatch Plus scores. Children (<16 years) and adults (>16 
years) were examined separately, as mentioned previously to avoid the potential bias from 
subjective data being completed by proxy.  The total data set results are shown in Figure 5.2. 
It can be seen that itchy subjects have higher Actiwatch Plus scores than controls and that 
those with liver disease associated itch appear to be scratching the most. There is much 
overlap, but second most itchy are those with atopic dermatitis (more subjects) and pruritus 
of unknown cause (very few subjects). 
 
Children 
Linear regression of log. actigraphy scores showed no effect of age (p=0.67) nor sex (0.365). 
Actiwatch Plus scores were, as expected, higher for atopic subjects than controls: mean (log) 
! 183!
actigraph score was 9.02 for atopics versus 8.29 for controls (p=0.021). VAS itch was not a 
significant predictor in either univariate (p=0.261) or multivariate (p=0.284) models.  
The relation between Actiwatch Plus score and VAS itch score is demonstrated in Figure 
5.3. A line of best-fit has been added but this does not significantly differ from zero. This 




Linear regression of log. actigraphy scores showed no effect of age nor sex. Mean log 
Actiwatch Plus score analysis showed a stepwise reduction in mean score through 10.4 for 
those with liver disease, 8.95 for those with atopic dermatitis, 8.99 for subjects with pruritus 
of unknown cause, 8.43 for psoriasis patients and 8.14 for controls. Pairwise t test are shown 
in Table 5.3, and it is clear that many of the comparisons were significant, notably for 
eczema patients compared to all other groups except pruritus of unknown cause. 
 
Mean VAS itch scores were 6.64, 4.83, 4.68 and 2.53 in patients with liver disease, psoriasis, 
atopic dermatitis and patients with itch of unknown cause. The only significant difference 
between these groups was between those with liver disease and those with itch of unknown 
cause (p=0.04, pairwise t test): the spread of values within each group was large. 
 
Univariate analyses demonstrated that both diagnosis (p<0.001) and VAS itch (p=0.042) 
were significant predictors of actigraphy scores but the R square value for VAS itch was 
small at 0.06. The R square for diagnostic category was more convincing at 0.51. Once 
diagnosis was entered into the regression, VAS itch was no longer significant (p=0.27). The 
relation by diagnostic group between VAS itch score and Actiwatch Plus score is shown in 
Figure 5.4. Lines of best-fit have been added but do not differ from zero. Thus, the 


































































Eczema Control Liver Psoriasis
Control 0.002 - - -
Liver <0.001 <0.001 - -
Psoriasis 0.018 0.356 <0.001 -
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Study 2: longitudinal study for 42 nights 
 
This experiment involved a different cohort of subjects from those recruited for Study 1: 20 
adults with eczema. 
 
a)* Characterising longitudinal objective and subjective scoring patterns using prospective 
42 night study: comparison of daily objective Actiwatch Plus score with daily VAS itch 
score 
 
Nocturnal Actiwatch Plus score and VAS itch scores were recorded over a 42-day study 
period.  Little relation was found between the Actiwatch Plus score and VAS itch. This 
finding is illustrated in Figure 5.5. Lines of best fit have not been added but the distribution 
of the data points clearly demonstrates no relationship between these two measures. 
Spearman’s rho correlation coefficient for each subject is listed in Table 5.4. 
 
The data in Table 5.4 needs to be considered cautiously as night-to-night for the same person 
cannot be assumed to be independent and so it is not meaningful to report correlations for 
each person. A different approach was therefore taken to the data: could forecasting analysis 
detect a pattern of scoring in either the objective or subjective data? The empirical 
autocorrelation structure of the VAS itch and actigraphy scores was examined (Figures 5.6 
and 5.7).  A line representing p=0.001 significance is plotted.  It can be seen that the pattern 
for actigraphy and for VAS itch is very different. For VAS itch, there is a clear pattern of 
autocorrelation most strong at a lag of one night, but visible up to five nights. For actigraphy 
there is no good evidence of any lag effect.   Time series modelling using moving averages 
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Subject Spearman's/rho Significance Number/of/pairs
1 0.119 0.523 36
2 0.264 0.125 37
3 0.146 0.040 35
4 0.287 0.105 33
5 ,0.377 0.184 14
6 0.009 0.959 39
7 0.091 0.605 35
8 0.500 0.860 22
9 0.444 0.057 19
10 ,0.010 0.053 38
11 ,0.164 0.528 17
12 ,0.063 0.734 32
13 0.081 0.657 33
14 ,0.114 0.653 19
15 0.263 0.101 40
16 0.241 0.245 25
17 0.214 0.351 21
18 0.111 0.565 29
19 ,0.155 0.514 20
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Study 2: longitudinal study for 42 nights 
 
 
b)* Comparison of objective and subjective measures of disease. 
 
All subjects bar one (who missed the middle assessment) completed the validated subjective 
symptom questionnaires DLQI (Dermatology Life Quality Index) and SF-36 (otherwise 
known as RAND-36) at the beginning, middle and end of the 42-day study period (as well as 
undertaking daily VAS scores). The researcher also examined the subjects to complete the 
disease extent measure, SCORAD, at the same time points. As an exploratory venture, the 
Day Reconstruction Method (DRM) was completed by the subject at the beginning, middle 
and end of the study too. The subjective and extent measures were compared to each other as 
well as to the objective Actiwatch Plus score. 
 
There was no significant difference in DLQI, SF-36 or SCORAD over the 42-night period 
(as analysed by ANOVA). It had been predicted that, since the DRM questionnaire took up 
to two and a half hours to complete, the number of episodes would decrease each time the 
participant had to repeat the process, but this was not the case (ANOVA confirms lack of 
difference). Table 5.5 summarises the DLQI, SF-36 and SCORAD score characteristics. 
Figure 5.8 summarises the DLQI, SF-36 and SCORAD scores plus the number of DRM 








Mean Median St dev Overall Mean Overall range
SF-36 Day 1 71.203 82.229 26.614
SF-36 Day 21 75.294 81.646 25.488
SF-36 Day 42 74.363 83.750 25.147
DLQI Day 1 8.400 5.500 7.148
DLQI Day 2 7.895 6.000 6.641
DLQI Day 3 8.450 4.500 7.970
SCORAD Day 1 22.075 14.500 15.240
SCORAD Day 21 17.895 14.500 13.915
SCORAD Day 42 18.500 13.500 15.628
73.578 21 to 104
8.254 1 to 26
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i)* Correlation data 
An expected negative correlation was found between the extensively validated DLQI and 
SF-36 raw scores (Pearson’s correlation coefficient=-0.814, p<0.001). The relationship was 
expected to be negative since a higher DLQI score indicates poor health whilst a lower SF-
36 indicates poor health (Ware & Sherbourne, 1992). There was a strong positive 
relationship between DLQI and DRM itch raw scores (Pearson’s correlation 
coefficient=0.786, p<0.001). These scores run in the same direction with regard to severity 
and so a positive correlation was expected. DRM itch was, strongly and negatively related to 
SF-36 (Pearson’s correlation coefficient=-0.677, p=0.001), again, correlation ran in the 
expected direction. There relationship between SCORAD and all other measures, subjective 
and objective is poor - none are significant, see Table 5.6. 
 
The DRM itch data shows a poor relationship with DRM raw scores for positivity (Pearson’s 
correlation coefficient=-0.004, p=0.986) and happiness (Pearson’s correlation coefficient=-
0.306, p=0.189). There is a significant positive correlation with DRM itch and raw scores for 
negativity (Pearson’s correlation coefficient=0.505, p=0.023), sadness (Pearson’s correlation 
coefficient=0.659, p=0.002) and strongest and perhaps most understandably with being 
uncomfortable (Pearson’s correlation coefficient=0.952, p<0.001). 
 
There is an expected negative directional correlation between Log.actiwatch score and SF-36 
(Pearson’s correlation coefficient = -0.382, p=0.082), but the relationship is weak. The 
relationship between Log.actiwatch and SCORAD and DLQI is also poor: Pearson’s 
correlation coefficient=0.275, p=0.240 and 0.327, p=0.160 respectively. Log.actiwatch score 
is no better related to DRM itch raw scores (Pearson’s correlation coefficient=0.153, 
p=0.519).  
 





































































































































































































































ii)* Global Health Question.  
This question was embedded in DRM twice: first at the beginning and then at the end. The 
reason for the two placements was to see if focussing the mind acutely by undertaking the 
DRM and minimising recall bias made any difference to the score. The mean score (each 
subject over three occasions) before and after DRM does not appear markedly different 
graphically, see Figure 5.10, but the variable is ordinal. The mean before is 2.88 (SEM 
±0.135) and after 2.59 (SEM ±0.113) and p=0.083 (paired t test).  A lower score means a 





















GHQ before GHQ after
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 Mean
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iii)* Day Reconstruction Method measured itch:  in and out of work. 
 
It is stated that being awake or being distracted reduces the perception of itch. The DRM 
questionnaire afforded the possibility of testing this theory. The questionnaire was adapted to 
include questions about how itchy the subject felt whilst they were inside or out of work. 
The results confirmed the effect: the mean percentage time (minutes) subjects felt incredibly 
itchy outside and inside work respectively were 12.967mins(SE±5.188) and 6.333mins 
(SE±1.992), p=0.487, the mean time subjects felt quite itchy outside or in work respectively 
were 29.608mins (SE±4.290) and 27.578mins (SE±5.913), p=0.541, the mean time 
respondents were hardly itchy outside or in work were 29.267mins (SE±3.991) and 
26.722mins(SE±3.735), p=0.574 respectively and finally, the means for not feeling itchy at 
all when outside and in work were 26.508mins (SE±5.769) and 38.944mins (SE±7.154), 
p=0.027. The trends suggests that distraction at work reduces the perception of itch but the 
only significant difference in means is in those not feeling itchy at all: as expected more 
people felt least itchy in work rather than out of work. The results are summarised in Figure 
































Mean   Standard deviation Standard error Paired t test
Incredibly itchy 12.967 23.201 5.188
Work Incredibly Itchy 6.333 8.908 1.992
Quite itchy 29.608 19.187 4.290
Work Quite itchy 27.578 26.443 5.913
Hardly noticeably itchy 29.267 17.847 3.991
Work Hardly noticeably itchy 26.722 16.704 3.735
Not at all itchy 26.508 25.801 5.769







The aim of this study was to use the Actiwatch Plus to characterise the features of night-to-
night variation in objective itch score and to compare this to subjective measures of itch and 
disease extent. The work builds upon previous studies and confirms that the relation between 
objective measures of scratch and subjective itch is poor.  
 
Study 1 demonstrated that there is no obvious relation between itch assessed using VAS 
scores and objective Actiwatch Plus scores for either children with eczema or adults with a 
range of diagnoses. Previous work has validated actigraphy against direct observation of 
children scratching at night(Benjamin et al., 2004; Bringhurst et al., 2004), and both 
scratching and restlessness are correlated with each other, and higher in those with atopic 
dermatitis than in controls. Itch related behaviour at night is not as stereotyped as when 
awake, and actigraphy is, we believe, a useful practical assay for scratch when compared 
with the time consuming nature of direct observation of video recordings. Although we 
analysed children and adults separately we saw no influence of sex or age on Actiwatch Plus 
score. The main determinant of differences in Actiwatch Plus score was diagnostic group: 
those with liver disease were the most severely affected. We have assumed that restlessness 
due to other factors differing between diagnostic groups is not confounding the scores. 
Although the subjective VAS itch scores differed between the different diagnostic groups, 
the differences were largely non-significant, again emphasising a disconnect between VAS 
scores and objective accelerometer score 
 
The large variation in objective accelerometer score was confirmed again in Study 1. It was 
shown that about 60% of variation was between subject and roughly 40% within subject. 
This fact emphasises that nocturnal movements vary from night to night within any one 
subject, and of course limits the power of actigraphy scores for experimental studies unless 
repeated sampling is carried out. 
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Study 2 afforded the opportunity to look in more detail at the relation between VAS itch and 
Actiwatch Plus score over time. Little convincing relation between subjective VAS and 
objective Actiwatch Plus was found even in the long-lasting 42-day study. Examination of 
the autocorrelation showed a very different pattern for actigraphy and VAS itch. The VAS 
itch scores clearly showed an effect of lag, and it is not clear why this should be. Subjects 
were asked to post their scores into ballot boxes in an attempt to minimise filling out of 
results in batches, and to attempt to minimise knowledge of the score on one day influencing 
the score on the next day. This strategy would not be entirely robust against ‘gaming’ 
(posting a batch of results at the end, for instance) and electronic diaries or other methods of 
continuous sampling would perhaps provide a better approach (Kahneman, 2004; Langan, 
Bourke, Silcocks, & Williams, 2006; Robinson & Clore, 2002b). We suspect that the 
presence of the temporal pattern for VAS itch scores (and not actigraphy) is more easily 
explained by subjects anchoring their scores based on recollection of previous scoring 
(Bjorner, 2005; Kahneman & Tversky, 1996). Overall – and whether we can explain the data 
or not – the results suggest that the use of VAS scores for itch is limited as a subjective 
measure of disease activity in the context of the chronic diseases we studied. 
 
In order to determine whether the problem was an inherent one with VAS scores or more 
generally to do with subjective assessment of disease, Study 2 drew in other validated 
subjective score of itch and of disease extent to compare to each other and to the objective 
Actiwatch Plus. These experiments proved that the disconnect is not because the VAS in 
itself is a flawed measure (it’s limitations are part of published literature, (Bjorner, 2005; 
Torrance et al., 2001)). The fact that there is a lack of relationship between DLQI, SF-36 and 
Actiwatch Plus score confirms the disconnect between subjective and objective. Since part 
of SCORAD is VAS itch, although it is a disease extent measure, it is not surprising that 
there was a lack of relationship between this and Actiwatch Plus score. Reassuringly, the 
subjective scores do correlate appropriately with each other. 
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This study also offered an opportunity to explore the use of a different questionnaire, the 
Day Reconstruction Method, designed by Daniel Kahneman who works in the field of well-
being research and cognitive behavioural psychology (Kahneman, 2004). It was designed to 
capture what must be one of the most difficult feelings to define, happiness. The publication 
which described the questionnaire (Kahneman, 2004) threw up some quite controversial 
findings: people happiest socialising with friends and not relatives, mothers finding childcare 
only one step better than their least satisfying activity, cleaning the house. The questionnaire 
captures ‘true’ emotion rather than stereotyped answers, the ones we feel we should give: 
‘Of course I’m happiest spending time with my husband/children.’ The questionnaire 
‘works’ by requiring the participant to build a diary of the day, hour by hour and relive each 
episode whilst asking questions about it. This reduces recall bias to a minimum – it is known 
that for most perception, how participants feel in the most recently past five minutes dictates 
the response even if the enquiry is about a longer period, for instance, the past week for 
DLQI, the past month for SF-36(Kahneman et al., 1993; Redelmeier & Kahneman, 1996; 
Redelmeier, Katz, & Kahneman, 2003). 
 
There was no better relationship between DRM measured itch and objective Actiwatch Plus 
score. It was reassuring, again, to see that DRM aspects correlated appropriately with the 
other subjective measures and that again SCORAD was not related to the score. It is 
intriguing to see that, even when recall bias is reduced to a minimum, the disconnect 
between subjective and objective still exists, there is obviously some elusive facet of disease 
that we can not directly measure with presently available tools. 
 
One of the most powerful tools for assessing overall health is the Global Health Question 
(GHQ), a deceptively simple question which just requires a simple choice of four responses. 
Decline in GHQ raw score can be tracked to a respondent’s death (Bjorner, 2005). The fact 
that the response changed for the worse after DRM in this study is interesting: it would 
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appear to suggest that after really thinking about the hourly impact of disease participants do 
feel worse about their disease and health. 
 
The impact that distraction can have on disease perception was an unexpected serendipitous 
aspect of itch perception which was captured by the DRM. The fact that participants did 
report being less troubled by itch whilst at work and more when not distracted at home is 
what had been expected. It demonstrates the sensitivity of the tool. 
 
One limitation of this study is that the work was based on those attending secondary care, 
and therefore was probably skewed towards patients with more severe disease, as reflected 
by the SCORAD scores. The subjects were volunteers and, since the study involved a 
significant amount of time and contact with the investigators, the study group may not be 
typical of the reference population, another limitation. It was not possible to prospectively 
control the severity of disease during the study period—if patient groups at the extreme of 
the severity of the symptom scale had been used it is possible different conclusions might be 
made, although the SCORAD scores for the eczema group were as high or higher than in 
many therapeutic trials. 
 
Overall, this experiment demonstrated that objective scoring using actigraphy (Actiwatch 
Plus or DigiTrac) may not be perfect but does confer a measure on a certain aspect of itchy 
disease. Some form of measurement of perception of disease or impact of disease on life 
should be utilised too but it should be borne in mind that the tools available to us now are not 
perfect either. To this researcher’s mind, although it is appealing to use subjective tools 
because, for instance, they are used often, they are used by prominent research teams or 


























To test widely used subjective-symptom measures for vulnerability to bias: are they 
measuring semantic beliefs about disease rather than actual experience? 
 
Background 
This work in this thesis has demonstrated a disconnect between objective and subjective 
symptom measures. Through the experiments previously described, I had validated and 
refined objective disease measurement in the form of actigraphy. The disconnect between 
objective and subjective score was still present and so the next logical step was to ascertain 
whether the problem or cause for the inconsistency was actually due to a ‘fault’ in the 
subjective scoring method. 
 
Subjective-symptom measures are widely used and most commonly validated by checking 
for reliability, responsiveness and validity. Reliability is checked by testing for internal 
consistency (Cronbach’s alpha), see Introduction, which ascertains that tools are measuring 
the same psychometric variable. Validity is checked by test-retest consistency. The 
subjective symptom tools had not been tested for vulnerability to bias. In these short 
experiments I tested the effects of focusing (Del Missier et al., 2007; T. D. Wilson et al., 
2000) and framing (Del Missier et al., 2007; Wright & Goodwin, 2002) biases on 
Dermatology Life Quality Index (DLQI), Global Health Question (GHQ) and visual 








A total of 215 patients were recruited.  For each study, consecutive patients who agreed to 
take part were enrolled from the Royal Infirmary’s Department of Phototherapy in 
Edinburgh. Details of specific diagnoses were not sought, the usual throughput of the 
Phototherapy department would suggest that the majority (70%) of the patients had psoriasis, 
a minority (roughly 10%) had eczema and 20% other conditions (for instance generalised 
pruritus). Most participants scored the DLQI in the region of 6–10, which equates to a 
“moderate” effect of the skin condition on the quality of life, this level of severity was 
expected inasmuch as recruitment was from secondary care.  
 
All study procedures and patient interactions were conducted using a consistent, written 
script. The interaction script and subject information sheet explained that the studies were to 
determine which sort of questionnaire or score was most accurate in assessing symptoms. 
The interventions were described in general terms (“You will be given a list of words to 
memorise” or “If you are randomised into a certain group you may see a film broadcast on 
terrestrial television”) in order to minimize unintentional “unblinding”.  
All participants completed the GHQ (“In general, for someone of your age, would you say 
that your health is excellent, very good, good or poor?”), DLQI and VAS of disease extent, 
itch and insomnia, always in the same order. 
Inclusion criteria 
•! Patients attending the Phototherapy department for treatment. 
•! Age >14 years 
•! Able to give meaningful consent.  
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Exclusion criteria 
•! Subjects under 14 years of age 
•! People not able to understand what is involved.  
 
Experiment 1 
My hypothesis was that, if subjects were exposed to certain mood-eliciting words, they would 
affect the subjective score accordingly, for instance, if they had read negative words, their 
subjective scores would suggest worse disease.  
 
Forty patients were randomised into two groups. Block randomisation was undertaken and 
all the paperwork for the study including instructions was placed in a sealed envelope so that 
the study was double-blinded.  
 
Group 1 were asked to read 10 negative words, had 1 minute to memorise them and were 
then asked to write them out. After this, they completed the GHQ, DLQI and the VAS’s of 
disease extent for itch and insomnia. The words are listed in Table 6.1. 
 
Group 2 went through an identical process but the participants were given a list of 10 neutral 
words. 
 
 One field of Psychology research has identified and used words which elicit certain 
affective states. Groups 1 and 2’s words, for this part of the experiment, are listed in Table 
6.1 and were taken from the ‘Balanced Affective Word List’ 
(http://www.sci.sdsu.edu/CAL/wordlist/origwordlist.html). The words were matched for 
total character and syllable length.  
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A further 41 patients were randomised into 2 groups: 
 
Group 3 were asked to read 10 negative words and then write them out (without the 
necessity of memorising them). The participants then completed GHQ, DLQI and VAS’s or 
disease extent, itching and insomnia. The words are in Table 6.2. Group 4 went through an 
identical process but participants were given a list of 10 positive words.  
 
Groups 3 and 4’s words were taken from the University of Florida’s NIMH Centre for the 
Study of Emotion and Attention (http://csea.phhp.ufl.edu/Media.html#bottommedia) and are 
listed in Table 6.2. Again, the words were matched for total character and syllable length. 
 
Experiment 2 
My hypothesis was that if a subject saw a film highlighting the negative aspects of having a 
skin disease, then this would make them focus on the negative aspects of living with their 
skin disease and so their subjective scores would imply that they had worse disease.  
 
Fifty-four patients were block randomised into two groups: 
 
Group 1 completed GHQ then VAS’s for disease extent, itch and insomnia, after having 
watched a 10 minute clip from a terrestrial television broadcast (‘Real Families: My Skin 
Could Kill Me’ broadcast before the ‘watershed’ on ITV1 in October 2005) about living with 
the severe skin condition, Harlequin ichthyosis.  
 









Group 1 Group 2



































All subjects were questioned in the same way and in the same experimental room, whether 
they had watched the film or not. The randomisation result (to watch the film or not) was 
included in the questionnaire envelope and was opened, with the interviewer being present in 
the study room, the interviewer then adopted the appropriate script (for whether the 
participant was to watch the film or not) from that point.  
 
Experiment 3 
In this study, the hypothesis was that if the DLQI focused on negative aspects of disease, 
then re-framing it into “neutral” frames should result in scores implying a better quality of 
life. We also hypothesized that if the DLQI focused on the negative, then this may negatively 
affect the responses to other subjective symptom scores.  
 
Eighty patients were randomised into two groups and each of these two groups further split 
into 2 sub-groups, giving a total of 4 sub-groups into which subjects were block-randomised. 
Half the subjects answered the GHQ (Global Health Questionnaire) and standard DLQI 
(Dermatology Life Quality Index,)(Finlay & Khan, 1994) whilst the other half answered an 
altered Dermatology Life Quality Index (ADLQI) and the standard Global Health 
Questionnaire. The ADLQI mirrored the standard DLQI but an attempt was made for each 
question to be re-written in a neutral frame, thereby, minimising the possibility of a positive 
or negative framing and potentially reducing the possibility of a stereotyped answer. The 
standard DLQI is shown in Figure 6.1a and the altered version in Figure 6.1b.  
 
Division of the two groups allowed the ordering of the examination to be manipulated, with 
half the subjects receiving the GHQ first and then either the DLQI or the ALDQI, with the 
other half receiving the GHQ second. 
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Demographic variables including age and sex, together with the results, were de-identified 
and recorded in Excel (Microsoft, Seattle). Statistical analyses were undertaken using R-
software (http://www.R-project.org) (Team RDC. A language in environment of statistical 










DERMATOLOGY LIFE QUALITY INDEX      DLQI 
Hospital No: Date:    Score: 
Name:  Diagnosis:  
Address:   
 
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE 
LAST WEEK.  Please tick one box for each question. 
 










2. Over the last week, how embarrassed or self conscious have you 










3. Over the last week, how much has your skin interfered with you going 












Not relevant ! 













Not relevant ! 
5. Over the last week, how much has your skin affected any social or 












Not relevant ! 
6. Over the last week, how much has your skin made it difficult for you 













Not relevant ! 








Not relevant ! 
7. 
If "No", over the last week how much has your skin been a problem at 
work or studying? 
A lot 
A little 








8. Over the last week, how much has your  skin created problems with 












Not relevant ! 













Not relevant ! 
10. Over the last week, how much of a problem has the treatment for your 













Not relevant ! 
 








AMENDED DERMATOLOGY LIFE QUALITY INDEX      DLQI 
Hospital No: Date:    Score: 
Name:  Diagnosis:  
Address:   
 
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE 
LAST WEEK.  Please tick one box for each question. 
 










2. Over the last week, has how happy or confident youíve been had 










3. If you think about everyday things such as going shopping or 












Not relevant ! 
4. When you think about what you chose to wear last week, did your 












Not relevant ! 
5. Did your choices regarding socialising/taking part in activities have 












Not relevant ! 
6. Did your choices regarding taking part in sporting activities have 













Not relevant ! 








Not relevant ! 
7. 
If you were at work or studying last week, did what you achieve 
have anything to do with your skin? 
A lot 
A little 








8. When you think about how well you have got on with your partner/ 
any close friends over the past week, has your skin got anything to 












Not relevant ! 
9. Considering your sex-life over the last week, is your skin relevant to it? Very much 
A lot 
A little 








Not relevant ! 
10. Compared to other daily activities, over the last week, how much 












Not relevant ! 
 





The majority of variables were non-normally distributed, medians were therefore compared 
using the Kruskal-Wallis (KW) analysis of variance (ANOVA) and using Fisher’s exact test 
for count data. The significance level was set at p<0.05. Due to the limited range of the GHQ 
questionnaire, these results were also examined using Fisher’s exact test but this did not alter 
any of the conclusions and is not presented. 
 
Experiment 1: the impact of affect-eliciting words.  
A total of 81 subjects were studied and their characteristics are shown in Table 6.3. There 
were four intervention groups, numbered 1 to 4 as mentioned previously. There were no 
significant differences in the sex allocation (Fishers test p=0.81) nor median ages (Kruskal 
Wallis, p=0.70) between the four groups. Median scores for the four groups and p values 
using the Kruskal Wallis ANOVA are shown in Table 6.3. As can be seen, there were no 
significant differences evident. 
 
Experiment 2: the impact of watching a film about living with a severe skin condition.  
54 subjects were studied. Their characteristics, the median group-scores and Kruskal-Wallis 
ANOVA results are shown in Table 6.4.  
 
There was no significant sex difference in the two groups, those who were shown the video 
and those who were not (Fisher, p=0.27). The median age of those shown the video was 52 
as compared with those who were not shown the video of 33, a difference that is highly 
significant (KW, p=0.001). However, scatter plots did not show any obvious relation 
between age and the outcome measures so this difference was ignored. Median scores and p 
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values for the Kruskal Wallis ANOVA are shown in Table 6.4. As can be seen, there are no 
significant differences evident.  
 
Experiment 3: re-wording DLQI into neutral frames.  
80 subjects completed this experiment and their characteristics are summarised in Table 6.5. 
GHQ and quality of life scores (QI) were examined following four ‘treatments.’ The first 
‘treatment,’ the DLQI, was compared with the second ‘treatment’, Altered-DLQI (ADLQI), 
and following this, the ordering of GHQ and DLQI/ADLQI were studied (hence treatment 
groups were numbered as follows: 1, 2 (DLQI) and 3, 4 (ADLQI).  
 
There were no significant differences in sex (Fisher, p=0.17) or age (KW, p=0.92) between 
the four groups. Median scores and Kruskal Wallis ANOVA across the four groups for QI 
(DLQI and ADLQI) and GHQ are listed in Table 6.5. These differences are not significant 
(KW for QI p=0.47 and GHQ p=0.76). The ordering had no effect on GHQ (p=0.60) or QI 
(p=0.5) scores and therefore groups 1 & 2, and 3 & 4 were combined. Medians for the 
ADLQI and the DLQI for these combined groups were 8.5 and 7, respectively, a difference 



















 Age in years: Sex Median DLQI Median GHQ Median VAS extent Median VAS itch Median VAS insomnia






























2.15 (0.90-4.33) 3.60 (1.50-7.20)
2.15 (1.08-4.33) 4.80 (2.85-5.73)
1.50 (0.55-3.95) 1.90 (0.70-5.75)
Age in years: Sex Median DLQI Median GHQ Median VAS extent Median VAS itch Median VAS insomnia





p=Kruskal-Wallis 0.34 0.20 0.50 0.11 0.21
3.90 (2.10-6.35)
35.8 (16-74) 9:18 9.00 (4.50-15.00) 2.00 (1.50-3.00) 3.20 (1.65-6.40) 2.70 (0.95-5.15) 2.20 (1.45-5.05)
50.3 (17-77) 14:13 8.00 (4.50-9.00) 3.00 (2.00-3.00) 4.50 (2.95-6.15) 2.00 (0.85-3.90)
 Age in years: Sex Median QI Median GHQ
mean (range)   M:F:Unknown (interquartile range) (interquartile range)
Group 1
DLQI then GHQ, n=21
Group 2
GHQ then DLQI, n=21
Group 3
ADLQI then GHQ, n=19
Group 4
GHQ then ADLQI, n=19
  p=Kruskal-Wallis 0.47 0.76
44.0 (17-76) 8:11:0 8.50 (6.00-13.00) 2.00 (1.75-3.00)
42.3 (19-81) 9:9:1 8.00 (6.75-10.50) 2.00 (1.00-3.00)
42.8 (16-79) 9:11:1 7.00 (4.50-11.00) 2.00 (2.00-3.00)




The results presented are, essentially, negative and, in that sense, they can be viewed as 
reassuring: the commonly used subjective symptom-measures we employ in dermatology are 
resistant to the forces of bias. Using the criteria of statistical significance, we were unable to 
significantly alter the scores with the various attempts at manipulation of the context or 
wording of the questionnaires or VAS.  
 
There are, however, a number of limitations to the work. Although we studied several 
hundred subjects, it is always possible that, with larger groups, differences that we observed 
may have been formally significant.  Second, even within the experimental paradigm we 
adopted, there were limitations to the way the experiments were carried out. For instance, 
although I used a video of a child affected with skin disease, I could not find a suitable video 
that I thought was meaningful to use as a control. It was extraordinarily difficult to alter the 
wording of the DLQI without producing a caricature of it. The differences seen between the 
altered DLQI and the genuine DLQI approach significance but, of course, interpretation of 
these differences is not straightforward. The fact that a different questionnaire produces a 
different median score should not be viewed as too surprising and nor does it invalidate in 
any way, even if the differences had been significant, the absolute score on the DLQI. It is 
just perhaps that the median value would differ rather than any relation between the DLQI 
and a host of other disease features.  
 
Although the study did not demonstrate any effects of framing or contextual factors in our 
study, the study itself was experimental and may not reproduce the sorts of real life factors 
that will influence the way people respond to questionnaires. The results do not mean that 
the tools are invulnerable to the effects of say, the stress of a clinic running late, liking or not 
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liking the clinician or ‘gaming’ scores to gain a particular goal, for instance, eligibility for a 
biologic treatment for psoriasis. It would be difficult to capture such influences. 
 
This experiment did not set out to compare different questionnaires, or measures of aspects 
of diseases - there is already a large literature on this and on the advantages and 
disadvantages of speciality or disease specific scoring systems versus more generic 
questionnaires, such as EuroQOL or SF-36, for instance. (Both, Essink-Bot, Busschbach, & 
Nijsten, 2007; Chren, Lasek, Quinn, & Covinsky, 1997; Hongbo, Thomas, Harrison, Salek, 
& Finlay, 2005).Much as the universe continues to expand, so, it seems, does the number of 
scoring systems being proposed and advocated in the literature. This study’s results were 
published and its final proposal was that if nothing else a ‘weather eye’ should be kept on the 
entire field of subjective-symptom measures and that tools should continue to be validated in 
the face of new or improved understanding of the human psyche. 
With respect to attempting to explain the disconnect between objective actigraph score and 
subjective scores of itch, the explanation was still outstanding. My final conclusion in this, 
the context of the thesis, therefore is this: inasmuch as the the tools tested seem robust in the 
face of pressure applied by biases, the disconnect between objective and subjective can not 
be explained by vulnerability of the subjective symptom tools to focus and framing bias. As 
mentioned above, they may be vulnerable to other pressures, but the study rules out the 














1)! To assess whether anonymised 3-D models of psoriasis change or improve perceived 
psoriasis extent. 
2)! To assess whether subjects’ own photographs would improve self-assessed extent in 
a clinical treatment setting. 
 
Background 
The evidence presented in this thesis, so far, demonstrates a poor relationship between 
objective and subjective disease scores. This made me consider another disconnect: between 
doctors’ and patients’ assessment of disease. If this exists, surely there is potential for 
dissatisfaction in the care interaction especially if there are different perspectives on what is 
considered an acceptable treatment outcome.  
 
When searching the literature, I just found one study which had investigated this in the field 
of quality of life (Janse et al., 2004). This meta-analysis found that there was more of a 
discrepancy between doctors’ and patients’ assessed subjective domains (cognition, emotion 
and pain) which was deemed ‘moderate to good,’ as opposed to objective domains 
(sensation, self care and mobility), which were ‘good to excellent.’ This is not unexpected as 
the objective items are more tangible. What was telling, however, was that they only found 
12 studies (from an original search of over 10,000 papers) where patient and doctor reports 
were included and, in fact, none of these included studies had actually reported the 
discrepancy in results(Janse et al., 2004).  
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It is not unexpected that these subjective-disease questionnaire results may diverge but there 
is also evidence of variance in measuring disease extent. Several studies have checked for 
intra- and inter-operator variability in scoring this in dermatology. Variability has been 
found in scoring eczema with the available tools (Charman et al., 1999) and  psoriasis 
(Marks, 1989; Ramsay & Lawrence, 1991) (Berth-Jones et al., 2006). It appears that the crux 
of the matter may be that neither patients nor practitioners are very accurate or reliable at 
estimating affected surface area coverage. In a study using one-dimensional cut-out models 
of psoriasis of known surface area coverage, it was shown that there was considerable 
difference in assessment: dermatologists under-estimated coverage whilst nurses over-
estimated and, the most accurate at assessing area were ‘rule of 9’-naïve and dermatology-
naïve medical students (Tiling-Grosse & Rees, 1993).   
 
It occurred to me that, perhaps, standardised photographs of known surface area coverage, 
which could be used by patients and doctors for comparison, could be helpful, however, 
problems with data protection and personal features preclude unbiased patient-to-photograph 
comparisons. Also, it is very difficult to achieve accurate calculation of the actual surface 
area covered on photographs due to their being 2-D representations of 3-D objects. Despite 
evolving technology, there are not yet good systems of determining psoriasis extent by a 
computer analysis of a photograph (Ashcroft, Wan Po, Williams, & Griffiths, 1999; Park et 
al., 2004; Savolainen, Kontinen, Alatalo, Röning, & Oikarinen, 1998). 
 
I therefore proposed a series of computer-generated images of increasing severity (or disease 
coverage). I wrote to the Dean of the Edinburgh College of Art to introduce myself and the 
potential study. I received a very helpful response. He introduced me to the artist, Beverley 
Hood, who worked in the field of animation, who had designed ‘avatars’ and who, therefore, 
was ideally suited and open to a collaboration. A series of 36 computer generated images 
comprising 36 disease severities or psoriasis coverages ranging from 1.95% to 62% were 
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designed. The models were anonymous, featureless figures, which, therefore, allowed an 
unbiased relationship between assessor and model: a blank canvas for the respondent to map 
himself or herself onto. 
 
The images were used, firstly, to investigate perception of disease extent across different 
medical and non-medical groups and, secondly, for patients to assess their own disease 
extent and to compare this with assessment with PASI and DLQI. The overall aim was to 
unify patients’ and doctors’ perspectives of extent and thus hopefully encourage more 
satisfying clinical interactions on both sides.  
 
The reasoning for introducing the other facet of own-photograph prompts to the second part 
of this study was to ascertain if the ‘hedonic treadmill’ (Kahneman, Diener, & Schwarz, 
1999; Riis et al., 2005) was affecting self-perception of disease-extent in a chronic disease, 
psoriasis. It was speculated that, if this were the case, adaption to the situation could tend to 
make patients assess their disease as less severe or extensive than it really was. The hedonic 
treadmill can, of course, work in the other direction too: if a patient is so used to their usual 
condition, they may not perceive the improvements that treatments effect. This was why the 
effect was tested on a group about to embark upon treatment. It had been noted in 
Phototherapy clinics that patients appeared pleasantly surprised (curiously) when seeing their 
own photographs at mid-way review. They mostly commented that they had improved more 
than they had thought. It was this anecdote and the cognitive behavioural theory which 
informed the second study. 
 
Method 
Development of the computer models. 
I selected photographs of psoriasis patients. A range of patterns and severities were selected 
from patients attending secondary care and included chronic plaque psoriasis and guttate 
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disease. The full range of available photographs did not include true erythroderma. The 
photographs were standardised (standard lighting and positional conditions), did not include 
the face and the subject had consented to their use for research and teaching. They were 
sorted into nine folders of increasing extent. It was expected that the severities would run 
from one to ten where one was no psoriasis and ten maximal, hence nine severities, starting 
at two, minimal psoriasis, on this scale. No formal measurements of affected surface area 
were made on the photographs. 
 
Meanwhile, the artist, Beverley Hood had created a humanoid 3-D figure or ‘avatar.’ When 
designing the body-shape of the model, a realistic, naturally proportioned, figure was 
purposefully produced – not an idealised, fantasy body commonly associated with computer 
generated models (viz. Lara Croft). Since it was recognised that the creation of each model 
would be so intricate, it was decided that, certainly initially (and for the purpose of this 
study) a model with female form only would be designed and therefore we would only 
recruit female patients for parts of the studies which involved the participants comparing 
themselves to the models. Figure 7.1 illustrates the ‘avatar’ without any psoriasis.  
 
The folders of psoriasis photographs were passed to the artist and she then created the 3-D 
models as representative composites of different disease coverage, they were not, therefore, 
mere illustrations of one patient photographed. A series of computer images comprising nine 
psoriasis severities (each with views of front, back, half front and half back) were designed 
using the 3-D character-modelling package, ‘Poser’ (Smith Micro Software Inc., Santa Cruz, 
CA) and the imaging software, ‘Adobe Photoshop’ (Adobe Systems Inc., San Jose, CA). 
 
Although only nine models of increasing severity were designed, the fact that the whole 
figure could be viewed from four different angles (front, back, half front and half back) 
provided 36 different percentage-coverage views available for evaluation. ‘Weighting’ of 
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severity relating to certain body sites affected: areas that cannot easily be covered, the face 
and the hands, has been demonstrated (Finlay & Coles, 1995). This is why our models were 
designed with deliberate avoidance of coverage in these sites. The first 3-D first models had 
unaffected faces in situ but sample respondents found these models harder to relate to – even 
the bland facial features were distracting – and so headless models were created. 
 Figure 7.2 demonstrates the psoriasis images created.  
 
The images of psoriasis-affected models had been entirely artistically created: it was not 
decided that they should represent certain percentage disease coverages ‘up front.’ 
Therefore, the percentage surface area covered by disease had to be discerned. The 3-D 
image was flattened in ‘Adobe Photoshop.’ The resulting image is best compared to an 
animal skin rug (see Figure 7.3a). The ‘Histogram’ feature of ‘Adobe Photoshop’ yields the 
number pixels of each colour. I therefore carefully coloured each plaque of psoriasis the 
opposite spectral colour from skin-colour (blue) having removed the top rendering layer of 
the image. The ‘Histogram’ feature could therefore reveal the number of pixels of psoriasis 
compared to unaffected skin.  Figure 7.3a shows an example of the flattened image and an 
example of the same image coloured in order to assess percentage disease coverage (Figure 
7.3b).  This flattened image allowed surface area coverage for the entire 3-D model, but not 
for the posed views, so these had to be estimated from the 3-D form, colouring the plaques 
blues and using the ‘Histogram’ feature as previously described. The surface area coverage 
for each image was calculated by dividing the number of pixels of plaque coverage by the 
entire image pixel number. Psoriasis coverage ranged from 1.95% to 62.00%, see Table 7.1. 
Figures 7.4 and 7.5 are graphs demonstrating the BSA (body surface area) % coverage of 
psoriasis in each 3-D pose (Figure 7.4) and combined and in order of BSA % extent in 






























































































Front Half front Half back Back
1 2.0 2.3 3.7 4.6
2 5.5 4.7 5.1 7.6
3 9.5 7.8 10.7 14.7
4 15.4 14.8 17.1 20.7
5 21.2 19.9 26.1 28.5
6 28.2 27.4 33.3 35.9
7 36.3 31.8 35.4 37.2
8 43.6 44.1 44.3 47.0
9 50.7 51.5 57.6 62.0
















































































































































































































































Study 1: Do standardised 3-D images of psoriasis improve inter-assessor consistency for 
disease extent? 
 
Study 1 participants 
60 participants were recruited: 12 dermatology doctors, 8 dermatology nurses, 5 general 
nurses, 10 medical students and 5 administrative staff as well as 20 female psoriasis patients 
The psoriasis patients were females approached consecutively who were attending the Royal 
Infirmary of Edinburgh’s Psoriasis and Phototherapy clinics. All study procedures and 
subject interactions were conducted with a consistent written script and answer-sheet.  
 
Study 1 protocol 
The 3-D models were presented in random order of severity in four separate folders. Each 
folder contained a different view (front, back, half front and half back) of the models. The 
folders were presented in the image viewing system of Mac OS X, Leopard (Apple, 
California). Table 7.2 shows the actual order of severities presented to the subject. Each 
participant was asked to: ‘Go through each image in order and give the model a score out of 
10 where 10 is the most severe and 0 the least severe. If you think two models are the same 
you can give the same score.’ They were also asked to pick one model that they thought 
best-represented ‘mild disease,’ one which represented ‘moderate’ disease and, finally, one 
model to represent ‘severe’ disease. This process was repeated for each folder and therefore, 
each view, and respondents had no access to their responses or to figures from the other 
‘views.’ Participants were also asked to score their Global Health Question (GHQ) response.  
 
The participants’ characteristics are summarised in Table 7.3. Disease extent was not 
formally assessed: moderate to severe level of disease was expected from the source of 













 Order of presentation Front Half front Half back Back
First folder 6 1 4 1
Second folder 1 3 7 7
Third folder 3 9 5 2
Fourth folder 2 6 3 9
Fifth folder 9 4 9 8
Sixth folder 4 7 1 5
Seventh folder 8 2 2 4
Eighth folder 7 5 6 3
Ninth folder 5 8 8 6
Position view and model severity
Type of respondent Number Median age, years (and range) Male:Female Median GHQ (and range)
Administrative assistant 5 54 (23-56) 1:4 3.0 (3.0-4.0)
Dermatology doctor 12 33.5 (27-51) 5:7 4.0 (3.0-4.0)
Dermatology nurse 8 47 (39-53) 2:6 2.5 (1.0-3.0)
General nurse 5 38 (20-51) 0:5 3.0 (2.0-4.0)
Medical student 10 22 (19-25) 6:4 3.5 (3.0-4.0)
Patient 20 46.5 (19-77) 0:20 1.88 (0-4.0)
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The scoring was found to be normally distributed, therefore parametric tests were 
undertaken: means were compared by standard ANOVA and linear regression and ANOVA 
performed when comparing respondent scores of extent to the models’ extent (Body Surface 
Area, BSA, %). 
 
The respondents were clustered as follows for the purposes of analysis: 
1)! Dermatology doctors, n=12: included Consultants and Registrars trained and 
practising in dermatology. 
2)! Dermatology nurses, n=8: nurses specifically trained in and practising in 
dermatology 
3)! General nurses, n=5: nurses from other specialities, Health Care Assistants (none of 
whom undertook specific dermatology care). 
4)! Administrative, n=5: staff who work in administrative roles such as receptionists, 
Medical Records staff. Also included ‘Research Technicians’ as these had no 
clinical dermatology experience. 
5)! Medical students, n=10: students on the first day of their dermatology attachment 
who had no previous dermatology experience. 




Study 2: Do standardised 3-D images of psoriasis and photograph prompts improve self 
assessed disease extent? 
 
Study 2 participants 
21 patients were recruited. All were female adult patients attending the Royal Infirmary of 
Edinburgh. Consecutive female patients were approached who were attending the 
Phototherapy or Psoriasis tertiary referral clinics. It was decided only to pick female patients 
as the computer models were female forms (as stated above). 
 
Patients who were about to commence phototherapy or systemic treatment were given 
information about the study. The patients were given time to consider the invitation to 
participate in the study, and then contacted again by telephone. Those who agreed to 
participate then had an appointment to meet the researcher arranged.  
 
The subjects’ median age was 40 (range 21 to 62 years). The mean baseline Global Health 
Question response was 2 (range 0 to 3). The baseline mean DLQI was 15.9 with a range of 3 
to 27 and mean baseline PASI was 8.9 with a range of 3.2 to 14.6. 
 
Inclusion criteria 
•! Psoriasis (as diagnosed by Consultant). 
•! Female 
•! Starting phototherapy/Ciclosporine/Biologics  
•! Age >16yrs 
 
Exclusion criteria 
•! Patients with other skin conditions 
•! Males 
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•! Not about to commence Phototherapy or systemic treatment 
•! Age <16yrs  
 
Study 2 protocol 
On the day that the treatment (Phototherapy or systemic treatment) was due to commence 
(Day 0), the patient met the researcher and: 
 
1)! Clinical, standardized photographs were taken.  
2)! PASI (Psoriasis Area Severity Index) was scored by the researcher.  
3)! The computer-generated models were presented in random order of severity in 
Leopard, Mac OS X (as in Study 1). Only ‘front’ and ‘back’ views were shown (as 
these approximated to the clinical photograph views). The participants had full 
control of which models to bring into central view and were shown how to move 
around amongst the images by using the computer keyboard. The participants were 
then asked to select the model which, “most represents how you feel about your 
psoriasis today.” This selection was called ‘Selection 1.’  
4)! Subjects then completed a VAS score of disease severity and DLQI.  
5)! The participants were then asked to look at that day’s (Day 0) photographs and then 
presented with a new viewing folder of images (presented in a different order) and 
asked to select a model which “most represents how you feel about your psoriasis 
today.” This selection was called ‘Selection 2.’ 
 
On Day 42, the patient and researcher met again.  
1)! Clinical photographs were taken 
2)!  The PASI scored by the (same) doctor.  
3)! The computer-generated models were presented in random order of severity in 
Leopard, Mac OS X (as on Day 0 and Study 1). The participants were asked to select 
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the model which, “most represents how you feel about your psoriasis today.” The 
chosen model was called ‘Selection 3.’  
4)! Subjects then completed a VAS score of disease severity and DLQI.  
5)! The participants were asked to look at that day’s (Day 42) photographs and then 
presented with a new viewing folder of images (presented in a different order) and 
asked to select a model which “most represents how you feel about your psoriasis 
today.” This model was called ‘Selection 4.’  
6)! Finally, the subjects were shown their own Day 0 photographs. Again, after studying 
these, they were presented with a further folder of images presented in a different 
order and asked to select a model “most represents how you feel about your psoriasis 
today.” This final chosen model was called ‘Selection 5.’ 
 
Please see Figure 7.6 for a flowchart of the study. Table 7.4 shows the actual order of 
severities presented to the subjects. 
 
Statistical analysis 
Data was analysed using software (Excel, Microsoft Ltd, USA and StatsDirect Ltd, United 
Kingdom). Pair-comparisons were made using Student’s t test as the data was normally 
distributed data and by ANOVA for comparison across several groups. Correlations were 
evaluated by using Spearman’s rho and linear regression of assessed score on actual pixel 































Study 1: Do standardised 3-D images of psoriasis improve inter-assessor consistency for 
disease extent? 
 
Participants were not selected or controlled for as this was an exploratory study, therefore 
the groups displayed differences beyond their being medical, non-medical or patients. Table 
7.3 summarises these features but importantly it should be noted that the age and Global 
Health Question (GHQ) results are significantly different across the groups. Notable 
differences are that the patients score the lowest median GHQ response, 1.88 (poorer general 
well-being) followed by dermatology nurses (median 2.5) the general nurses and 
administrative staff (median 3), medical students (median 3.5) and finally, dermatology 
doctors (median 4). The ages of the groups from oldest to youngest are: administrative staff 
(median 54 years), dermatology nurses (median 47 years), patients (median 46.5 years), 
general nurses (median 38 years), dermatology doctors (median 33.5 years and finally 
medical students, (median 22 years). The groups were compared and found to be 
significantly different for age and GHQ score response (ANOVA, p<0.001). Since baseline 
differences in the groups had been demonstrated, scoring differences were expected too 
across the different respondent groups. 
 
Comparing how the different groups score the models for extent ‘out of ten.’ 
Each group of participants’ assessed severity correlated positively and linearly with the 
actual severity (actual pixel coverage), even when all 36 severity-extents were viewed in 
random order. These mean scores and standard deviation for each pose and each respondent 
group are summarized in Table 7.5. There is a lot of data to in the table and the easier way to 
appreciate the results is via the graphs. Figure 7.7 includes graphs showing the mean scores 
for all respondents’ severity score out of 10 (different labels for each group) compared to 
actual BSA % coverage of poses. It can be seen that dermatology doctors tend to score less 
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generously with respect to severity (lower part of the scatter) compared to non-medical and 
non-dermatologically trained respondents (higher part of the scatter).  
 
ANOVA analysis of respondent group for severity (1 through to 9) is summarised in Table 
7.6. When scoring the ‘front’ pose, dermatology doctors score lowest (mean 5.11) followed 
by dermatology nurses (mean 5.21), then medical students (mean 5.23), then patients (mean 
5.39), administrative staff (mean 5.64) and finally the most generous were general nurses 
(mean 6.38). The order of scoring for ‘half front’ pose, from lowest to highest is: 
dermatology doctors (mean 4.74), dermatology nurses (mean 4.75), medical students (4.99), 
patients (mean 5.54), administrative staff (mean 5.56) and the highest scorers were general 
nurses (mean 6.07). The order of scoring for ‘half back’ pose, from lowest to highest is: 
dermatology doctors (mean 4.89), dermatology nurses (mean 5.06), medical students (5.18), 
administrative staff (mean 5.56), patients (mean 5.62), and the highest scorers were general 
nurses (mean 6.07). The order of scoring for ‘back’ pose, from lowest to highest is: 
dermatology doctors (mean 4.95), medical students (5.20), dermatology nurses (mean 5.29), 
administrative staff (mean 5.60), patients (mean 6.01), and the highest scorers were general 
nurses (mean 6.16). The group differences were not significantly different when analysed by 
ANOVA for the ‘front’ pose (p=0.183. They were just significant for ‘half front’ (p=0.019) 
and not for ‘half back’ (p=0.087). The group differences were significantly different for the 




































































































































































































































































































































































































































































































































































Groups Count Sum Mean Variance F P-value
Front Admin 45 254 5.644 8.598
Front Derm doctor 108 552 5.111 6.492
Front Derm nurse 72 375 5.208 4.956
Front Gen nurse 45 287 6.378 10.468
Front Med student 90 471 5.233 8.383
Front Patient 180 970 5.389 8.831
Half front Admin 45 250 5.556 7.889
Half front Derm doctor 108 512 4.741 5.558
Half front Derm nurse 72 342 4.750 5.937
Half front Gen nurse 45 273 6.067 9.882
Half front Med student 90 449 4.989 7.427
Half front Patient 180 998 5.544 8.484
Half back Admin 45 250 5.556 7.298
Half back Derm doctor 108 529 4.898 6.261
Half back Derm nurse 72 364 5.056 4.842
Half back Gen nurse 45 273 6.067 9.200
Half back Med student 90 466 5.178 7.114
Half back Patient 180 1011 5.617 7.925
Back Admin 45 252 5.600 6.018
Back Derm doctor 108 535 4.954 5.278
Back Derm nurse 72 381 5.292 4.322
Back Gen nurse 45 277 6.156 8.134
Back Med student 90 468 5.200 5.960







Figure 7.8 shows each respondent groups’ mean severity score compared to the actual 
severity (BSA % coverage) and the regression of assessed severity on actual severity. All 
groups demonstrated a correlation coefficient of greater than 0.94 and the group showing the 
strongest relationship with the least spread around the mean was ‘Dermatology Doctors.’ 
The group with most variance was ‘General nurses’ which included nurses from other 
specialities and non-specialist trained Health Care Assistants. 
 
Linear regression of subject’s severity assessment on actual disease coverage demonstrated a 
median gradient 0.142 (range 0.117-0.154, SE slope ±0.006; median intercept 1.94 (range 
1.621-2.266); analysis of variance for regression p<0.001; R square 0.875-0.951. Table 7.7 
demonstrates the correlation coefficients and linear regression analysis of assessed severity 


































































































































































R R"square Standard"error Intercept Slope ""Standard"error"of"slope p3value
Administrative"staff 0.973 0.946 0.594 2.004 0.142 0.006 <0.001
Dermatology"doctors 0.967 0.936 0.589 1.712 0.127 0.006 <0.001
Dermatology"nurses 0.975 0.951 0.468 2.125 0.117 0.005 <0.001
General"nurses 0.936 0.875 1.03 2.266 0.154 0.010 <0.001
Medical"students 0.968 0.937 0.645 1.621 0.141 0.006 <0.001
Patients 0.971 0.942 0.646 1.882 0.149 0.006 <0.001
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Comparing how the different groups assign the models categories: mild, moderate and 
severe 
 
The comparison of selection of models for ‘mild,’ ‘moderate’ and ‘severe’ disease was 
limited to dermatology practitioners (doctors and nurses) in comparison to the psoriasis 
patients. The results are summarized in Figure 7.9 and Table 7.8.  
 
Figure 7.9 contains a clustered bar chart of all groups’ mean responses and the standard 
deviation. It can be seen that the results/responses are broadly the same across the 
respondent type. The graph illustrates that the variance is more restricted in the dermatology-
trained (doctors and nurses) than in the untrained. 
 
Table 7.8 summarises the means and ANOVA of the responses across the groups. The 
difference in response depending on the type of person is significantly different for mild, 
moderate and severe disease. As mentioned earlier, the groups were not matched for many 







































Mean1Admin Mean1Derm1 doctor Mean1Derm1 nurse Mean1Gen1nurse Mean1Med1student Mean1Patients
Groups Count Sum Mean Variance F P4value
Mild8Admin 20 67.588 3.379 1.289
Mild8Derm8doctor 48 163.388 3.404 1.115
Mild8Derm8nurse 32 112.432 3.514 2.021
Mild8Gen8nurse 20 103.532 5.177 17.675
Mild8Med8student 40 213.988 5.350 15.626
Mild8Patient 80 284.507 3.556 1.949
Moderate8Admin 20 431.565 21.578 69.290
Moderate8Derm8doctor 48 989.612 20.617 43.761
Moderate8Derm8nurse 32 822.456 25.702 82.197
Moderate8Gen8nurse 20 326.490 16.325 83.188
Moderate8Med8student 40 800.007 20.000 38.760
Moderate8Patient 80 1265.632 15.820 65.151
Severe8Admin 20 1108.930 55.447 22.530
Severe8Derm8doctor 48 2582.708 53.806 49.485
Severe8Derm8nurse 32 1752.803 54.775 32.791
Severe8Gen8nurse 20 1108.930 55.447 22.530
Severe8Med8student 40 2173.125 54.328 45.732





The data in Table 7.9 is the comparison of assessment for a model to represent mild, 
moderate and severe disease for the dermatology-trained (doctors and nurses) versus 
patients. There is no significant difference when each group assesses mild disease: means 
3.45% and 3.56% respectively (p=0.137) with the same range of response, 1.96% to 7.61%. 
There is a large and significant difference (p<0.001) when the groups assess moderate 
disease: the mean for dermatology-trained is 22.65% as opposed to 15.82% for patients. The 
ranges of selected disease for moderate are also quite different and significantly so: the 
dermatology-trained chose 9.48% to 46.97% and patients chose a range of 4.69% to 51.51%. 
The assessment of severe disease is just significantly different (p=0.040) for the dermatology 
trained (mean is 54.19%) versus patients’ (mean is 50.40%). The lower threshold for severe 
disease for the dermatology-trained was 31.75% and for patients, much  
lower at 14.686%. The maximal disease choices were the same for the dermatology-trained 
and patients (62.008%). 
!
 
Overall, the models and extent selected for ‘mild’ disease were the same for dermatology 
practitioners compared to patients. The range of models considered representative for 
‘moderate’ and ‘severe’ disease was larger for both dermatology practitioners and patients, 
although the range was larger for the patients (not to a significant level, however). With 
respect to the selection of the models representative of ‘severe’ disease, patients had a 
significantly lower threshold compared to dermatology practitioners when patients selected 





















Study 2: Do standardised 3-D images of psoriasis and photograph prompts improve self 
assessed disease extent? 
 
Table 7.10 details the raw scores from this part of the study. As would be expected, since the 
subjects were undergoing treatments (phototherapy or starting systemic treatment), the 
validated disease extent and subjective score- measures show improved disease, or reduced 
extent over time. The raw scores and means are detailed in Figure 7.10.  
 
The subjective disease scores improved over time. The DLQI was significantly reduced over 
time: the start of the study mean score was 15.9 and the end of study mean 8.1 (p=0.001), 
suggesting improved quality of life. SF-36 scores were significantly increased, indicating an 
improvement in quality of life: start mean was 54.7 and end mean was 69.9 (p=0.012). The 
GHQ mean was not significantly different but rose, suggesting improved well-being: mean 
at the start 1.9 and at the end 2.3 (p=0.111). The mean VAS of extent fell significantly from 
6.3 to 2.8 (p=0.001). 
 
Measure of disease extent fell over the treatment period. The PASI decreased significantly, 
the start mean was 8.9 and the end mean 4.9 (p<0.001). Extent as measured by self-
comparison of patients to the 3-D models also fell significantly overall from the start of the 
study (mean 21.8) to the end (mean 9.0), p<0.001. 
 
This seems to be a pertinent point at which to present information about the 3-D models’ 
psoriasis extent scores (not PASI per se, as there was no data to score for close-up 
assessment of the plaques such as scaling, etcetera from the models but extent measured as if 
PASI). My (blinded) extent scores of the models correlate positively (as expected) and 
linearly with actual extent. Regression analysis yields an R of 0.974, R square of 0.948 with 



























































































































































































































































































































































































































































































































































































































































































Selection of models and the effect of clinical photographs 
One of the aims of this study was to see if self-expressed disease extent could be improved 
by showing the respondents photographs of themselves. In part 1, they scored their extent as 
expressed by comparison to the 3-D models (selection 1) then saw their photographs from 
that day then scored themselves (against 3-D model) again (selection 2). The theory was that, 
since perceived disease may be different from reality, the photographs (of reality) should 
give the patients a prompt and improve scoring.  
 
In part 2, they scored their extent by comparing themselves to the 3-D models (selection 3) 
then re-scored themselves having seen that days photographs (selection 4) and, finally, they 
were shown their start of study photographs and scored themselves again (selection 5). The 
theory here was that by reminding respondents of how bad they had been at the start and 
reminding them of their present state may provide a necessary reality-check to improve their 
perception of their own disease and perception of their improvement with treatment.  
 
Figure 7.12 summarises the results. The graph show that generally the extent scores rise after 
prompting with photographs. At the start of the study, the mean score prior to seeing the 
photographs was 21.5 and this rose to 22.0, a non-significant rise, after seeing the 
photographs (p=0.110).  
 
As previously mentioned, the mean photograph-determined extent score significantly fell 
from Day 0 compared to Day 42 (means overall 21.8 at the start and 9.0 at Day 42).  
 
At the end of the study, the first selected model of extent mean was 6.5. After seeing that 
day’s pictures, the selected model BSA% coverage rose to 8.9 (p=0.17). When re-scoring 
after having seen the start of study photographs, the self-assessed extent rose to 11.6, 
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p=0.184 when selection 4 was compared to selection 5. The difference in scoring was 
significantly different (p=0.032) when selection 3 (no photograph prompt) was compared to 
selection 5 (baseline photograph prompt). See Figure 7.12 for graphical summary. 
 
The results suggest that the photographs manipulate the self-scoring in some way, but 
whether this was in a helpful way or not was not clear. In an attempt to address this, the 
relationship of self-assessed disease extent (3-D model BSA% coverage) was examined, The 
results are summarised in Figure 7.13 and the regression analysis is detailed in Table 7.11. 
There is a lot of variance and this is only improved when the mean Day 0 and Day 42 scores 































































































































































































































































R R"square Standard"error Intercept Slope Standard"error"of"slope ANOVA"p=
PASI"1"vs"Selection"1 0.526 0.276 15.189 0.333 2.374 0.881 0.014
PASI"1"vs"Selection"2 0.402 0.162 13.100 9.160 1.456 0.760 0.071
"PASI"1"vs"Mean"Day"0 0.531 0.282 12.074 4.746 1.915 0.701 0.013
PASI"2"vs"Selection"3 0.583 0.339 5.631 1.965 0.929 0.335 0.014
PASI"2"vs"Selection"4 0.450 0.203 11.021 2.693 1.279 0.655 0.070
PASI"2"vs"Selection"5 0.460 0.211 10.508 5.484 1.252 0.624 0.063





In this experiment I have presented realistic, but anonymous 3-D models of psoriasis with, 
thanks to their basis on graphical display, a known and accurate percentage surface area 
coverage of disease. This pilot study demonstrates that these figures were easy for different 
groups to relate to and that the presentation system using Mac OS X, Leopard, user-friendly 
(even for elderly people who had never used a computer before). The consistency and 
accuracy of all groups’ scores of severity when using the 10-point scale is encouraging.  
 
It was not expected or designed that the 3-D models should provide a linear scale but this 
seems to have been the case, as I have demonstrated. PASI is not a linear scale (Carlin, 
Feldman, Krueger, Menter, & Krueger, 2004). The lower scores cluster at the bottom of the 
range but the spectrum of disease extent that the models represented seems to have been at 
the linear area of the relationship of extent when measured against body surface area as seen 
in Figure 7.11. A linear scale should provide a more sensitive measure of extent. 
 
Study 1 demonstrated, that with the aide of the models, all types of people, the dermatology 
naïve, dermatology practitioners and patients could, almost entirely consistently and linearly 
score disease extent. Dermatology doctors and nurses tended to score lower BSA, perhaps 
because they were always comparing the model to the most severe disease in their mind’s 
eye and this level of severity was not a possibility to the non-dermatology respondents. 
There was a significant difference when groups score were compared across respondent type 
but there was scope for confounding here as the groups were different for other reasons (age, 
gender, GHQ). The main variability in scoring was for the ‘back’ view, which was 
significantly different across groups, but since the other views were more consistently 
scored, overall, consistency was the rule. 
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The beneficial effect of the models, in drawing together different groups’ perspectives of 
disease extent when using the 10-point scoring system should be compared and contrasted to 
the effect that the models, along with the three-point scale of mild, moderate and severe 
disease elicits. These comments from respondents allude to different groups’ perspectives on 
disease: from a patient, “They’re all severe compared to me”; from a few doctors, “None of 
them are really severe.” 
 
This study demonstrates an increase in the variance in the groups assessed severity once 
assessors are required to choose from the three categories of mild, moderate and severe 
disease. Patients and the dermatology-trained were in alignment regarding mild disease. 
Patients considered disease severe at a lower threshold than the dermatology trained – not 
surprising as the dermatology practitioners are working in a secondary and tertiary care 
setting. The concept of moderate disease is, I think, quite obscure and this is reflected by the 
large variance in scoring for this severity. Again, patients had a lower threshold for this than 
the dermatology trained individuals. It could be argued that the concept of ‘moderate 
disease’ is an abstract phenomenon even to dermatology practitioners (and therefore more 
prone variation) and irrelevant to patient groups. Any marked Likert scale may not be an 
ideal scoring method as has been demonstrated in experimental itch studies (Wahlgren, 
1995). In view of this study’s findings, I would suggest that the use of categories such as 
mild, moderate and severe disease is avoided. 
 
Study 2 put the 3-D models into the clinical situation. Patient-assessed disease extent (using 
the models) was compared to doctor-assessed extent (using PASI). It has previously been 
shown that there is a poor correlation between doctor and patient assessed disease extent 
(Jacobson & Kimball, 2004). Another study suggested that the SAPASI, or self-assessed 
PASI bore a close resemblance to doctor assessed PASI but, in the study which mooted this 
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(Sampogna, Sera, Abeni, IDI Multipurpose Psoriasis Research on Vital Experiences 
(IMPROVE) Investigators, 2004), the extent of disease was based on the doctor’s assigning 
a percentage to the patients’ shaded area on a line-drawing and so any inaccuracy in 
assessing percentage surface area would not be evident.  
 
The clinical part of our study demonstrated that a significant decrease improvement in 
disease after six week’s worth of treatment. This was evidenced by the usual validated 
subjective scores (DLQI and SF-36) improving significantly and disease extent scores, 
doctor’s, i.e. PASI or patients’, i.e. VAS extent improving significantly too. The self-scoring 
as expressed by BSA% from the 3-D model selection improved significantly too.  
 
It was suspected that the patients’ perception of disease extent would alter if they could see 
their clinical photographs. This suspicion grew from a clinical observation that, in 
Phototherapy mid-way review clinics, patients commonly expressed surprise at how much 
they had improved after they saw their ‘Start’ photographs and from appreciating the 
potential effects of the ‘hedonic treadmill’ (Kahneman et al., 1999). In fact, our study 
demonstrated that our subjects thought that they had significantly more disease at week 6 
after seeing their ‘Start’ photographs (the opposite of what we expected). The correlation 
coefficients between patient and doctor assessed disease weaken and become less significant 
after patients see their photographs, this would suggest that it is better, therefore, to rely on a 
patient’s ‘gut instinct’ of just how extensive their disease is. 
 
One major limitation of this study is that the subjects in the clinical part of the study all had 
to be female (in order for them to be able to relate reliably to the female-form models). It has 
been shown that there is a gender difference in the perception of disease extent (R. K. 
Roenigk & Roenigk, 1978; Schmid-Ott, Jaeger, Kuensebeck, Ott, & Lamprecht, 1996) and 
so it would be valuable to develop male models and repeat the study with male subjects. 
! 268!
Some may also consider the fact that the system is not ‘dynamic’ to be a limitation. This may 
or may not be the case. It would be of great interest to compare a patient’s, or doctor’s 
perception of disease if a computer model existed which allowed the disease extent to be 
‘drawn on’ and the pixel coverage calculated.  However, the model may not be useful 
clinically if the perspective prejudice was reflected in the ‘drawing on process.’ Apart from 
this, there would be problems relating to accuracy as the model would not have the same 
surface area as the subject and accuracy of representation on the model may not be realistic 
or achievable (in the clinic scenario) as it is time consuming to accurately transcribe each 
actual plaque onto a model. 
 
The most severe model actually only had a disease surface-area coverage of 62%. It would 
appear that overestimation of severe disease is commonplace (see previous 
descriptions(Ramsay & Lawrence, 1991)) and is possibly unavoidable if we continue to 
estimate it in the same way. The textbook definition of erythroderma requires greater than 
80% surface area coverage. Having developed these models, my perspective of body surface 
area has changed too: I genuinely doubt that the definition of erythroderma, with 80% BSA 
coverage can be realistic now that I appreciate what 80% coverage really means. My 
experience is that patients are routinely described as erythrodermic who are not 80% covered 
in disease. Part of the issue, as illustrated by the Tiling-Grosse (Tiling-Grosse & Rees, 1993) 
and Lawrence (Ramsay & Lawrence, 1991) papers, is that many small plaques increase the 
error in judging surface-area. I would propose that small-plaque models were developed to 
use accordingly.  
 
With the ready availability of photographic services in hospitals, it may appear sensible to 
employ computerised image analysis to quantify disease extent, however this analysis is still 
unreliable, despite advances in technology. The main problem is that this system involves 3-
D analysis of a 2-D image photograph (Ashcroft et al., 1999; Savolainen et al., 1998) 
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Secondly, there is lack of distinction between diseased and non-diseased skin and this is 
complicated by the effects of shadow, the optical effect of scaling etc. so a straightforward 
computer algorithm to ‘tell psoriasis from ‘normal skin’ is not yet achievable (Ahmad 
Fadzil, Ihtatho, Mohd Affandi, & Hussein, 2009). Photographic systems exist where there 
are cameras mounted ‘in the round’ which capture an image and then software ‘morphs’ 
them into a digitised 3-D representation but the systems are not perfect and, commonly, 
‘gaps’ appear in the image and their availability is limited. It may seem remarkable that, in 
the days where 3-D printing is quite readily available we can not access a similar technology 
for psoriasis but a certain amount of extrapolation is required for these algorithms to work 
and this would not be appropriate in a clinical or, most particularly, a trial situation. 
 
It is important to ‘have a handle’ on patients’ perspective on disease extent, since, whilst a 
study may demonstrate the chances of reducing the percentage PASI with a certain 
treatment, if the difference is not perceptible or worthwhile to the patient, can or should it be 
considered useful? If the assessment and response to treatment of a disease is not viewed 
from the same perspective, patient and doctor groups may be communicating at crossed-
purposes meaning dissatisfaction for both parties. Such accurate assessment would also be 
sensible in making decisions regarding the distribution of wealth in the health services. 
 
In summary, in a collaboration with the Edinburgh College of Art, I have developed a novel 
system of psoriasis severity models, using graphical display. I have shown that respondents 
are able to relate to the models and that, the models’ use, along side a 10-point scale, results 
in consistent and accurate scoring of disease-extent. Importantly, the combination of the 
models and scale seems to unite respondents’ perspective on the disease. I have 
demonstrated that patients can, quite effectively, score their self-disease extent using the 3-D 
models I developed and that their own photographs were not necessarily a benefit to them, if 







Since conclusions for separate experiments are placed throughout the thesis, for easier 
accessibility, I will summarise them here. 
 
Chapter 1: Direct observation of subjects in order to quantify and characterise itch-
related movement. 
Direct observation and recording of movement remains the ‘gold-standard’ for quantifying 
itch-related movements. I developed an improved infra-red videoing system which allowed 
recording of individuals, in their own homes, for up to twelve hours. Using this system, I 
made recordings of children with atopic dermatitis and characterised the itch-related 
movements.  
 
Nocturnal movements were categorised into: generalised movement, which is not 
specifically itch-related; rub, rhythmical movements where fingernails are not the point of 
contact with the skin and scratch, rhythmical movements where fingernails make contact 
with the skin.  
 
All subjects demonstrated the itch-related movements but were also noted to be generally 
restless. The mean frequencies of action for each movement were: generalised movement, 
0.48Hz (SD±0.25); rub, 0.98Hz (SD±0.36) and scratch, 1.85Hz.  
 
These results concurred with previous suggested frequency of action  of scratch in humans 
derived from electronic data in subjects (Felix & Shuster, 1975) and in scratch simulated by 
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adults (Aoki et al., 1980). The study achieved its aim of characterising human itch-related 
movement and demonstrating that it is possible to separate itch-related movement from 
generalised movement on the basis of frequency of action. 
 
In order to put the results in context, and because detailed information about frequency of 
action of scratch was available for mice (Brash et al., 2005), in a small experiment I 
observed different mammals scratching behaviour. Frequency of action was higher, or the 
movement faster, in the smallest animals (mouse 12.5Hz) and lower or slower in larger 
animals (gorilla largest, 1.3Hz followed by humans, 1.85Hz). I postulated that the frequency 
of action related most closely to limb length, but standardised measurements for this were 
not available. The frequency of action did correlate closely with standard mass and standard 
length of the animal, the relationship was not linear, but was best expressed by a power 
relationship. The closest correlation was between the mass of the animal and frequency of 
action. 
 
Chapter 2: Introduction and further validation of the use of accelerometers to measure 
itch-related movement. 
Having improved the data extraction from these devices, by writing new macros and having 
checked functionality with regard to using the devices to record for longer than one night, I 
performed validation studies of these devices against infrared videoing in short consecutive 
night studies. These studies set about checking if the night-to-night variation in score 
previously noted was a ‘real’ phenomenon.  
 
It was found that the variation in score was ‘real’ when validated against videoing but that, 
in the early evening and morning this was likely to be due to inaccuracy in the subject-
recorded sleep and wake-times. This phenomenon had previously been reported in 
accelerometer sleep-studies (van den Berg et al., 2008) but not validated against video-
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recordings. There was good correlation in Actiwatch Plus detected movement and video 
recorded, directly-observed movement during sleep. No particular patterns in activity were 
found – these had been examined as it had previously been mooted that sleep stage may 
determine scratching activity (Savin et al., 1973; 1975). As a result of this chapter’s findings, 
much longer longitudinal studies were proposed, but also, it was decided to see if newer 
technologies could improve upon the Actiwatch Plus’s motion capture. 
 
Chapter 3: Validation of a newer accelerometer: DigiTrac 
A newer accelerometer became available. Due to improvements in technology, it was able to 
store more detailed data and sense in more axes such that ‘frequency of action’ data would 
be extractable. Since itch-related movement had been proven to be rhythmical and have a 
certain range of ‘frequency of action’ (Chapter 1), this device was attractive. 
 
Once I acquired some of these DigiTrac accelerometers, I had to perform some basic 
validation tests. The machines were found to be acceptably precise when compared against 
each other: the coefficient of variance (CV) was highest at low acceleration (14.3%) and 
lowest at high acceleration (6.8%). Since the industry standard for CV is 20%, these findings 
assured precision. 
 
I then moved on to assess the DigiTrac’s ability to capture simulated itch-related movement. 
FFT analysis of the DigiTrac output clearly demonstrated scratch and rub movements. 
Encouragingly, the peak activity on FFT corresponded with the ‘frequency of action’ of itch-
related movement directly observed in actual subjects (so not simulated scratch) in Chapter 
1.   
 
Before the DigiTrac could really be put into clinical experimental use, I had to determine 
which measuring axis of the three available, I should use to best detect itch-related 
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movement. In actual fact, there was not much difference between the ability to capture itch-
related movement in any axis, so just in the interests of consistency, I proposed that the X 
axis be used from then on. 
 
Finally, since I felt that walking was the most likely rhythmical movement to reduce 
specificity of itch-related movement overnight, this movement was characterised on 
DigiTrac recordings and compared to itch-related movement. It was found that walking had 
a different FFT profile to itch-related movement, but that most FFT activity was at 2-3Hz 
and since itch-related movement has a range of 0.5-2.5Hz there was potential for confusion 
(or confounding). The study highlighted that discrimination of movement could also be 
improved by considering the ‘frequency of action’ and also the magnitude of activity, 
something which had not previously been contemplated. 
 
Chapter 4: Clinical experiments using the DigiTrac accelerometers 
The DigiTrac were used in itchy subjects to validate and characterise the readout/capture in 
patients (as opposed to healthy subjects simulating scratch). Six children with atopic 
dermatitis were infrared videoed at home and wore the DigiTrac. First, an ‘itch spectrum’ 
was determined by plotting the amount of time undertaking scratch versus rub versus 
generalised movement on video. The majority of movement that occurred between 50-550G-
s was scratch (but not exclusively scratch). Subjects were motionless at less than 50G-s and 
movement was just as likely to be generalised or itch-related over 550G-s. Secondly, the 
DigiTrac were validated against Actiwatch Plus successfully. It was suspected that walking 
movement may have clouded clarity of the DigiTrac recording: as discovered in Chapter 3, 
the spectra did overlap. 
 
On the basis of the observations, it was hypothesised that the data should first be ‘enriched’ 
for the frequency range 0.5-2.5Hz. Since little or no movement was detected below 50-
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100G-s and larger amplitude, non-itch-related movement occurred at greater than 400-500G-
s, a second ‘enrichment’ was proposed for an amplitude range: either 100-400G-s or 50-
550G-s. Therefore, it was assumed that enriching for this frequency of action and amplitude 
of movement of DigiTrac should provide the most specific and discriminating measure of 
itch-related movement and this led to the next study. 
 
This small exploratory study involved itchy adults and children (n=9) with different itchy 
disorders and compared them to controls (n=12). The DigiTrac FFT outputs were ‘enriched’ 
for different ranges of filter for ‘frequency of action’ (0.5-2.5Hz and 0.5-5Hz) and 
‘amplitude’ (50-550G-s and 100-400G-s), suggested by previous studies’ observations so 
that the maximal separation of subjects from controls could be determined. Overall, 
enrichment for both ‘frequency of action’ and ‘amplitude’ improved separation of itchy 
subjects from controls. There was a marginally superior separation for enrichment by 
‘frequency of action’ 0.5-2.5Hz and ‘amplitude’ 100-400G-s. 
 
A larger study was then undertaken. It compared 26 subjects with atopic dermatitis to 26 
control subjects on short runs of consecutive nights and one aim was to see if the large night-
to-night variation in accelerometer score was also a feature of DigiTrac recordings, i.e., 
whether it was detected by a specific itch-movement detector (as opposed to a generalised 
movement detector, the Actiwatch Plus). The study, through scoring disease-extent with 
SCORAD, also determined the relationship of objective to subjective scores and physician 
assessed disease-extent. 
 
The results demonstrated that the DigiTrac FFT output could separate itchy subjects from 
controls. A large variance in score was found for subjects and a smaller one for controls. 
Layers of enrichment, stepwise first for ‘frequency of action’ and then for ‘amplitude’ 
improved the separation of itchy subjects from controls. The enrichment seemed to work by 
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reducing variance in the control group. The greatest separation from the itchy compared to 
controls was for the combined three-night data. This suggests that lack of power may have 
been an issue. Power had not been calculated formally as this had been a pilot study.  
 
The study confirmed that there was large night-to-night variation in score, this was found to 
be a ‘real’ phenomenon and also confirmed a disconnect between subjective disease-score 
and objective itch measured as DigiTrac score. These had both been findings of work with 
the Actiwatch Plus. Furthermore, the objective accelerometer DigiTrac score did not have a 
good relationship with physician-assessed extent, SCORAD, even when subtracting the 
subjective score-component. 
 
I took a moment, at this point, to reflect on what I had discovered. I had proven that 
Actiwatch Plus and DigiTrac accelerometers were both suitable and validated for the 
purpose of capturing itch-related movement in studies. I had discovered that there was true 
large variation in objective accelerometer score night-by-night within and between person, 
but I had only assessed this in small clusters of nights: would this ‘even out’ or demonstrate 
a pattern over time? The results also kept telling me that there was a disconnect between the 
objective and subjective disease scores, again, only in small cluster studies: would these 
even out or demonstrate a pattern over time. I next had to try to explain and investigate these 
issues. 
 
Chapter 5: Measuring itch over time in chronic disease 
This chapter reports longitudinal studies which addressed a few issues specifically including 
the night-to-night variation in accelerometer score and subjective/objective score disconnect 
in some instances over a period of six weeks. For shorter clusters, 68 adults and 50 children 
with any itchy condition were recruited. The six-week study recruited a separate 20 adult 
patients with any itchy skin condition and involved subjects wearing the Actiwatch Plus 
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accelerometers every night for 42 nights whilst scoring VAS of itch and insomnia daily. 
Other subjective measures of disease, SF-36, DLQI and GHQ were assessed and disease 
extent was calculated using SCORAD. 
 
The study confirmed the great variation in accelerometer scores: about 60% was between 
subject and 40% within subject. This finding limits the usefulness of actigraphy in 
experimental studies, unfortunately. The accelerometer scores were found not to be 
influenced by age or sex. The main determinant of differences in score was disease type: 
liver disease most severely affected, followed by other causes of itch including atopic 
dermatitis and psoriasis. Controls had lower scores. 
 
The study confirmed the lack of relationship between subjective and objective itch scores. 
This was true for children with eczema and adults with a variety of itchy disorders. The 
second part of the study afforded the capability to compare the subjective and objective over 
a much longer time than any other study had allowed, six weeks. Still little convincing 
evidence of a relationship between the subjective VAS of itch and actigraphy was found. 
The fact that a strong autocorrelation pattern of scoring was found in the VAS data is 
interesting: it appears that subjects revolve scores around an individual anchor-point, even 
without access to the previous day’s scores (viz ballot box). This is a recognised ‘anchoring’ 
phenomenon(Ariely, Loewenstein, & Prelec, 2003; Kahneman & Sugden, 2005). An effect 
of lag was found in the autocorrelation of VAS scores. This is difficult to explain. No such 
autocorrelation effect was found in the actigraphy scores. Overall, these results are not very 
encouraging for the accuracy or validity of VAS scores. 
 
The use and comparison of other subjective symptom tools answered the question as to 
whether the disconnect was due to flaws in the VAS, or due to systematic differences in 
objective and subjective disease measurements. The fact that none of the subjective disease 
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tools had a convincing relationship with actigraphy, but did with each other, suggests that the 
disconnect is basically subjective versus objective. SCORAD (±subjective components) did 
not correlate well with subjective or objective tools. 
 
Trialling the new DRM questionnaire was an interesting exercise. Never having used it 
before, it was instructive to see that the form took between 30 minutes to 2hrs 30 minutes to 
complete. This renders it impractical for regular clinic use. Again, DRM responses 
correlated well with the other validated subjective tools, SF-36, DLQI, VAS, but not with 
actigraphy or SCORAD (±subjective components). Two intriguing findings surfaced from 
using the DRM. The first was that the GHQ result worsened at the end of the process 
compared to the start: this suggests that, when giving a true rather than gut reaction, subjects 
do feel worse about their health. The difference was not significant but the number of 
participants was small. The second was that distraction from itch when at work and vice 
versa was significantly displayed in the scores. 
 
Whilst there were limitations (discussed at the end of this chapter), overall these studies 
demonstrated that objective scoring using actigraphy may not be perfect but does confer a 
measure on a certain aspect of itchy disease. Some form of measurement of perception of 
disease or impact of disease on life should be utilised too but it should be borne in mind that 
the tools available to us now are not perfect nor tell the whole picture either.   
 
Chapter 6: The effect of bias on subjective disease scores. 
Subjective-symptom measures are widely used and most commonly validated by checking 
for reliability, responsiveness and validity. The subjective symptom tools commonly used in 
dermatology had not been tested for vulnerability to bias. In these short experiments I tested 
the effects of focussing and framing biases on Dermatology Life Quality Index (DLQI), 
Global Health Question (GHQ) and visual analogue scores (VAS). 
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215 patients with different conditions and moderate disease (as measured by DLQI) were 
recruited. Three different studies were undertaken: the first required people to read and/or 
write mood eliciting words prior to completing the subjective disease scores, the second 
required a group to see a film about a person living with severe disease then complete the 
tools and, finally, the last study compared the usual DLQI with an amended one rewritten to 
be more neutrally framed.  
 
None of the interventions made any significant differences to any of the subjective scores. 
Although a ‘negative’ result, the findings were reassuring as they suggested that the 
subjective symptom scores are robust to the effects of focus and framing bias. The results do 
not mean that the tools are invulnerable to the effects of say, the stress of a clinic running 
late, liking or not liking the clinician or ‘gaming’ scores to gain a particular goal, for 
instance, eligibility for a biologic treatment for psoriasis. The poor relationship between 
subjective and objective score remained unexplained and whilst the subjective disease tools 
were impervious to these rather basic bias-manipulations, it should not be assumed that the 
subjective tools are perfect or sufficient to measure a disease unilaterally. 
 
Chapter 7: Effect of computer-generated 3-D models and photographs on self and third 
person measurement of disease-extent in psoriasis 
A poor relationship between disease-extent scores (SCORAD and PASI) and objective 
accelerometer score had been determined in Chapters 4, 5 and 6. This encouraged me to 
scrutinise these disease-extent measurement tools. I discovered that intra and inter-operator 
variability had been detected despite the use of these standardised tools (Charman et al., 
1999; Ramsay & Lawrence, 1991). I also discovered that work had been carried out on 
estimation of surface area in the trained and untrained (Tiling-Grosse & Rees, 1993). 
Estimation of BSA seemed likely to be the source of inter-operator variance. The fact that 
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doctors underestimated disease whilst dermatology naïve medical students were more 
accurate at gauging BSA made me wonder where patients would fit in, especially in the 
context of having read that patients were potentially not always aware of their own severity 
of disease as they had adapted to it over time, ‘the hedonic treadmill’ (Brickman, Coates, & 
Janoff-Bulman, 1978; Frederick & Loewenstein, 1999; Kahneman et al., 1999). I decided to 
try to unify perspective of disease between doctors and patient in an effort to improve 
communication between the parties. 
 
In a collaboration with Edinburgh College of Art, anonymous 3-D computer models were 
created which simulated psoriasis. Models of nine different known severities were designed.  
These models were based on photographs of a range of psoriasis severities and were, quite 
inadvertently found to increase in severity, expressed as percentage Body Surface Area 
(%BSA), linearly. PASI is not a linear scale, thus reducing its sensitivity at the lower 
severity of disease (Carlin et al., 2004). 
 
In a first study, it was demonstrated that all groups of respondents (n=60), dermatology 
trained and not, and even patients, scored randomly presented models accurately. Doctors 
tended to underestimate disease and most variance in scoring was found in general nurses. It 
was found that there was more variation in scoring if, rather a score out of 10 was to be 
chosen, the respondents were required to assign the models as having mild, moderate or 
severe disease. This could represent a problem previously reported in Likert scales 
previously (Wahlgren, 1995). It could also be due to the fact that concepts of mild, moderate 
and severe disease are more abstract, especially moderate disease which had most variance 
in scoring. 
 
In the second part of the study, female psoriasis patients, about to commence treatment were 
required to score their disease-extent with the aide of the 3-D models, with and without the 
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aide of photographs. The study involved 21 patients with mild to moderate psoriasis and 
monitoring over six weeks – including PASI, DLQI and VAS. As expected the subjective 
scores and disease-extent scores improved over time, including the 3-D picture scores. The 
subjective scores correlated well with each other.  
 
When it came to the effect of the photographs on patient assessed disease, it appeared that 
showing them reduced corroboration between doctor and patient-score extent. The 3-D 





Subjects for all studies were recruited from secondary and tertiary care clinics. The subjects 
were, therefore, skewed towards those with more severe disease, especially those with 
eczema as evidenced by the SCORAD scores (higher than those typically reported in trials).  
 
The subjects ‘volunteered’, this selects patients of a different type from the average clinic 
attender. Some of the studies allowed a significant amount of time with the investigator 
(Chapter 5), another step away from the general norm. It was not possible to control the 
severity of disease throughout the study period: patients at the extremes of severity may have 
responded differently.   
 
In the psoriasis studies reported in Chapter 7, subjects were about to embark upon therapy. 
There was no way of ‘blinding’ this event from patient or investigator. As a result, an 
expectation of improvement may have resulted in bias.  
 
Compliance: assumptions had to be made for accelerometer studies regarding compliance as, 
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whilst it was sometimes reported by subjects that they had forgotten to wear the 
accelerometer, subjects did not always mention this. It was obvious from ‘eye-balling’ the 
summary scores if the watch had been worn or not and so, if this were the case, since the 
impetus was on separating disease from controls, these night-scores were excluded. 
Compliance tables are detailed in with the appropriate study results.  
 
As well as the accelerometers, compliance was required in the subjective form filling. This 
was easy to confirm if questionnaires were completed in the investigator’s presence (SF-36, 
DRM, GHQ) but not so straightforward for daily VAS scores. Sometimes there were ‘honest 
omissions’ forms left unfilled, but I had no way of proving that scores were made daily and 
not done in batches or without a prompt of the previous day’s score – although I tried to 
encourage daily scores and blinding by providing a ballot box in the Chapter 5 study.  
 
An obvious limitation of the 3-D psoriasis models is that they are female form. This may 
have had implications for the first part of the study when males and females respondents 
were required to ‘score’ the models but based on the fact that this was a third person process, 
it was expected that it should not be. The female 3-D models also made it imperative that 
only female patients were recruited to the part of the second study where respondents had to 
score themselves against the models. The results of this study should not be extrapolated to 
males without validation, especially since sex differences in the effect of psoriasis exist (R. 
K. Roenigk & Roenigk, 1978). Finally, the most severe 3-D model only had a disease 
surface-area coverage of 62% whilst true erythroderma is 80% coverage. This should not 
have been a problem as long as none of the study participants were erythrodermic (and they 
were not) but would be a problem if studies/use of the models was to be extended. 
 
All of these studies were, essentially, exploratory. As a result, ‘power’ could not be 
calculated. There is a strong possibility, therefore, that with larger groups some differences 
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would have become formally significant. This is particularly pertinent to the separation of 
the itchy subjects’ from controls’ actigraphy scores throughout the thesis and to the ‘Effect 








My research started with the aim of solving the problem of measuring itch. It evolved into 
aiming to improve measuring disease. Whilst I cannot say that I have entirely solved these 
problems, I can say that I have made significant inroads into understanding itch, its 
associated behaviour and its measurement. I have also scratched the surface (genuinely, no 
pun intended) of understanding the other disease-measurement tools and how they measure 
another aspect of living with disease. I hope the work will inform further research and help, 
eventually to success in the goal of accurate measurement.  
 
The studies in this thesis approached measuring disease from the objective angle first. I have 
shown that a simple accelerometer, the Actiwatch Plus, is a convenient and validated way to 
capture objective itch-related movement, even over a long period of time - up to six weeks. I 
have developed and validated the use of another accelerometer, DigiTrac. This device was 
expected to be superior, as it could detect ‘frequency of action’ of movement and I had 
proven that itch-related movement was rhythmical (Chapter 1). In video-studies I 
characterised the different ‘frequencies of action’ of itch-related movement in humans: 
scratch and rub. I showed that the itch-related movements, demonstrated in patients with 
itchy disease, were separate and different from the activity of generalised movement 
(Chapter 1). I put humans’ frequency of itch-related movement in context by comparing it to 
other mammals’ (Chapter 1). I proved human itch-related ‘frequency of action’ by using 
gold standard video recording and this was consistent with previous proposals by Shuster 
(Felix & Shuster, 1975) and Aoki (Aoki et al., 1980), of action at about 2Hz. However, a 
finding from my characterizing the ‘frequency of action’ of walking study in Chapter 3, 
should have alerted me to a problem: walking peaked at about 2 to 3 Hz. Itch-related 
movement peaked at about 0.5 to 2.5 Hz. There was an overlap.  
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The simple fact of the matter is that a lot of human movement is rhythmical – limbs swing 
about the pendulum of joints – consider your arm swinging as you walk. Factoring in my 
animal-scratch experiment’s finding that mass predicts ‘frequency of action’, along with the 
observation that a lot of animal characteristics are related to their size overall, I suspect that 
all human movement occurs at a frequency of between 0.5 to 3 Hz. Therefore, perhaps my 
hope of discriminating itch-related movement from other movements was overly optimistic. 
I tried to negotiate this problem by filtering of the amplitude of movement. One limitation to 
this is that it also had the potential to filter out movement in the non-DigiTrac-wearing limb. 
This would reduce the sensitivity of detection of itch-related movement overall. 
 
Nevertheless, despite my not being a trained signal analyst, I believe that I developed the 
output such that DigiTrac could detect specific itch–related movement to a discriminating 
degree (to separate itchy subjects’ scores from controls’).  
 
My studies do not suggest that either accelerometer is superior to the other. The DigiTrac 
can offer very detailed information but this may not be necessary. Actiwatch Plus scores can 
separate itchy subjects from control to a similar degree to DigiTrac. Both accelerometers 
demonstrate great variance in score especially in itchy subjects. I demonstrated that 
accelerometer score could predict disease group (itchy versus controls and specifically liver 
disease from other itchy disease). Actiwatch Plus is possibly superior to DigiTrac as it is a 
simple device, therefore, data analysis is quicker and more straightforward. Actiwatch Plus 
is also smaller and is generally more convenient as it can be set to measure and issued to 
subjects for several weeks. Another reason to explain why, despite the more detailed 
movement monitoring, the DigiTrac was found not to be highly superior to Actiwatch Plus 
in detecting itch-related movement, may be to do with the factory-fitted bandpass filters 
incorporated in the machines. It could well be that the filter incorporated in Actiwatch Plus, 
may have, in fact made them precisely fit for the purpose of detecting and itch-related and 
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human movement (see Chapter 2.I). 
 
One final comment on accelerometer technology which I would not like to go unnoticed is 
that both devices, Actiwatch Plus and DigiTrac were supplied with their own user-friendly 
interface software. Tempting though it was to use this, I am glad that I validated it as I 
discovered ‘bugs’ in the software for both devices. The raw accelerometer data can be 
accessed in .csv files and exported into Excel. This is safer than relying on the company-
supplied software for accuracy’s sake. Software errors happen, some have devastating 
consequences, viz destruction of NASA ‘Mariner 1’ rocket in 1962 due to an incorrect 
formula in FORTRAN, fives deaths in the 1980’s due to a bug in the controlling code for 
Therac-25 radiation machines. Obviously, bugs in this software would not have the potential 
for such harm but is worth knowing to avoid it before using the devices in an experimental 
situation where truly valid results are a necessity. The error found was a jump in code such 
that time and activity was then disconnected. This effect would have caused increasing error 
with time, so would be a real problem with long study periods. 
 
There are two major findings in this work: proof of large night-to-night variation in objective 
accelerometer scores and poor correlation between objective-accelerometer measured itch 
and subjective scores or physician scores of disease-extent. I believe that I have thoroughly 
proved the veracity of the first finding: night-to-night variation exists within and between 
people, especially the itchy. The finding was repeatedly shown: in Actiwatch Plus and 
DigiTrac studies, in small clusters of nights and even in long, six-week studies. I suppose, 
having proved the phenomenon, it would be remiss not to try to explain it to some extent. I 
suspect that there are many fleeting factors which may affect itch in clinical disease and 
account for the night-to-night variation in objective itch score. It is now clear that there are, 
at least, two pathways for itch signaling (see Introduction). I suspect that in chronic itchy 
conditions, inflammatory factors (skin disease) and/or central factors (for instance opioids in 
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cholestasis) are the main driver(s) behind the sensation. Consider atopic dermatitis: I suspect 
the cytokine system and even proteases (viz. house dust associated serine proteases 
activating itch via PAR-2 (Kauffman, Tamm, Timmerman, & Borger, 2006)) ‘prime the 
system.’ This would set a background level of itch. Then other factors could be 
superimposed, more transiently, to allow for night-to-night change. We know that heat 
exacerbates itch sensation, therefore a hot day, a hot bath, or a hot curry could make for an 
itchier night. An argument just prior to bed and the associated vasodilation might quite easily 
be seen to affect itchiness. We also know that there are central, cortical factors that can affect 
itch, therefore factors which make sufferers more aware of their condition could transiently 
the increase its awareness and therefore activity: I have been driven mad by itch whilst 
reading books and papers about it. The central activation of itch may be why patients so 
often tell us that their skin is worse when they are stressed (although there are other 
pathways potentially culpable for this). Finally, although I believe that the literature quite 
clearly suggests that itch in atopic dermatitis is most likely not histamine-mediated, atopics’ 
predisposition to Type I allergy obviously paves the way for transient histamine–mediated 
exacerbation of it. In clinic, I have observed atopic dermatitis patients with periorbital 
eczema, not responding to topical steroids and emollients.  If Type I allergy to mould is 
demonstrated (a common problem in student flats, it would appear) and antihistamines are 
prescribed in addition to the usual steroid and emollient, on review, they are transformed. 
Perhaps some of the night-to-night variation is therefore explained by superimposed Type I 
disease to foods, or other mediators.  
 
Some variance in accelerometer score was observed within person and between subjects in 
the control group. This was not at all to the same same degree as it was in the subjects. I 
suspect this is due to transient phenomena detailed above but without the inflammatory or 
central ‘priming’ of the itch-pathway. 
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The second major findings of this study, was the disconnect between objective and 
subjective measures of itch. It is accepted that an objective measure of disease, no matter 
how logical it is, cannot hope to express the impact a disease or symptom has on a person or 
on their emotional state.  The formalized quantification of this effect was borne out of the 
most well-meaning of principles: really discerning how a person feels about their disease or 
health state and then aiming to improve in "goodness" for all apropos Jeremy Bentham and 
John Stuart Mill's aim of utilitarianism. However, on examining the literature it appears to 
me that the basic principle has been lost along the way, probably, I hate to say, in an effort to 
rationalize health spending in a situation of limited resources (Nord, 1999). There is a 
proliferation of quality of life assessment tools but it is not clear what exactly they are 
measuring and most importantly whether they represent what an actual patient feels or 
thinks. I had no idea that quality of life schools and questionnaires were developed by asking 
a healthy person what they imagined it might be like to live with the condition (Nord, 1999). 
This methodology seems essentially flawed. It also appears, however, that people actually 
living in certain situations or with certain conditions find it hard to clearly express, via 
quality-of-life surveys, how they feel.  
 
One issue is thought to be the ‘hedonic treadmill’ (Brickman et al., 1978; Kahneman et al., 
1999). It is this which makes patients with chronic disease on haemodialysis  score a better 
quality of life than someone with an acute disease: just because they have got used to the 
"awfulness" of the situation (Riis et al., 2005). Adaptation or the ‘hedonic treadmill’ also 
accounts for paraplegics’ life-satisfaction score settling to near pre-accident levels, one year 
later (Brickman et al., 1978). It can happen with happiness too, with lottery winners being 
shown to be no happier than controls (Brickman et al., 1978). It surprised me to read that 
patients with terminal disease score a better quality of life than those without (Fayers, 2005). 
Psychologists argue that this to do with not having to deal with uncertainty: at least they 
know what is certainly going to happen, soon. It also raises questions about the validity of 
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quality-of-life scores as far as I am concerned. 
 
Over the past 25 years, researchers working in the fields of Economics and Cognitive 
Behavioural Psychology, have sought to provide clarity to the situation, as I have alluded to 
above. They have also sought to raise awareness of the systematic problems with measuring 
subjective symptoms. In-roads have been made in understanding how episodic, experiential 
memories differ from semantic stereotyped ones and trying to improve tools in order to tap 
into these and into how biases can affect answers elicited from questions (Kahneman, 2004; 
Robinson & Clore, 2002a; 2002b). One anecdote which can help to explain the difference in 
episodic and semantic memories is by recalling a roller-coaster ride. When you remember 
the ride, you remember a collective memory of the event: it was exciting, it was scary, I felt 
sick. You do not actually relive each second. If you did have the kind of memory which 
enabled you to remember, in second-by-second detail, you would have no desire or 
requirement to repeat the experience. Our brains simply can not store such detailed 
information in a readily accessible manner as there is not enough room. 
 
Acknowledgement of the superior quality of episodic experiential memory has made its way 
into the field of medicine in the form of diarizing. Paper journals or forms can be completed. 
Subjects can defeat researchers by lack of compliance. One (rather sneaky) group placed 
light sensors into diaries to check if they had been completed daily or if many forms were 
filled in retrospect and confirmed their suspicions of so call ‘parking lot compliance’ (Smyth 
& Stone, 2003). As technology and our connection with it improves, apps or online reporting 
may improve the experiential monitoring and patients’ compliance.  
 
In my research, I compared my version of experiential reporting, daily VAS scores, to the 
objective accelerometer scores over weeks. No correlation was found between the scores. 
Interestingly, however, significant autocorrelation was detected for the VAS score, despite 
! 289!
the respondents seemingly having been blinded to the previous day’s score (by posting it in a 
ballot box). This suggests VAS are open to the effects of another bias, ‘anchoring effect’ 
(Ariely et al., 2003; Kahneman & Sugden, 2005). This is a situation where an individual 
scores around their own individual reference point. 
 
My studies showed was that there was, at least, a corroboration between the subjective tools 
tested. It appears that whatever they are testing, they are testing it reliably. The fact that the 
symptom-tools were robust in the face of my imposed biases is reassuring regarding 
reliability too. There still remains, however, an unexplained disconnect between the 
subjective and objective scores: some other facet of disease which is, as yet, intangible and 
which is, as a consequence, immeasurable.  
 
Since undertaking this research, I find it depressing to see how many studies are published 
which make statements purely on the basis of subjective disease scores, especially in the 
field of itch. For instance, a recently published study has stated that the itch in lichen planus 
is nothing to do with IL-31, although it is expressed in this condition, because the VAS 
scores of itch were not affected by different levels of the cytokine (Welz-Kubiak, 
Kobuszewska, & Reich, 2015). I accept that subjective tools have a value in the clinical 
situation, surely objective ones do in a trial or experimental one. An argument in times gone 
by would have been that accelerometers are difficult and expensive to acquire, but I really do 
think that small cheap devices are possible with improvements in present technology and it 
may even be possible to install an app on a device the patient already owns, an Applewatch, 
for instance. 
 
An editorial comment about the paper I published from these studies, which tested subjective 
measures to bias, made a very interesting point: despite measuring patient reports in clinical 
trials, the data is most often not reported (Williams, 2010). My considering other disconnects 
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and ‘perspective on disease’ led me to the last tranche of my studies. The views of patients 
and doctors are not necessarily united even though they aspire to the same goal, successful 
treatment. If doctors are honest, they really want to see an improvement in a patient's 
condition if they have prescribed a treatment. They have also seen the whole spectrum of 
disease, unlike a patient, and so their weighing up of severity may well be different to their 
patient’s. Meanwhile, patients only have themselves and their own experienced severity for 
reference. 
 
When investigating the two perspectives, I found it amazing that this has been so neglected 
by the majority of quality of life literature. In one meta-analysis, of over 10,000 papers, only 
twelve contained data from both groups and none clearly reported it (Janse et al., 2004). It 
seems obvious that if patient and doctor have different views on what is an acceptable 
outcome, there is a huge chance of disenchantment on both sides. Work summarized in this 
thesis has shown how faceless, featureless, 3-D models of psoriasis are able to unite 
perspective on extent of disease, from dermatologists through general nurses and even to 
patients. Taking inspiration from published work I had read about in the field of Well-being 
research (Kahneman et al., 1999), I also decided to see if the models and own-patient 
photographs would sway personally assessed extent of disease. Curiously, seeing their own 
photographs reduced corroboration between patient and doctor-assessed extent. I am not sure 
why this should be. Perhaps the photographs were an unpleasant ‘reality check’ to the 
patients and influenced the score accordingly. 
 
As it stands, the 3-D pictures are only in the female form. I would love to extend the study 
and to acquire equivalent 3-D male models. I really do think that the models could prove a 
helpful aide in the day-to-day clinical and trial settings. One particularly helpful feature of 
them is that their extent increases linearly. A linear scoring pattern is more sensitive to 
change than a clustered model. PASI clusters scores at the lower end of the severity 
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spectrum and so is less sensitive to change here.  
 
Overall, I have shown that you can measure itch objectively. The objective scores do not 
marry with subjective scores and since they measure different aspects of disease, both should 
be registered. Clinical doctors and researchers need to be aware of biases and perspectives 
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There is a widespread belief that subjective accounts of 
disease are key components of measures of disease seve-
rity and quality of life. In the present study we have set 
out to test this hypothesis using visual analogue scales 
(VAS) for itch, as a subjective measure, and actigraphy 
as an objective measure. One-hundred and seventeen 
itchy children and adults (and 25 controls) were studied 
for clusters of nights (total number 1,654) and actigraphy 
scores and VAS itch taken daily. Fifty-six percent of the 
night-to-night variation in actigraphy scores occurred 
between different individuals, while 44% was intra-sub-
ject. Neither age nor sex (children’s or adults’) predicted 
actigraphy scores, and the only significant predictor of 
actigraphy score was disease type (p = 0.001, r2 = 0.51). In 
a multivariate model VAS itch score was not a significant 
determinant of actigraphy scores for either children or 
adults (p = 0.26). In order to see if there was a relation bet-
ween VAS itch and actigraphy within the same patients 
(rather than between patients), 20 eczema patients wore 
the actigraph and scored VAS itch nightly for 42 nights. 
Little relationship was found between the actigraphy 
score and the VAS itch. Empirical autocorrelation analy-
sis of VAS itch and actigraphy score reveal a clear auto-
correlation for subjective VAS scores that was not found 
for the objective actigraphy score. Our data suggest a 
dissociation between scratch and perceived or recalled 
itch. One explanation is that VAS itch scores suffer from 
considerable anchoring, and context bias, and that their 
use in measures of disease severity is problematic. Key 
words: actigraphy; pruritus; visual analogue scale; bias. 
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In recent years there has been a considerable growth 
in interest in subjective measures of disease severity in 
dermatology (1–3). Much of the focus of this effort has 
been on attempts to measure the impact of disease on 
an individual sufferer, accepting that objective accounts 
may be inadequate to express disease impact. To take 
an example, the impact of psoriasis affecting, say, 50% 
of the body area may be greater in a person who likes to 
regularly swim compared with somebody who does not 
swim (4). An objective score such as the PASI (5) will 
not reflect these aspects of disease that are important 
(4). These arguments are widely acknowledged and ac-
cepted (6–8). 
Some measures of disease severity or disease impact 
include individual subjective measures such as itch. 
An example would be the SCORAD, which includes 
subjective accounts of itch using a visual analogue scale 
(VAS) (9). Inclusion of itch in such scores is predicated 
on the idea that distress due to itch may provide infor-
mation on suffering that is not fully accounted for by 
other measures (1, 10).
Measurement of itch presents its own problems (10). 
Itch is arguably the principal symptom of skin disease 
(10–12). Like pain, itch is subjective and it is difficult 
to see how it can be measured except by subjective ac-
count. However, much as pain has consequences – acute 
pain, for instance, may be accompanied by vocalisation, 
or an increase in heart rate – itch provokes the desire 
to scratch (10), a behaviour that may be independently 
verified. A number of strategies have been suggested for 
how to measure scratch and building on pioneering work 
by Felix & Shuster (13) we have used wristworn ac-
celerometers or actigraphs (Actiwatch Plus, Cambridge 
Neurotechnology), worn at night to record scratch as a 
proxy measure of itch, having validated this technique 
against infrared videoing of children and manual scoring 
of scratch movements (14, 15). As compared with earlier 
work, our focus has been to develop strategies that can 
be used by subjects in their own homes and that take 
advantage of digital recording and analytical methods. 
Others have followed analogous approaches (16–18). 
Our goal can be considered analogous to the use of peak 
flow meters to monitor disease severity in asthma, in that 
we wish to develop a symptom tool that can be used for 
longitudinal monitoring of disease activity. 
One unexpected finding from our previous work 
on children was that there was little relation between 
subjective accounts of itch and objective measurements 
recorded using an actigraph – despite the latter being 
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validated by direct observation of scratch behaviour 
through infrared videoing of children in bed at night 
(15). This raises an important issue: assessment, recall 
and formulation of subjective accounts may be prone 
to error or artefact (19–22). If this is accepted, then 
whatever the virtues of subjectively recalled impacts 
of disease, error remains.
Our aim in the present work was to explore the rela-
tion between subjective accounts of itch using visual 
analogue scales, and scratch assessed objectively using 
actigraphs. In the process we also wished to address 
some limitations of our previous work (14,15): rather 
than examining correlations between subjects, we exa-
mined scores for each subject at multiple time points 
such that within-person correlations between itch and 
scratch could be examined. Our results are subject to 
more than one interpretation, but suggest that subjective 
measures of itch in this particular context may indeed 
be prone to artefact, perhaps due to anchoring bias (7, 
23, 24), and that their uncritical use of them may be 
misleading. 
METHODS
Ethical permission was received from Lothian NHS Ethics 
Committee for all experiments. 
Study 1
Sixty-eight itchy adults and 50 itchy children were recruited. 
Twelve adult controls and 12 child controls also took part. The 
subjects were recruited from clinics at the Royal Infirmary of 
Edinburgh. In so far as was practical, consecutive eczema pa-
tients were approached and given information about the study. 
For inclusion in the study, all participants had to be older than 3 
months of age and be able to provide consent or have a parent/
guardian willing to do so. Subjects had to have been diagnosed 
by a Consultant Dermatologist as having a characteristically 
itchy skin condition and to have complained of an associated 
symptom of itch. Controls had no evidence of skin disease and 
reported no symptom of itch. The participants were given time 
to consider the invitation to take part in the study and then 
contacted again by telephone. Those who agreed to participate 
then had an appointment to meet the researcher arranged. Writ-
ten, informed consent was acquired from all participants and 
guardians of participants. 
Sample sizes were chosen opportunistically, based on avai-
lability and what was considered practical in the light of prior 
experiments (14, 15)
Table I details the subjects and specifies their diagnosis and 
characteristics. All the child subjects had atopic eczema. The 
broad groups of diagnoses for adult subjects were: eczema, 
psoriasis, cholestatic liver disease and pruritus of unknown 
cause (PUC). A total of 1,654 nights were studied: 1,573 subject 
nights and 81 control nights.
Subjects were requested to wear the actigraph on the wrist of 
their dominant hand (for consistency’s sake, but also please see 
reference for further explanation (14)) for three to seven nights. 
Every day of the study, the participants also completed 10-cm 
VAS for extent, itch and insomnia. In the case of children, adults 
(parent/guardian) completed the scores for the participants.
Study 2
Twenty patients were recruited. All were adult eczema patients 
attending the Royal Infirmary of Edinburgh. For inclusion into 
the study, the participant had to be 16 years old or over and have 
atopic dermatitis, as diagnosed by a Consultant Dermatologist. 
They were approached as described for Study 1 and similarly 
gave written, informed consent. Eleven females and nine men 
agreed to participate. Table I gives the subjects’ characteristics. 
(Although not a designated part of this study, SCORAD scores 
were available for the volunteers: the median was 34.2 with a 
range of 9.7 to 67.7). 
All subjects were issued with an actigraph and instructed 
to wear it on the wrist of their dominant hand every night for 
the next 42 nights. A total of 761 nights were studied (patients 
forgot to take part on some nights).
All subjects were issued with dated sheets showing the VAS 
for itch, disease extent and insomnia. All of the subjects had a 
‘ballot’ box and they were instructed to post each day’s scoring 
sheet into the ballot box immediately after completing it. The 
sheet for day 0 was completed and deposition demonstrated to 
the researcher by the participant. On (or as near to) day 21 of the 
study, the participant and researcher met so that the actigraph 
could be checked for full functionality. On (or as near to) day 
42 of the study, the researcher met with the participant to collect 
the actigraph and download its data, and to collect the completed 
forms – all, it was expected, to be contained in the ballot box.
Actigraphy
The digital accelerometer used was the Actiwatch Plus (Cam-
bridge Neurotechnology, Cambridge, United Kingdom). This 
instrument detects and measures movement by utilising a piezo-
electric accelerometer that logs the integration of intensity, 
amount and duration of movement in three axes. The Actiwatch 
senses and logs 32 times/s and a summation value is available 
for the measurement epoch. Epoch length was set at one mi-
nute. The Actiwatch is supplied with a proprietary reader that 
enables downloading to a computer. The digital accelerometer 
output was exported to software (Excel; Microsoft Ltd, Seattle, 
USA) for analysis. The nocturnal score was a simple sum of all 
the scores logged between 1 am and 5 am (a time range shown 
in previous unpublished studies to exclude most extraneous 
ambulatory movement).
Table I. Principal demographic characteristics of the study subjects
Total
n F:M ratio










Study 1 Child subjects 50 24:26 6.92 2–15 229 50 0 0 0
Child controls 12 10:2 10.33 6–14 42 N/A N/A N/A N/A
Adult subjects 67 40:27 43.5 16–78 1344 30 25 4 8
Adult controls 13 8:5 38.23 24–71 39 N/A N/A N/A N/A
Study 2 Adult subjects 20 9:11 40.55 16–67 761 20 0 0 0
AD: atopic dermatitis; PUC: pruritus of unknown cause; F: female; M: male. Subjects were classified according to age: child, <16 years; adult, >16 years.
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Statistical analyses
Data was managed using Excel (Microsoft Ltd, Seattle, USA.) 
and exported to ‘R’ v2.9 running on a Mac OS 10.6 for all 
statistical analyses (25). In order to differentiate between 
adults completing their own subjective symptom scores and 
child subjects – who required an adult to complete them for 
them – analyses which involved examination of VAS itch 
scores were conducted separately for those under and over 16 
years old. Actiwatch scores are non-normally distributed and 
were log-transformed (14, 15). For studies comparing disease 
groups, where data were available for more than one night, 
mean scores were used. 
Within- and between-night analyses were performed by 
ANOVA using person as a factor (26). Following univariate 
analyses, accelerometer scores were modelled using linear 
regression with sex and disease treated as factors and age and 
VAS as continuous variables. Non-significant terms were remo-
ved from the model and levels of each factor compared using 
pairwise Student’s t-tests with Holm’s correction (25,26). 
For Study 2, VAS itch and log actigraph scores were model-
led using a mixed-effect model with person as the unit using 
the nmle package in ‘R’. Since this does not take full account 
of the correlation structure, the autocorrelation function in ‘R’ 
(‘acf’) was used and moving model averages compared using 
ANOVA. Detailed exploration of different lag periods or diffe-
rent classes of time series models was not performed. Graphical 
representation of the autocorrelation structure shows to what 
extent a score on day n, is correlated with scores on subsequent 
successive days (n+1, n+2, n+3...).
RESULTS
Study 1
Determinants of actigraphy scores. For the majority of 
subjects, readings from three or more nights were avail-
able. Fifty-six percent of the variation was between-
person and 44% within-person (i.e. due to variation 
from night to night for the same person) (ANOVA). 
Means for each subject were calculated for subsequent 
analyses. Children (subjects <16 years old) and adults 
(>16 years) were examined separately. The total data 
set is shown in Fig. 1.
Children. Linear regression of log actigraphy scores 
showed no effect of age (p = 0.67) or sex (p = 0.365). 
As expected, scores were higher for subjects with 
atopic dermatitis than controls: mean log actigraphy 
score 9.02 vs. 8.29 (p = 0.021). VAS itch was not a 
significant predictor in either univariate (p = 0.261) 
or multivariate (p = 0.284) models. Fig. 2 shows the 
relation between actigraphy and VAS itch scores (the 
slope of the regression line shown is not significantly 
different from 0).
Adults. Sex and age had no effect on actigraphy scores. 
Mean log actigraphy scores were 10.4, 8.95, 8.43, 8.99 
and 8.14 in patients with liver disease, atopic dermati-
tis, psoriasis, pruritus of unknown cause and controls 
respectively. Measures of uncorrected effect can be 
seen in Fig. 1, and a matrix of Holm-corrected pairwise 
Student’s t-tests performed following linear regres-
sion using pooled error is shown in Table II. As can 
be seen, scores were significantly higher for subjects 
with liver disease compared with other disease groups 
and controls. Scores for subjects with atopic dermatitis, 
but not those with psoriasis, were significantly higher 
than in controls.
Mean VAS itch scores were 6.64, 4.83, 4.68 and 2.53 
in patients with liver disease, psoriasis, atopic dermatitis 
and patients with itch of unknown cause, respectively. 
The only significant difference between these groups 
was between those with liver disease and those with 
itch of unknown cause (p = 0.04; Student’s t-test). The 
spread of the values within each group was large.
Fig. 1. Study 1. Mean overnight actigraphy score for all participants (children 
and adults) separated by diagnosis: control, liver (= hepatic itch), unknown 
(= pruritus of unknown cause), psoriasis and atopic dermatitis.














Fig. 2. Study 1. Regression analysis of children’s mean log overnight actigraphy 
score and visual analogue scale (VAS) itch score. A ‘best-fit’ regression line 
(slope not significantly different from 0) is shown.
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In univariate analyses both diagnosis (p < 0.001) and 
VAS itch (p = 0.042) were significant predictors of ac-
tigraphy scores, but the r2 value for VAS itch was only 
0.06 (r2 for diagnostic category = 0.51). Once diagnosis 
was entered into the regression equation, VAS itch was 
no longer significant (p = 0.27). The relation, by diag-
nostic group, between VAS itch score and actigraphy 
is shown in Fig. 3 (best-fit lines are shown, but their 
slopes do not differ significantly from 0).
Study 2
In a different cohort of 20 adults with eczema, ac-
tigraphy and VAS itch scores were recorded over 42 
nights. Scatter plots of VAS itch against actigraphy are 
shown for each of the twenty persons in Fig. 4. It can 
be seen that there appears to be little relation between 
actigraphy and VAS itch scores. Because scores from 
night to night for the same person cannot be assumed to 
be independent, we initially modelled the data using a 
mixed-effect model with person as the grouping factor. 
In order to take account of the correlation structure, 
we then compared this model (using ANOVA) with 
a simple moving average model using the corARMA 
function (25, 26) with a delay of 2 or 3 days. This model 
provided a better fit to the data (p < 0.001). The empi-
rical autocorrelation structure for VAS itch is shown 
in Fig. 5, with a dashed line representing statistical 
significance (p = 0.001) plotted. The autocorrelation 
bar crossing the p = 0.001 dashed line indicates that the 
data on successive days are highly correlated. This is 
most evident for lags of 1 to 3 days (the correlation on 
day 0 is of course perfect as the same figure is being 
compared), but the stepwise diminution of the height 
of the autocorrelation bar reflects a diminution of the 
correlation from any one day (n) over subsequent 
successive days (n+1, n+2, n+3...). No pattern for 
autocorrelation was seen for actigraphy scores (data 
not shown).
DISCUSSION
The current work builds upon previous studies and in 
large part confirms that the relation between objective 
measures of scratch and VAS itch is poor. Before discus-
sion, some limitations of the work are highlighted.
The work was based on those attending secondary 
care, and therefore was probably skewed towards pa-
tients with more severe disease, as reflected by the 
SCORAD scores. Patients were volunteers and, since 
the study involved a significant amount of time and 
contact with the investigators, the study group may not 
Table II. Summary of principal differences between actigraphy 
scores for adults by diagnostic group. Pairwise comparisons are 
made using Student’s t-tests with pooled error following linear 
regression. Mean log scores are: control, 8.14; liver, 10.4; PUC, 
8.99; psoriasis, 8.43 and AD, 8.95.
Control Liver PUC Psoriasis
Liver < 0.0001 – – –
PUC 0.0782 0.0034 – –
Psoriasis 0.3564 0.0001 0.3033 –
AD 0.0015 0.0001 0.8884 0.0184
PUC: pruritus of unknown cause; AD: atopic dermatitis.
Fig. 3. Study 1. Regression analysis of adults’ Actiwatch mean log overnight 
score and visual analogue scale (VAS) itch score separated by diagnostic group: 
psoriasis, unknown cause (= pruritus of unknown cause), atopic dermatitis 
and liver itch (= hepatic itch.) ‘Best-fit’ regression lines are shown (none of 
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Fig. 4. Study 2. Individual scatter plots of visual analogue scale (VAS) itch 
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be typical of the reference population. We obviously 
were not able to control prospectively the severity of 
disease during the study period – if patient groups at 
the extreme end of the scale for symptom severity had 
been used, it is possible different conclusions might 
have been made, although the SCORAD scores for 
the eczema group were as high or higher than in many 
therapeutic trials.
In study 1 we have shown that there is no obvious 
relation between itch assessed using VAS scores and 
actigraphy scores for either children with atopic der-
matitis or adults with a range of diagnoses (see Fig 2 
and 3. Previous work has validated actigraphy against 
direct observation of children scratching at night, and 
both scratching and restlessness are correlated with each 
other, and higher in those with atopic dermatitis than in 
controls (14, 15). Itch-related behaviour at night is not 
as stereotyped as when awake, and actigraphy is, we be-
lieve, a useful practical assay for scratch when compared 
with the time-consuming nature of direct observation of 
video recordings. Although we analysed children and 
adults separately, we saw no influence of sex or age on 
actigraphy scores. The key determinant of differences in 
actigraphy scores was diagnostic group, with those with 
liver disease the most severely affected. This assumes, 
however, that restlessness due to other factors differing 
between diagnostic groups is not confounding our scores 
– an assumption that needs to be tested. Although VAS 
itch scores differed between the different diagnostic 
groups, the differences were largely non-significant, 
again emphasising a disconnect between VAS scores 
and actigraphy.
In study 1 we showed that approximately 60% of the 
recorded variation was between-subject and approx-
imately 40% within-subject. This fact emphasises that 
nocturnal movements vary from night to night within 
any one subject, and of course limits the power of ac-
tigraphy scores for experimental studies unless repeated 
sampling is carried out. It is quite possible that other 
factors – night of the week and work patterns – contri-
bute to this within-person variation, as well as variation 
in the disease that is causing the scratch. We have not 
specifically examined these factors. 
In study 2 we had a chance to look in more detail at 
the relation between VAS itch and actigraphy over time. 
Again, we saw little convincing relation, and examina-
tion of the autocorrelation shows a very different pat-
tern for actigraphy and VAS itch. The VAS itch scores 
clearly show an effect of lag, and the question is: why? 
We asked our subject to post their scores in an attempt 
to minimise the filling out of results in batches, and to 
limit knowledge of the score on one day influencing 
the score on the next day. This strategy is not foolproof 
and electronic diaries or other methods of continuous 
sampling would perhaps provide a better approach (27, 
28). We suspect that the presence of the temporal pattern 
for VAS itch scores (and not actigraphy) is more easily 
explained by subjects anchoring their scores based on 
recollection of previous scoring (7, 23). Whether or not 
this is indeed the correct interpretation, coupled with the 
results of study 1, our data suggest that the use of VAS 
scores for itch may be limited in their utility as a sub-
jective measure of disease activity in the context of the 
chronic diseases we studied. We suspect that objective 
scores such as actigraphy – however imperfect – deserve 
more attention for monitoring disease activity.
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Subjective-symptom tools used in dermatology have ra-
rely been experimentally tested for cognitive “focus” and 
“framing” biases. We investigated the effects of affective 
biases on the Dermatology Life Quality Index (DLQI), 
the Global Health Question and visual analogue scores. 
Two experiments tested the response to affect-eliciting 
words and film. We demonstrated no significant dif-
ference in median DLQI scores for subjects exposed to 
negative vs. neutral words (medians 8.5 and 9.5, respec-
tively), or negative vs. positive words (medians 6.0 and 
9.0, respectively, overall p = 0.41.) Median DLQI scores 
were similar for groups who had (8.0), or had not (9.0), 
seen a video clip about a severe skin condition (p = 0.34). 
Finally, we compared an Amended DLQI (ADLQI), the 
DLQI re-worded into neutral “frames”, with the stan-
dard DLQI. ADLQI median scores were higher (ADLQI 
8.25, DLQI 6.75), but not significantly so (p = 0.47). We 
have been unable to demonstrate any effects of the biases 
studied, but the statistical power of our study is modest. 
Key words: dermatology; bias; quality of life.
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It is widely accepted that objective measures of disease 
based on patho-biological variables are insufficient to 
measure the personal impact of disease. There are at 
least two reasons for this. First, we do not have objective 
correlates of many states, such as pain or itch (1, 2), and 
secondly, how the disease process affects an individual 
person will depend on a range of individual and con-
textual factors. For instance, the visibility of extensive 
psoriasis may be a greater burden to an individual who 
likes to go swimming, than to an individual who never 
goes swimming. Another example is that a person who 
previously had very severe disease, for instance bad 
childhood eczema, will use that as a comparator for 
their present state: their current disease state might be 
viewed differently if there was no previous history of 
skin disease (3).
In recent years, a number of tools have been develo-
ped with the goal of measuring the functional burden of 
disease as experienced by the patient. Examples include 
the Global Health Questionnaire (GHQ), which has 
been used to provide an overall assessment of patient-
perceived health (4), whilst another generic tool, the 
visual analogue scale (VAS), has been used as a measure 
of a range of symptoms such as itch or pain (5–7). For 
skin disease, one of the most widely used tools is the 
Dermatology Life Quality Index (DLQI) (8, 9). The 
designers of the tool had practicality in mind – it was 
considered a priority that the tool should be short and 
quick to answer, in order to aid assessment during clinic 
visits, and thus this 10-question tool was designed. In 
a medical and economic climate where resources are 
scarce, the assessment of quality of life and how it 
may be influenced by medical intervention has become 
a major research programme. In England, the British 
Association of Dermatologists and the National Institute 
of Health and Clinical Excellence (NICE) has advoca-
ted the use of the DLQI as a disease assessment tool 
for patients with psoriasis, to determine whether they 
should receive certain expensive biological therapies 
(10) (http://www.nice.org.uk/Guidance/TA134).
Work over the last 25 years, in cognitive psychology 
and especially in the field of happiness research, has 
revealed a number of problems surrounding the measu-
rement of subjective states, quality of life and utility (for 
reviews, see Kahneman et al. (11)). First, and strange 
as it may initially appear, individuals may not be able 
to access their own feelings (12, 13), and the way in 
which information is gathered may alter, or influence, 
the patient’s own perception of their own feelings (3, 
14–16). Secondly, a number of cognitive limitations 
may limit the value of subjective knowledge: patients 
may not be able to remember changes in their functional 
status, nor predict the effects of particular interventions 
or change in state (12, 13, 17–19). 
In the present paper, we set out to explore the effects 
of contextual or “framing” biases on commonly used 
subjective measures including the DLQI in dermatology. 
We use the term “framing bias” widely to include bias 
that stems from how the feeling, emotion or symptom is 
enquired about. Questions can be “framed” in language 
or presented in a context that may elicit a stereotyped 
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answer; for instance, by implying that an aspect of di-
sease should be considered as a negative phenomenon, 
leading a respondent to consider this aspect as negative 
where they did not before (3). Secondly, the immediate 
context may alter how individuals perceive their own 
symptoms. For example, patients frequently anchor or 
skew their own assessment of disease by reference to 
others who they think are less or more fortunate (3, 5).
We therefore designed three experiments in which 
either the wording of the DLQI was altered, or the 
immediate context in which individuals completed the 
DLQI, GHQ or VAS for common symptoms was mani-
pulated. The manipulation was performed using video, 
listing of negative or neutral words, and alterations in 
the actual wording of the DLQI.
METHODS
Participants
An opportunistic sample of 215 patients was recruited. Because 
of the absence of similar prior work, formal power calculations 
were not performed. For each study, consecutive patients who 
agreed to take part were enrolled from the Royal Infirmary’s 
Department of Phototherapy in Edinburgh. Details of specific 
diagnoses were not sought, the usual throughput of the pho-
totherapy department would suggest that the majority (70%) 
of the patients had psoriasis, a minority (approximately 10%) 
had eczema and 20% other conditions (for instance generalized 
pruritus). Ethics committee approval was granted by the Lothian 
Ethics Committee (LREC reference: 06/S1104/56). 
All study procedures and patient interactions were conducted 
using a consistent, written script. The interaction script and 
subject information sheet explained that the studies were to 
determine which sort of questionnaire or score was most accu-
rate in assessing symptoms. The interventions were described in 
general terms (“You will be given a list of words to memorise” 
or “If you are randomised into a certain group you may see a 
film broadcast on terrestrial television”) in order to minimize 
unintentional “unblinding”.
All participants completed the GHQ (“In general, for someone 
of your age, would you say that your health is excellent, very 
good, good or poor?”), DLQI and VAS of disease extent, itch and 
insomnia, always in the same order. The DLQI is a 10-question 
tool, the score of which is acquired by summing the score for 
each question. The higher the DLQI score, the more severely their 
quality of life is affected (maximum score 30.) Most participants 
scored in the region of 6–10, which equates to a “moderate” effect 
of the skin condition on the quality of life.
Experiment 1
Our hypothesis was that, if subjects were exposed to certain 
mood-eliciting words, they would affect the subjective score 
accordingly, for instance, if they had read negative words, their 
subjective scores would suggest worse disease.
Forty patients were randomized into two groups. Group 1 were 
asked to read 10 negative words, had one minute to memorize 
them and were then asked to write them out. After this, they com-
pleted the GHQ, DLQI and the VAS of disease extent for both itch 
and insomnia. Group 2 went through an identical process, but the 
participants were given a list of 10 neutral words (certain fields 
of psychology research have identified and use words that elicit 
certain affective states.) The words for this part of the experiment 
are listed in Table I and were taken from the “Balanced Affective 
Word List” (http://www.sci.sdsu.edu/CAL/wordlist/origwordlist.
html). The words were matched with respect to total character 
and syllable length. A further 41 patients were randomized into 
two groups. Group 3 were asked to read 10 negative words 
and then write them out (without the necessity of memorizing 
them). The participants then completed GHQ, DLQI and VAS 
or disease extent, itching and insomnia. Group 4 went through 
an identical process, except participants were given a list of 10 
positive words. These words were taken from the University of 
Florida’s NIMH Centre for the Study of Emotion and Attention 
(http://csea.phhp.ufl.edu/Media.html#bottommedia) and are 
listed in Table I. The source of affect-eliciting words was altered 
as this afforded a larger scope of words with more recent and 
more extensive validation. Again, the words were matched for 
total character and syllable length.
Experiment 2
Our hypothesis was that if a subject saw a film highlighting 
the negative aspects of having a skin disease, then this would 
make them focus on the negative aspects of living with their 
skin disease and so their subjective scores would imply that 
they had worse disease. 
Fifty-four patients were randomized into two groups, with 
Group 1 completing GHQ then VAS for disease extent, itch and 
insomnia, after having watched a 10-min clip from a terrestrial 
television broadcast (“Real Families: My Skin Could Kill Me”, 
which was broadcast before the “watershed” on ITV1 in October 
2005) about living with the severe skin condition, Harlequin 
ichthyosis. Group 2 just completed the subjective tools without 
having watched the television clip. All subjects were questioned 
in the same way and in the same experimental room, whether 
or not they had watched the film. The randomization result 
(to watch the film or not) was included in the questionnaire 
envelope and was opened, with the interviewer present in the 
study room, the interviewer then adopted the appropriate script 
(for whether or not the participant was to watch the film) from 
that point. 
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Experiment 3
In this study, our hypothesis was that if the DLQI focused on 
negative aspects of disease, then re-framing it into “neutral” 
frames should result in scores implying a better quality of life. 
We also hypothesized that if the DLQI focused on the negative, 
then this may negatively affect the responses to other subjective 
symptom scores. 
Eighty patients were randomized into two groups and each 
of these two groups further split into two sub-groups, giving a 
total of four sub-groups. Half the subjects answered the GHQ 
and standard DLQI, whilst the other half answered an altered 
DLQI (ADLQI) and the standard GHQ. The ADLQI mirrored 
the standard DLQI, but an attempt was made for each question 
to be re-written in a neutral frame, thereby, minimizing the 
possibility of a positive or negative framing and potentially 
reducing the possibility of a stereotyped answer. The ADLQI 
is shown in the electronic appendix (http://adv.medicaljournals.
se/article/abstract/10.2340.00015555-0768/app1). Division of 
the two groups allowed the ordering of the examination to be 
manipulated, with half the subjects receiving the GHQ first, and 
then either the DLQI or the ADLQI, with the other half receiving 
the GHQ second.
Demographic variables including age and sex, together with 
the results, were de-identified and recorded in Excel. Statistical 
analyses were undertaken using R-software (http://www.R-
project.org (20)). 
RESULTS
Examination of raw data, not surprisingly, showed 
that the majority of variables were non-normally dist-
ributed. Medians were therefore compared using the 
Kruskal-Wallis (KW) analysis of variance (ANOVA), 
or for count data, Fisher’s exact test for r × c contin-
gency tables. Formal significance was taken at p < 0.05. 
Because of the limited range of the GHQ questionnaire, 
results were also examined using Fisher’s exact test, 
but this did not alter any of the conclusions and is not 
presented.
Experiment 1
The impact of affect-eliciting words. A total of 81 sub-
jects were studied and their characteristics are shown in 
Table II. There were four intervention groups, numbe-
red 1–4, as mentioned above. There were no significant 
differences in the sex allocation (Fishers test, p = 0.81) 
nor median ages (Kruskal-Wallis, p = 0.70) between 
the four groups. Median scores for the four groups and 
p-values using the Kruskal-Wallis ANOVA are shown 
in Table II. As can be seen there are no significant dif-
ferences evident.
Experiment 2
The impact of watching a film about living with a severe 
skin condition. A total of 54 subjects were studied. 
Their characteristics and the median group-scores and 
Kruskal-Wallis ANOVA are shown in Table III. 
There was no significant sex difference between 
the two groups, those who were shown the video and 
those who were not (Fisher, p = 0.27). The median age 
of those shown the video was 52 compared with those 
who were not shown the video of 33; a difference that 
is highly significant (KW, p = 0.001). However, scatter 
plots did not show any obvious correlation between 







Median VAS (interquartile range)
Extent Itch Insomnia
Group 1 (Neg) 
n = 20
39.8 (17–71) 12/8 8.50 (5.00–11.75) 2.00 (1.00–2.00) 3.60 (2.80–5.60) 2.15 (0.90–4.33) 3.60 (1.50–7.20)
Group 2 (Neut) 
n = 20
41.4 (18–68) 9/11 9.50 (5.75–14.25) 2.00 (2.00–2.00) 3.70 (1.80–5.30) 2.15 (1.08–4.40) 4.80 (2.85–5.73)
Group 3 (Neg) 
n = 19
39.0 (20–72) 10/9 6.00 (2.00–10.50) 2.00 (2.00–3.00) 2.50 (0.60–5.00) 1.50 (0.55–3.95) 1.90 (0.70–5.75)
Group 4 (Pos) 
n = 22
37.4 (16–74) 11/11 9.00 (2.25–12.50) 2.00 (2.00–3.00) 4.80 (2.50–7.50) 1.30 (0.40–3.00) 3.40 (1.30–6.00)
p = Kruskal-Wallis 0.41 0.44 0.35 0.46 0.27
DLQI: Dermatology Life Quality Index; GHQ: Global Health Question; VAS: visual analogue scale.













50.3 (17–77) 14/13 8.00 (4.50–9.00 3.00 (2.00–3.00) 4.50 (2.95–6.15) 2.00 (0.85–3.90) 3.90 (2.10–6.35)
Group 2 (no video)
n = 27
35.8 (16–74) 9/18 9.00 (4.50–15.00) 2.00 (1.50–3.00) 3.20 (1.65–6.40) 2.70 (0.95–5.15) 2.20 (1.45–5.05)
p = Kruskal-Wallis 0.34 0.20 0.50 0.11 0.21
DLQI: Dermatology Life Quality Index; GHQ: Global Health Question; VAS: visual analogue scale.
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age and the outcome measures, so this difference was 
ignored. Median scores and p-values for the Kruskal-
Wallis ANOVA are shown in Table IV. As can be seen, 
there are no significant differences evident. 
Experiment 3
Re-wording DLQI into neutral frames. A total of 80 
subjects were studied and their characteristics are 
summarized in Table IV. GHQ and quality of life sco-
res (QI) were examined following four “treatments”. 
The first “treatment”, the DLQI, was compared with 
the second “treatment”, ADLQI and, following this, 
the ordering of GHQ and DLQI/ADLQI were studied 
(hence treatment groups were numbered as follows: 1, 
2 (DLQI) and 3, 4 (ADLQI.) 
There were no significant differences in sex (Fisher, 
p = 0.17) or age (KW, p = 0.92) between the four groups. 
Median scores and Kruskal-Wallis ANOVA across the 
four groups for QI (DLQI and ADLQI) and GHQ are 
listed in Table IV. These differences are not significant 
(KW for QI p = 0.47 and GHQ p = 0.76). The ordering 
had no effect on GHQ (p = 0.60) or QI (p = 0.5) scores 
and therefore groups 1 and 2, and 3 and 4 were com-
bined. Medians for the ADLQI and the DLQI for these 
combined groups were 8.5 and 7, respectively, a dif-
ference that was close to statistical significance with a 
p-value of 0.07 (Kruskal-Wallis test).
DISCUSSION
The results presented are, essentially, negative and, 
in that sense, they can be viewed as reassuring. Using 
the criteria of statistical significance we were unable to 
significantly alter the scores with the various attempts 
at manipulation of the context or wording of the ques-
tionnaires of VAS. There are a number of limitations 
to the work we present.
Although we studied 215 subjects, we did so in the 
absence of formal power calculations and a type II error 
is always possible. Whereas, if the effect of any biases 
had been major, then we may have detected it, more 
modest effects will probably have gone undetected. 
We cannot rule out clinically relevant effects, although 
our data provide the effect estimates for future studies. 
Secondly, even within the experimental paradigm we 
adopted, there were limitations to the way the experi-
ments were carried out. For instance, although we used 
a video of a child affected by skin disease, we did not 
find a suitable video that we thought was meaningful 
to use as a control. We also found it extremely difficult 
to alter the wording of the DLQI without producing a 
caricature of it. The differences seen between the altered 
DLQI and the genuine DLQI approach significance, 
but of course, interpretation of these differences is not 
straightforward. The fact that a different questionnaire 
produces a different median score is not unexpected and, 
even if the difference had been significant, it does not 
invalidate, in any way, the use of the DLQI. Another 
facet of this experiment is that it demonstrates that the 
DLQI itself would not appear to bias answering of other 
scores: the GHQ scores were similar whether the parti-
cipants had been exposed to DLQI or to the supposedly 
neutral-framed ADLQI.
Although we have not demonstrated any effects of 
framing or contextual factors in our study, the study 
itself was experimental and may not reproduce the 
sorts of real life factors that will influence the way 
people respond to questionnaires. For instance, and 
rather mundanely, a patient whose appointment has 
been delayed excessively, one can imagine, might be 
considered more likely to weight his or her own disease 
more heavily. It would be difficult to capture such influ-
ences. Furthermore the use of measures such as DLQI as 
justification for therapy (or denial of therapy) as in the 
UK is also much more complex than some appreciate 
(21). Clinical anecdote suggests that patients are quite 
capable of “gaming” the system to achieve what they 
feel are appropriate, and one should remember that 
quality of life, health status and patients’ perception 
of these measures are distinct (21). It is difficult not to 
imagine that if patients are meaningfully consented, and 
the purpose of the DLQI as a justification of clinical 
need is explained, that patients will not moderate their 
answers accordingly.
Finally, it was not our purpose to compare different 
questionnaires, or measures of aspects of diseases. There 
is already a large literature on this and on the advantages 
and disadvantages of speciality or disease-specific sco-
ring systems vs. more generic questionnaires, such as 









Group 1 (DLQI then GHQ) n = 21 45.1 (28–68) 14/6/1 6.50 (2.75–10.75) 3.00 (2.00–3.00)
Group 2 (GHQ then DLQI) n = 21 42.8 (16–79) 9/11/1 7.00 (4.50–11.00) 2.00 (2.00–3.00)
Group 3 (ADLQI then GHQ) n = 19 42.3 (19–81) 9/9/1 8.00 (6.75–10.50) 2.00 (1.00–3.00)
Group 4 (GHQ then ADLQI) n = 19 44.0 (17–76) 8/11/ 8.50 (6.00–13.50) 2.00 (1.75–3.00)
p = Kruskal-Wallis 0.47 0.76
DLQI: Dermatology Life Quality Index; ADLQI: Amended Dermatology Life Quality Index; GHQ: Global Health Question; QI: Quality of Life Index 
score.
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EuroQOL or SF-36, for instance (22–24). We do feel 
that it is important, however, that in view of the fact 
that there is an increasing literature on the design, use, 
limitations of various disease-scoring systems and on 
cognitive psychology as a whole, that this information 
is acknowledged and used to continue to validate the 
subjective tools that we commonly use.
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don’t! need! to! see! it.! The! only! rule! is! that! you! shouldn’t! look! at! Packet! 3! before! having!
completed!Packet!2.!!
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•! Give! each! episode! a! brief! name! that! will! help! you! remember! it! (for! example,!
“commuting!to!work”,!or!“at!lunch!with!B”,!where!B!is!a!person!or!a!group!of!people).!!
!







































Episode*name* Time*began* Time*ended* Notes*to*self:*What!happened?!How!you!felt?!
!
! !
1M_________! __________! __________!! _______________________________!
!
!
2M!_________! __________! __________!! _______________________________!
!
!
3M!_________! __________! __________!! _______________________________!
!
!
4M!_________! __________! __________!! _______________________________!
!
!
5M!_________! __________! __________!! _______________________________!
!
!
6M!_________! __________! __________!! _______________________________!
!
!
7M!_________! __________! __________!! _______________________________!
!
!
8M!_________! __________! __________!! _______________________________!
!
!
9M_________! __________! __________!! _______________________________!
!
!













Episode*name* Time*began* Time*ended* Notes*to*self:*What!happened?!How!you!felt?!
!
! !
1A!Lunchtime! __________! __________!! _______________________________!
!
!
2A!_________! __________! __________!! _______________________________!
!
!
3A!_________! __________! __________!! _______________________________!
!
!
4A!_________! __________! __________!! _______________________________!
!
!
5A!_________! __________! __________!! _______________________________!
!
!
6A!_________! __________! __________!! _______________________________!
!
!
7A!_________! __________! __________!! _______________________________!
!
!
8A!_________! __________! __________!! _______________________________!
!
!
9A_________! __________! __________!! _______________________________!
!
!













Episode*name* Time*began* Time*ended* Notes*to*self:*What!happened?!How!you!felt?!
!
! !
1E!Dinnertime! __________! __________!! _______________________________!
!
!
2E!_________! __________! __________!! _______________________________!
!
!
3E!_________! __________! __________!! _______________________________!
!
!
4E!_________! __________! __________!! _______________________________!
!
!
5E!_________! __________! __________!! _______________________________!
!
!
6E!_________! __________! __________!! _______________________________!
!
!
7E!_________! __________! __________!! _______________________________!
!
!
8E!_________! __________! __________!! _______________________________!
!
!
9E_________! __________! __________!! _______________________________!
!!
!




















































































































Impatient!for!it!to!end!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Happy!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!0!! 1!! 2!! 3!! 4!! 5!! 6!
!
Frustrated/annoyed!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!0!! 1!! 2!! 3!! 4!! 5!! 6!
!
Depressed/sad!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.! 0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Competent/capable!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Hassled/pushed!around!.!.!.!.!.!.!.!.!.!.!.!.!.!0!! 1!! 2!! 3!! 4!! 5!! 6!
!
Warm/friendly!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Angry/hostile!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!0!! 1!! 2!! 3!! 4!! 5!! 6!
!
Worried/anxious!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Enjoying!myself!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!0!! 1!! 2!! 3!! 4!! 5!! 6!!!!
!
Criticized/put!down!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Tired!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Itchy!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!!0!! 1!! 2!! 3!! 4!! 5!! 6!
!



































































Impatient!for!it!to!end!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Happy!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!0!! 1!! 2!! 3!! 4!! 5!! 6!
!
Frustrated/annoyed!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!0!! 1!! 2!! 3!! 4!! 5!! 6!
!
Depressed/sad!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.! 0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Competent/capable!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
Hassled/pushed!around!.!.!.!.!.!.!.!.!.!.!.!.!.!0!! 1!! 2!! 3!! 4!! 5!! 6!
!
Warm/friendly!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!0!! 1!! 2!! 3!! 4!! 5!! 6!!
!
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!Much** Somewhat** Pretty* Somewhat** Much**
worse** **worse** ***typical** ***better** ***better**
!
! 1!! 2!! 3!! 4!! 5!!
!!






















Much** Somewhat** Pretty* Somewhat** Much**
worse** **worse** ***typical** ***better** ***better**
!












0* means* that* others* would* see* you* as* about* average.* A* +3* means* it* is* much* more*





! Much*less** ***About** Much*more**
* than*others** **average** than*others**
*
enthusiastic!! C3!! C2!! C1!! 0!! +1!! +2!! +3!!
!
optimistic!! C3!! C2!! C1!! 0!! +1!! +2!! +3!!
!
laughs!easily!! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!
very!healthy! C3!! C2!! C1!! 0!! +1!! +2!! +3!
! !
always!sees!the!bright!side!! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!
comfortable!everywhere!! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!
enjoys!good!food!! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!
enjoys!being!in!company!! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!
pessimistic! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!!
often!worries!for!nothing!! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!
a!bit!depressed!!! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!
often!angry!! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!
tense!and!uncomfortable! C3!! C2!! C1!! 0!! +1!! +2!! +3!
!









































__!very!satisfied! !__!satisfied!! __!not!very!satisfied!! __not!at!all!satisfied!!
!
!
!
!
!
!
!
You*have*now*completed*the*survey.*Please*review*each*
packet*to*be*sure*you*have*answered*all*the*questions.*!
!
!
!
!
!
After*you*have*checked*your*answers,*put*all*of*the*
numbered*packets*(except*the*diary*if*you*wish*to*keep*it)*in*
the*large*envelope.**
*
*
*
*
*
Thank*you*very*much*for*participating*
